Rapid Molecular Detection of Tuberculosis and Rifampi

New England Journal of Medicine 363, 1005-1015

DOI: 10.1056/nejmoa0907847

Citation Report

#	Article	IF	Citations
1	Tuberculosis Infection Control in Healthcare Settings. , 0, , 361-379.		0
2	Local control of pulmonary resistance and lung compliance in the canine lung. Journal of Applied Physiology, 1975, 39, 580-589.	1.2	8
4	Potential impact of rapid diagnostic tests on improving antimicrobial use. Annals of the New York Academy of Sciences, 2010, 1213, 70-80.	1.8	31
6	MDR Tuberculosis — Critical Steps for Prevention and Control. New England Journal of Medicine, 2010, 363, 1050-1058.	13.9	168
7	Active case-finding for TB in the community: time to act. Lancet, The, 2010, 376, 1205-1206.	6.3	17
8	Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2010, 10, 688-698.	4.6	116
9	Xpert ^{\hat{A}^{\otimes}} MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?. Expert Review of Molecular Diagnostics, 2010, 10, 937-946.	1.5	149
10	Tuberculosis Diagnosis — Time for a Game Change. New England Journal of Medicine, 2010, 363, 1070-1071.	13.9	164
11	Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens. Journal of Clinical Microbiology, 2011, 49, 3967-3970.	1.8	87
12	Detecting Drug-Resistant Tuberculosis. Molecular Diagnosis and Therapy, 2011, 15, 189-194.	1.6	24
13	Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Review of Anti-Infective Therapy, 2011, 9, 415-430.	2.0	72
14	Systematic Review and Meta-Analysis of Antigen Detection Tests for the Diagnosis of Tuberculosis. Vaccine Journal, 2011, 18, 1616-1627.	3.2	85
15	Comparison of the Xpert MTB/RIF Test with an IS $\langle i \rangle$ 6110 $\langle i \rangle$ -TaqMan Real-Time PCR Assay for Direct Detection of Mycobacterium tuberculosis in Respiratory and Nonrespiratory Specimens. Journal of Clinical Microbiology, 2011, 49, 1772-1776.	1.8	147
16	Xpert MTB/RIF: a New Pillar in Diagnosis of Extrapulmonary Tuberculosis?. Journal of Clinical Microbiology, 2011, 49, 2540-2545.	1.8	303
17	Xpert $<$ sup $>$ $\hat{A}^{\otimes} <$ /sup $>$ MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiology, 2011, 6, 1067-1082.	1.0	391
18	Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 132-140.	2.5	283
19	Comparison of Two Molecular Methods for Rapid Diagnosis of Extrapulmonary Tuberculosis. Journal of Clinical Microbiology, 2011, 49, 3065-3067.	1.8	111
20	Etiology and management of genitourinary tuberculosis. Nature Reviews Urology, 2011, 8, 678-688.	1.9	99

#	Article	IF	CITATIONS
21	Recent Advances in the Laboratory Detection of Mycobacterium tuberculosis Complex and Drug Resistance. Clinical Infectious Diseases, 2011, 52, 1350-1355.	2.9	69
22	Tuberculose: le réveil d'une belle endormie. Revue Des Maladies Respiratoires Actualites, 2011, 3, 532-537.	0.0	2
25	Microsystem Technologies for Medical Applications. Annual Review of Chemical and Biomolecular Engineering, 2011, 2, 355-378.	3.3	23
26	Tuberculosis assays: past, present and future. Expert Review of Anti-Infective Therapy, 2011, 9, 457-469.	2.0	56
27	A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools [State of the art series. Operational research. Number 8 in the series]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 996-1004.	0.6	36
28	Mycobacterial Sepsis and Multiorgan Failure Syndrome. Annual Update in Intensive Care and Emergency Medicine, 2011, , 531-542.	0.1	1
29	Xpert ^{\hat{A}^{\otimes}} MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1567-1572.	0.6	118
30	Evaluation of a simple loop-mediated isothermal amplification test kit for the diagnosis of tuberculosis. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1211-1217.	0.6	103
33	Rapid Molecular Detection of Extrapulmonary Tuberculosis by the Automated GeneXpert MTB/RIF System. Journal of Clinical Microbiology, 2011, 49, 1202-1205.	1.8	314
34	Evaluation of the GeneXpert MTB/RIF Assay for Rapid Diagnosis of Tuberculosis and Detection of Rifampin Resistance in Pulmonary and Extrapulmonary Specimens. Journal of Clinical Microbiology, 2011, 49, 4138-4141.	1.8	253
35	Rapid Detection of Mycobacterium tuberculosis Complex and Rifampin Resistance in Smear-Negative Clinical Samples by Use of an Integrated Real-Time PCR Method. Journal of Clinical Microbiology, 2011, 49, 1137-1139.	1.8	136
36	Induced Pluripotent Stem Cells in Long-QT Syndrome. New England Journal of Medicine, 2011, 364, 181-182.	13.9	8
37	Update in Tuberculosis and Nontuberculous Mycobacterial Disease 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 180-185.	2.5	14
39	Current Concepts in the Management of Tuberculosis. Mayo Clinic Proceedings, 2011, 86, 348-361.	1.4	151
40	Risk factors for false-negative results of QuantiFERON-TB Gold In-Tube assay in non-HIV-infected patients with culture-confirmed tuberculosis. Diagnostic Microbiology and Infectious Disease, 2011, 70, 324-329.	0.8	22
41	Multidrug-resistant tuberculosis presenting as a solitary splenic mass in an immunocompetent patient. Diagnostic Microbiology and Infectious Disease, 2011, 70, 522-524.	0.8	2
42	Diagnostics as essential tools for containing antibacterial resistance. Drug Resistance Updates, 2011, 14, 95-106.	6.5	99
43	Evaluation of Fluoromycobacteriophages for Detecting Drug Resistance in Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2011, 49, 1838-1842.	1.8	37

#	ARTICLE	IF	Citations
44	Role of the Clinical Mycobacteriology Laboratory in Diagnosis and Management of Tuberculosis in Low-Prevalence Settings. Journal of Clinical Microbiology, 2011, 49, 772-776.	1.8	48
45	Diagnosis of pulmonary tuberculosis in a microbiological laboratory. Médecine Et Maladies Infectieuses, 2011, 41, 509-517.	5.1	12
47	Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities. Clinical Microbiology Reviews, 2011, 24, 314-350.	5.7	387
48	A role for systems epidemiology in tuberculosis research. Trends in Microbiology, 2011, 19, 492-500.	3.5	71
49	Biosensor diagnosis of urinary tract infections: a path to better treatment?. Trends in Pharmacological Sciences, 2011, 32, 330-336.	4.0	82
50	Bronchoscopy in suspected pulmonary TB with negative induced-sputum smear and MTD® Gen-probe testing. Respiratory Medicine, 2011, 105, 1084-1090.	1.3	19
51	Assays for drug resistant tuberculosis in high burden countries. Lancet Infectious Diseases, The, 2011, 11, 161-162.	4.6	2
52	Assays for drug resistant tuberculosis in high burden countries – Authors' reply. Lancet Infectious Diseases, The, 2011, 11, 162.	4.6	1
53	Use of a WHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infectious Diseases, The, 2011, 11, 533-540.	4.6	47
54	Reducing mortality from HIV infection and tuberculosis. Lancet Infectious Diseases, The, 2011, 11, 494-495.	4.6	5
55	Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infectious Diseases, The, 2011, 11, 819-824.	4.6	294
56	Xpert MTB/RIF for diagnosis of pulmonary tuberculosis. Lancet Infectious Diseases, The, 2011, 11, 802-803.	4.6	4
57	XDR tuberculosis. Lancet Infectious Diseases, The, 2011, 11, 585.	4.6	3
58	Diagnosis of Mycobacterium tuberculosis using molecular biology technology. Asian Pacific Journal of Tropical Biomedicine, 2011, 1, 89-93.	0.5	22
59	WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. European Respiratory Journal, 2011, 38, 516-528.	3.1	718
61	Advances in rapid diagnosis of tuberculosis disease and anti-tuberculous drug resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 34-40.	0.3	32
62	Tuberculosis. Lancet, The, 2011, 378, 57-72.	6.3	670
63	Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet, The, 2011, 377, 1495-1505.	6.3	902

#	Article	IF	Citations
64	Improving tuberculosis diagnostics and treatment. Lancet, The, 2011, 377, 1467-1468.	6.3	9
65	Xpert MTB/RIF test for tuberculosis. Lancet, The, 2011, 378, 481-482.	6.3	4
66	Xpert MTB/RIF test for tuberculosis. Lancet, The, 2011, 378, 482.	6.3	3
67	Tuberculosis in prisons in sub-Saharan Africa – a potential time bomb. South African Medical Journal, 2011, 101, 107.	0.2	18
68	Extensively resistant tuberculosis in the lands Down Under. Medical Journal of Australia, 2011, 194, 565-566.	0.8	5
69	Detection of rifampin-resistant genotypes in Mycobacterium tuberculosis by reverse hybridization assay. Memorias Do Instituto Oswaldo Cruz, 2011, 106, 139-145.	0.8	8
70	Clinical application of high throughput molecular screening techniques for pharmacogenomics. Pharmacogenomics and Personalized Medicine, 2011, 4, 109.	0.4	10
71	Presentaciones en cartel. Biomedica, 2011, 31, 72.	0.3	0
72	Clinical data and molecular analysis of Mycobacterium tuberculosis isolates from drug-resistant tuberculosis patients in Goiás, Brazil. Memorias Do Instituto Oswaldo Cruz, 2011, 106, 655-661.	0.8	7
73	Containing a Global Threat: The Virulence of Tuberculosis in Developed and Developing Countries. Global Journal of Health Science, 2011, 3, .	0.1	0
74	Fatores associados ao atraso no diagn \tilde{A}^3 stico da tuberculose pulmonar no estado do Rio de Janeiro. Jornal Brasileiro De Pneumologia, 2011, 37, 512-520.	0.4	50
76	International Spread of MDR TB from Tugela Ferry, South Africa. Emerging Infectious Diseases, 2011, 17, 2035-7.	2.0	22
77	Bridging Implementation, Knowledge, and Ambition Gaps to Eliminate Tuberculosis in the United States and Globally. Emerging Infectious Diseases, 2011, 17, 337-342.	2.0	17
78	Extensively drugâ€resistant tuberculosis: New Zealand's first case and the challenges of management in a lowâ€prevalence country. Medical Journal of Australia, 2011, 194, 602-604.	0.8	6
79	Integrating tuberculosis and HIV services. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2011, 26, 55-59.	0.2	2
80	Why ethics matters in tuberculosis prevention, care and control [Editorial]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 3-5.	0.6	2
81	Nucleic Acid Amplification Tests for Diagnosis of Smear-Negative TB in a High HIV-Prevalence Setting: A Prospective Cohort Study. PLoS ONE, 2011, 6, e16321.	1.1	30
82	Validation of a Clinical-Radiographic Score to Assess the Probability of Pulmonary Tuberculosis in Suspect Patients with Negative Sputum Smears. PLoS ONE, 2011, 6, e18486.	1.1	14

#	Article	IF	CITATIONS
83	Cost-Effectiveness Analysis of Diagnostic Options for Pneumocystis Pneumonia (PCP). PLoS ONE, 2011, 6, e23158.	1.1	44
84	How Do Patients Who Fail First-Line TB Treatment but Who Are Not Placed on an MDR-TB Regimen Fare in South India?. PLoS ONE, 2011, 6, e25698.	1.1	10
85	Self-Reported Risks for Multiple-Drug Resistance among New Tuberculosis Cases: Implications for Drug Susceptibility Screening and Treatment. PLoS ONE, 2011, 6, e25861.	1.1	18
86	Comparison of Quantitative Techniques including Xpert MTB/RIF to Evaluate Mycobacterial Burden. PLoS ONE, 2011, 6, e28815.	1.1	87
87	Times have Changed! The Molecular Revolution in TB Diagnostics and Detection of Drug Resistance. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2011, 26, 229-234.	0.2	O
88	Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation. BMJ, The, 2011, 343, d5376-d5376.	3.0	65
89	Pneumococcal Pneumonia in Preschool Children. Pediatric Infectious Disease Journal, 2011, 30, 183-184.	1.1	1
90	Rapid Diagnosis of Smear-negative Tuberculous Osteoarthritis by Real-time Polymerase Chain Reaction on Bone Tissue. Pediatric Infectious Disease Journal, 2011, 30, 184.	1.1	O
91	Reducing tuberculosis-associated early mortality in antiretroviral treatment programmes in sub-Saharan Africa. Aids, 2011, 25, 1554-1555.	1.0	9
92	Survival in XDR TB: Shifting the Curve and Shifting the Paradigm. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 89-91.	0.9	2
93	Active Tuberculosis Case-Finding Among Pregnant Women Presenting to Antenatal Clinics in Soweto, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, e77-e84.	0.9	64
94	Antiretroviral Therapy and Tuberculosis: What's the Connection and What's the Way Forward?. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 255-257.	0.9	2
95	Pneumococcal Pneumonia in Preschool Children. Pediatric Infectious Disease Journal, 2011, 30, 183.	1.1	2
96	Pulmonary infections: †le terrain est tout, le microbe n'est rien'. Current Opinion in Pulmonary Medicine, 2011, 17, 131-133.	1.2	0
97	2010: The year in review, Part I [Year in review 2010]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1149-1153.	0.6	12
98	High sensitivity of chest radiograph reading by clinical officers in a tuberculosis prevalence survey. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1308-1314.	0.6	62
99	Paying attention to tuberculosis suspects whose sputum smears are negative [Editorial]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 427-428.	0.6	4
100	Diagnostic management and outcomes of pulmonary tuberculosis suspects admitted to a central hospital in Malawi. Public Health Action, 2011, 1, 2-5.	0.4	7

#	Article	IF	CITATIONS
101	Drug Susceptibility Testing for Optimizing Tuberculosis Treatment. Current Pharmaceutical Design, 2011, 17, 2863-2874.	0.9	13
102	Multiplex allele-specific polymerase chain reaction for detection of isoniazid resistance in <i>Mycobacterium tuberculosis</i> . International Journal of Tuberculosis and Lung Disease, 2011, 15, 799-803.	0.6	7
103	Sustained viral response after only 6 weeks of peginterferon and ribavirin treatment for acute hepatitis C in a HIV-1-infected patient. Aids, 2011, 25, 1553-1554.	1.0	1
104	The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score. Aids, 2011, 25, 1006-1009.	1.0	8
105	Improving TB diagnosis: difference between knowing the path and walking the path. Expert Review of Molecular Diagnostics, 2011, 11, 241-244.	1.5	15
106	Active case finding in contacts of people with tuberculosis. The Cochrane Library, 2011, , CD008477.	1.5	30
107	Year in review 2010: Tuberculosis, pleural diseases, respiratory infections. Respirology, 2011, 16, 564-573.	1.3	1
108	Changing epidemiology of respiratory pathogens and the role of improved diagnostics. Respirology, 2011, 16, 873-875.	1.3	0
109	The †frozen state' of drug-resistant tuberculosis: notes from the field in Abkhazia. Internal Medicine Journal, 2011, 41, 805-808.	0.5	3
110	Demographic characteristics and opportunistic diseases associated with attrition during preparation for antiretroviral therapy in primary health centres in Kibera, Kenya. Tropical Medicine and International Health, 2011, 16, 579-584.	1.0	17
111	Achieving STOP TB Partnership goals: perspectives on development of new diagnostics, drugs and vaccines for tuberculosis. Tropical Medicine and International Health, 2011, 16, 819-827.	1.0	18
112	Resistance to firstâ€line tuberculosis drugs in three cities of Nigeria. Tropical Medicine and International Health, 2011, 16, 974-980.	1.0	26
113	Increasing access to the MDRâ€₹B surveillance programme through a collaborative model in western Kenya*. Tropical Medicine and International Health, 2012, 17, 374-379.	1.0	6
114	British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Medicine, 2011, 12, 517-524.	1.0	108
115	Tuberculosis in pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 226-231.	1.1	59
116	Tuberculosis: an unpredictable long-standing human companion still in need of rapid diagnostic tests. Clinical Microbiology and Infection, 2011, 17, 799.	2.8	0
118	Immunological biomarkers of tuberculosis. Nature Reviews Immunology, 2011, 11, 343-354.	10.6	455
119	Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nature Reviews Microbiology, 2011, 9, 204-213.	13.6	178

#	Article	IF	CITATIONS
120	Point-of-care nucleic acid testing for infectious diseases. Trends in Biotechnology, 2011, 29, 240-250.	4.9	688
121	Tuberculosis in prisons in sub-Saharan Africa – the need for improved health services, surveillance and control. Tuberculosis, 2011, 91, 173-178.	0.8	73
122	Toward a low-cost compact array microscopy platform for detection of tuberculosis. Tuberculosis, 2011, 91, S54-S60.	0.8	21
124	Microbial Genomics and Infectious Diseases. New England Journal of Medicine, 2011, 365, 347-357.	13.9	156
125	Drug-resistant tuberculosis: an insurmountable epidemic?. Inflammopharmacology, 2011, 19, 131-137.	1.9	13
128	The Use of Diagnostic Systems for Tuberculosis in Children. Indian Journal of Pediatrics, 2011, 78, 334-339.	0.3	25
129	The Urgent Need for New Diagnostics for Symptomatic Tuberculosis in Children. Indian Journal of Pediatrics, 2011, 78, 449-455.	0.3	24
130	Laboratory diagnosis of spinal tuberculosis: past and present. ArgoSpine News and Journal, 2011, 23, 120-124.	0.1	3
131	Improving the Diagnosis of Tuberculosis: From QuantiFERON to New Techniques to Diagnose Tuberculosis Infections. Current HIV/AIDS Reports, 2011, 8, 153-163.	1.1	6
132	Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research. Journal of the International AIDS Society, 2011, 14, S5.	1.2	8
133	Point-of-care testing (POCT): Current techniques and future perspectives. TrAC - Trends in Analytical Chemistry, 2011, 30, 887-898.	5.8	416
134	Immunology in Tuberculosis: Challenges in Monitoring of Disease Activity and Identifying Correlates of Protection. Current Pharmaceutical Design, 2011, 17, 2853-2862.	0.9	11
135	A Multisite Assessment of the Quantitative Capabilities of the Xpert MTB/RIF Assay. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1076-1084.	2.5	102
136	You have to find TB to treat TB [Editorial]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 854-854.	0.6	1
137	Rapid Molecular Detection of Tuberculosis. New England Journal of Medicine, 2011, 364, 182-185.	13.9	9
138	What Is Thwarting Tuberculosis Prevention in High-Burden Settings?. New England Journal of Medicine, 2011, 365, 79-81.	13.9	17
139	Management of adolescents and adults with febrile illness in resource limited areas. BMJ: British Medical Journal, 2011, 343, d4847-d4847.	2.4	60
140	GeneXpert® MTB/RIF for rapid detection of <i>Mycobacterium tuberculosis</i> in pulmonary and extra-pulmonary samples [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1274-1275.	0.6	24

#	Article	IF	Citations
141	Tuberculosis Drug Development. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1107-1113.	2.5	13
142	Epidemiology of Tuberculosis and HIV: Recent Advances in Understanding and Responses. Proceedings of the American Thoracic Society, 2011, 8, 288-293.	3.5	56
143	Novel Developments in the Epidemic of Human Immunodeficiency Virus and Tuberculosis Coinfection. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 987-997.	2.5	29
144	Suitability of Xpert MTB/RIF and Genotype MTBDR <i>plus</i> for Patient Selection for a Tuberculosis Clinical Trial. Journal of Clinical Microbiology, 2011, 49, 2827-2831.	1.8	37
145	Dried Culture Spots for Xpert MTB/RIF External Quality Assessment: Results of a Phase 1 Pilot Study in South Africa. Journal of Clinical Microbiology, 2011, 49, 4356-4360.	1.8	30
146	Alternative Methods of Diagnosing Drug Resistance—What Can They Do for Me?. Journal of Infectious Diseases, 2011, 204, S1110-S1119.	1.9	22
147	A single Xpert MTB/RIF test of sputum for diagnosis of tuberculosis and multidrug resistance shows high sensitivity and specificity and reduces diagnosis and treatment delays. Evidence-Based Medicine, 2011, 16, 174-175.	0.6	5
148	Treatment Outcomes of Isoniazid-Resistant Tuberculosis Patients, Western Cape Province, South Africa. Clinical Infectious Diseases, 2011, 53, 369-372.	2.9	70
149	Evaluation of the Cepheid Xpert MTB/RIF Assay for Direct Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens. Journal of Clinical Microbiology, 2011, 49, 1621-1623.	1.8	214
150	Evaluation of Tuberculosis Diagnostics: Establishing an Evidence Base Around the Public Health Impact. Journal of Infectious Diseases, 2011, 204, S1187-S1195.	1.9	21
151	Changing Concepts of "Latent Tuberculosis Infection―in Patients Living with HIV Infection. Clinical and Developmental Immunology, 2011, 2011, 1-9.	3.3	65
152	Update on tuberculosis: TB in the early 21st century. European Respiratory Review, 2011, 20, 71-84.	3.0	37
153	Optimizing Second-Line Therapy for Drug-Resistant Tuberculosis: the Additive Value of Sequencing for Multiple Resistance Loci. Antimicrobial Agents and Chemotherapy, 2011, 55, 3968-3969.	1.4	2
154	Comparison of Two Nucleic Acid Amplification Assays, the Xpert MTB/RIF Assay and the Amplified Mycobacterium Tuberculosis Direct Assay, for Detection of Mycobacterium tuberculosis in Respiratory and Nonrespiratory Specimens. Journal of Clinical Microbiology, 2011, 49, 3659-3662.	1.8	51
155	Pyrosequencing for Rapid Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Strains and Clinical Specimens. Journal of Clinical Microbiology, 2011, 49, 3683-3686.	1.8	30
156	Mechanical Disruption of Lysis-Resistant Bacterial Cells by Use of a Miniature, Low-Power, Disposable Device. Journal of Clinical Microbiology, 2011, 49, 2533-2539.	1.8	96
157	Rapid Diagnosis of Extensively Drug-Resistant Tuberculosis by Use of a Reverse Line Blot Hybridization Assay. Journal of Clinical Microbiology, 2011, 49, 2546-2551.	1.8	32
158	New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 2011, 17, 134-141.	1.2	65

#	Article	IF	Citations
159	Tuberculosis in the 21st century. Clinical Medicine, 2011, 11, 353-357.	0.8	3
160	Reply to Lawn et al Clinical Infectious Diseases, 2011, 52, 277-278.	2.9	7
161	Performance of Xpert MTB/RIF RUO Assay and IS <i>6110</i> Real-Time PCR for Mycobacterium tuberculosis Detection in Clinical Samples. Journal of Clinical Microbiology, 2011, 49, 3458-3462.	1.8	71
162	The global fight against HIV/AIDS. Aids, 2011, 25, 1556-1558.	1.0	1
163	Diagnostic Accuracy of a Urine Lipoarabinomannan Enzyme-Linked Immunosorbent Assay for Screening Ambulatory HIV-Infected Persons for Tuberculosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 219-223.	0.9	30
164	Optimum time to start antiretroviral therapy in patients with HIV-associated tuberculosis: before or after tuberculosis diagnosis?. Aids, 2011, 25, 1003-1006.	1.0	5
165	Modernizing Surveillance of Antituberculosis Drug Resistance: From Special Surveys to Routine Testing. Clinical Infectious Diseases, 2011, 52, 901-906.	2.9	25
166	Reducing tuberculosis-associated mortality among people with HIV. Aids, 2011, 25, 1556.	1.0	O
167	The rise and fall of methicillin-resistant Staphylococcus aureus infections in HIV patients. Aids, 2011, 25, 1001-1003.	1.0	23
168	HIV and Tuberculosis: a Deadly Human Syndemic. Clinical Microbiology Reviews, 2011, 24, 351-376.	5.7	562
169	Xpert MTB/RIF Assay for Diagnosis of Pleural Tuberculosis. Journal of Clinical Microbiology, 2011, 49, 4341-4342.	1.8	98
170	Polymorphisms in Isoniazid and Prothionamide Resistance Genes of the Mycobacterium tuberculosis Complex. Antimicrobial Agents and Chemotherapy, 2011, 55, 4408-4411.	1.4	15
171	Mutations in <i>gidB</i> Confer Low-Level Streptomycin Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 2515-2522.	1.4	130
172	The Clinical Microbiology Laboratory in the Diagnosis of Lower Respiratory Tract Infections. Journal of Clinical Microbiology, 2011, 49, .	1.8	19
173	Cepheid GeneXpert MTB/RIF Assay for Mycobacterium tuberculosis Detection and Rifampin Resistance Identification in Patients with Substantial Clinical Indications of Tuberculosis and Smear-Negative Microscopy Results. Journal of Clinical Microbiology, 2011, 49, 3068-3070.	1.8	130
174	Molecular Detection of Resistance Determinants. Journal of Clinical Microbiology, 2011, 49, .	1.8	26
175	Improved Polyacrylamide-Based Artificial Sputum with Formalin-Fixed Tubercle Bacilli for Training of Tuberculosis Microscopists. Journal of Clinical Microbiology, 2011, 49, 3604-3609.	1.8	8
176	Tuberculosis Screening in Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Stretching Diagnostics to the Limits. Clinical Infectious Diseases, 2011, 52, 276-277.	2.9	7

#	Article	IF	CITATIONS
178	Viewpoint TB Diagnostics: What Does the World Really Need?. Journal of Infectious Diseases, 2011, 204, S1196-S1202.	1.9	35
179	Poor Prognosis of HIV-Associated Tuberculous Meningitis Regardless of the Timing of Antiretroviral Therapy. Clinical Infectious Diseases, 2011, 52, 1384-1387.	2.9	14
180	Adjunctive Tests for Diagnosis of Tuberculosis: Serology, ELISPOT for Site-Specific Lymphocytes, Urinary Lipoarabinomannan, String Test, and Fine Needle Aspiration. Journal of Infectious Diseases, 2011, 204, S1130-S1141.	1.9	62
181	Advances in the Diagnosis of Pulmonary Tuberculosis in HIV-Infected and HIV-Uninfected Children. Journal of Infectious Diseases, 2011, 204, S1151-S1158.	1.9	50
182	Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study. PLoS Medicine, 2011, 8, e1001067.	3.9	251
183	What Research Is Needed to Stop TB? Introducing the TB Research Movement. PLoS Medicine, 2011, 8, e1001135.	3.9	22
184	Evaluation of qPCR-Based Assays for Leprosy Diagnosis Directly in Clinical Specimens. PLoS Neglected Tropical Diseases, 2011, 5, e1354.	1.3	63
185	Simple Rapid Near-Patient Diagnostics for Tuberculosis Remain Elusiveâ€"Is a "Treat-to-Test―Strategy More Realistic?. PLoS Pathogens, 2011, 7, e1002207.	2.1	10
186	Diagnostics for tuberculosis: Time to usher in a new era. Indian Journal of Medical Microbiology, 2011, 29, 2-3.	0.3	3
187	Serological Testing Versus Other Strategies for Diagnosis of Active Tuberculosis in India: A Cost-Effectiveness Analysis. PLoS Medicine, 2011, 8, e1001074.	3.9	63
188	Reporter Phage and Breath Tests: Emerging Phenotypic Assays for Diagnosing Active Tuberculosis, Antibiotic Resistance, and Treatment Efficacy. Journal of Infectious Diseases, 2011, 204, S1142-S1150.	1.9	28
189	Commercial Serological Tests for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis: An Updated Systematic Review and Meta-Analysis. PLoS Medicine, 2011, 8, e1001062.	3.9	209
190	Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis. PLoS Medicine, 2011, 8, e1001120.	3.9	264
191	A Multi-Country Non-Inferiority Cluster Randomized Trial of Frontloaded Smear Microscopy for the Diagnosis of Pulmonary Tuberculosis. PLoS Medicine, 2011, 8, e1000443.	3.9	54
192	Speed and Convenience Aren't Everything with Diagnostics. PLoS Medicine, 2011, 8, e1001113.	3.9	4
193	An automated molecular test for Mycobacterium tuberculosis and resistance to rifampin (Xpert) Tj ETQq $1\ 1\ 0.78$	34314 rgB ⁻ 0.6	T /gverlock 1
194	Inpatient management of severe malnutrition: time for a change in protocol and practice. Annals of Tropical Paediatrics, 2011, 31, 97-107.	1.0	25
195	Developing Molecular Amplification Methods for Rapid Diagnosis of Respiratory Tract Infections Caused by Bacterial Pathogens. Clinical Infectious Diseases, 2011, 52, S338-S345.	2.9	31

#	Article	IF	CITATIONS
196	Comparison of Xpert MTB/RIF with Other Nucleic Acid Technologies for Diagnosing Pulmonary Tuberculosis in a High HIV Prevalence Setting: A Prospective Study. PLoS Medicine, 2011, 8, e1001061.	3.9	149
197	Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis. PLoS Medicine, 2011, 8, e1001063.	3.9	56
198	Tuberculosis in Antiretroviral Treatment Services in Resource-Limited Settings: Addressing the Challenges of Screening and Diagnosis. Journal of Infectious Diseases, 2011, 204, S1159-S1167.	1.9	112
199	GeneXpertâ€"A Game-Changer for Tuberculosis Control?. PLoS Medicine, 2011, 8, e1001064.	3.9	141
200	Utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with tuberculous intrathoracic lymphadenopathy: a multicentre study. Thorax, 2011, 66, 889-893.	2.7	166
201	Rapid Detection of <i>rpoB</i> Gene Mutations Conferring Rifampin Resistance in Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2012, 50, 2433-2440.	1.8	29
202	The Surprising Diversity of Mycobacterium tuberculosis: Change You Can Believe In. Journal of Infectious Diseases, 2012, 206, 1642-1644.	1.9	7
203	Consensus Statement on Diagnostic End Points for Infant Tuberculosis Vaccine Trials. Clinical Infectious Diseases, 2012, 54, 493-501.	2.9	19
204	Prevention, Diagnosis, and Treatment of Tuberculosis in Children and Mothers: Evidence for Action for Maternal, Neonatal, and Child Health Services. Journal of Infectious Diseases, 2012, 205, S216-S227.	1.9	98
205	Routine Use of Microbial Whole Genome Sequencing in Diagnostic and Public Health Microbiology. PLoS Pathogens, 2012, 8, e1002824.	2.1	450
206	Trends in tropical medicine research in India. Indian Journal of Pharmacology, 2012, 44, 1.	0.4	3
207	The impact of new tuberculosis diagnostics on transmission: why context matters. Bulletin of the World Health Organization, 2012, 90, 739-747.	1.5	51
208	Screening and Rapid Molecular Diagnosis of Tuberculosis in Prisons in Russia and Eastern Europe: A Cost-Effectiveness Analysis. PLoS Medicine, 2012, 9, e1001348.	3.9	44
209	Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLoS Medicine, 2012, 9, e1001347.	3.9	168
210	Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bulletin of the World Health Organization, 2012, 90, 111-119D.	1.5	230
211	The Small Membrane Filter Method of Microscopy to Diagnose Pulmonary Tuberculosis. Journal of Clinical Microbiology, 2012, 50, 2096-2099.	1.8	23
212	The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis. European Respiratory Journal, 2012, 39, 626-634.	3.1	23
213	TB and MDR-TB: what is new in 2012?. Breathe, 2012, 9, 100-111.	0.6	2

#	ARTICLE	IF	CITATIONS
214	Characteristics and Early Outcomes of Patients With Xpert MTB/RIF-Negative Pulmonary Tuberculosis Diagnosed During Screening Before Antiretroviral Therapy. Clinical Infectious Diseases, 2012, 54, 1071-1079.	2.9	73
215	False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications [Technical note]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 206-208.	0.6	60
216	National Survey of Drug-Resistant Tuberculosis in China. New England Journal of Medicine, 2012, 366, 2161-2170.	13.9	559
217	Automated Tuberculosis Diagnosis Using Fluorescence Images from a Mobile Microscope. Lecture Notes in Computer Science, 2012, 15, 345-352.	1.0	40
218	Increased and Expedited Case Detection by Xpert MTB/RIF Assay in Childhood Tuberculosis: A Prospective Cohort Study. Clinical Infectious Diseases, 2012, 54, 1388-1396.	2.9	131
219	Lung infections in the HIV-infected adult. Current Opinion in Pulmonary Medicine, 2012, 18, 253-258.	1.2	18
221	Pediatric tuberculosis. Current Opinion in Pediatrics, 2012, 24, 319-328.	1.0	27
222	Multidrug Resistance Among New Tuberculosis Cases. Epidemiology, 2012, 23, 293-300.	1.2	13
223	Tuberculosis and HIV in people who inject drugs. Current Opinion in HIV and AIDS, 2012, 7, 345-353.	1.5	34
224	The Use of an Automated Quantitative Polymerase Chain Reaction (Xpert MTB/RIF) to Predict the Sputum Smear Status of Tuberculosis Patients. Clinical Infectious Diseases, 2012, 54, 384-388.	2.9	41
225	The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. European Respiratory Journal, 2012, 40, 990-1013.	3.1	211
226	The Ethics of Testing a Test: Randomized Trials of the Health Impact of Diagnostic Tests for Infectious Diseases. Clinical Infectious Diseases, 2012, 55, 1522-1526.	2.9	14
227	Training Laboratory Technicians from the Ethiopian Periphery in the MODS Technique Enables Rapid and Low-Cost Diagnosis of Mycobacterium tuberculosis Infection. American Journal of Tropical Medicine and Hygiene, 2012, 86, 683-689.	0.6	4
228	Rapid Implementation of New TB Diagnostic Tests: Is It Too Soon for a Global Roll-Out of Xpert MTB/RIF?. American Journal of Tropical Medicine and Hygiene, 2012, 87, 197-201.	0.6	24
229	Can a Simple Flotation Method Lower the Limit of Detection of Mycobacterium tuberculosis in Extrapulmonary Samples Analyzed by the GeneXpert MTB/RIF Assay?. Journal of Clinical Microbiology, 2012, 50, 2272-2276.	1.8	23
230	The Diagnostic Performance of the GenoType MTBDR <i>plus</i> Version 2 Line Probe Assay Is Equivalent to That of the Xpert MTB/RIF Assay. Journal of Clinical Microbiology, 2012, 50, 3712-3716.	1.8	103
231	Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?. European Respiratory Journal, 2012, 40, 161-168.	3.1	60
232	An eXpert AFB Smear?. Clinical Infectious Diseases, 2012, 54, 389-391.	2.9	4

#	Article	IF	CITATIONS
233	Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9557-9562.	3.3	132
234	The Xpert® MTB/RIF assay evaluation in South Korea, a country with an intermediate tuberculosis burden. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1471-1476.	0.6	16
235	Diagnosis of tuberculosis and drug resistance: what can new tools bring us? [State of the art series. New tools. Number 1 in the series]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 860-870.	0.6	62
237	Linking Surveillance with Action against Drug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 399-401.	2.5	10
238	The Beginning of the <i>rpoB</i> Gene in Addition to the Rifampin Resistance Determination Region Might Be Needed for Identifying Rifampin/Rifabutin Cross-Resistance in Multidrug-Resistant Mycobacterium tuberculosis Isolates from Southern China. Journal of Clinical Microbiology, 2012, 50, 81-85.	1.8	48
239	First Evaluation of an Improved Assay for Molecular Genetic Detection of Tuberculosis as Well as Rifampin and Isoniazid Resistances. Journal of Clinical Microbiology, 2012, 50, 1264-1269.	1.8	74
240	Community-based Targeted Case Finding for Tuberculosis and HIV in Household Contacts of Patients with Tuberculosis in South Africa. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1110-1116.	2.5	102
241	Rapid molecular detection of pulmonary tuberculosis in HIV-infected patients in Santiago, Chile. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1349-1353.	0.6	19
244	Developments in Chemical Approaches to Treat Tuberculosis in the Last Decade. Current Medicinal Chemistry, 2012, 19, 488-517.	1.2	14
245	RNA profiling pathogens. Science-Business EXchange, 2012, 5, 408-408.	0.0	O
246	Challenges facing lipoarabinomannan urine antigen tests for diagnosing HIV-associated tuberculosis. Expert Review of Molecular Diagnostics, 2012, 12, 549-551.	1.5	9
247	Rapid Identification of Mycobacteria and Drug-Resistant Mycobacterium tuberculosis by Use of a Single Multiplex PCR and DNA Sequencing. Journal of Clinical Microbiology, 2012, 50, 326-336.	1.8	30
248	RNA signatures allow rapid identification of pathogens and antibiotic susceptibilities. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6217-6222.	3.3	94
249	Direct Detection of Mycobacterium tuberculosis Complex in Clinical Samples by a Molecular Method Based on GenoQuick Technology. Journal of Clinical Microbiology, 2012, 50, 2089-2091.	1.8	9
250	Effectiveness of an Integrated Real-Time PCR Method for Detection of the Mycobacterium tuberculosis Complex in Smear-Negative Extrapulmonary Samples in an Area of Low Tuberculosis Prevalence. Journal of Clinical Microbiology, 2012, 50, 513-515.	1.8	79
251	i• ² GFP10, a High-Intensity Fluorophage, Enables Detection and Rapid Drug Susceptibility Testing of Mycobacterium tuberculosis Directly from Sputum Samples. Journal of Clinical Microbiology, 2012, 50, 1362-1369.	1.8	69
252	Evaluation of the Xpert MTB/RIF Assay at a Tertiary Care Referral Hospital in a Setting Where Tuberculosis and HIV Infection Are Highly Endemic. Clinical Infectious Diseases, 2012, 55, 1171-1178.	2.9	68
253	Experience of Médecins Sans Frontià res in laboratory medicine in resource-limited settings. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1221-1227.	1.4	3

#	Article	IF	CITATIONS
254	Clinical Evaluation of COBAS TaqMan PCR for the Detection of <i>Mycobacterium tuberculosis </i> hand <i>M. avium </i> Complex. Tuberculosis Research and Treatment, 2012, 2012, 1-5.	0.2	3
255	An IMS/ATP Assay for the Detection of <i>Mycobacterium tuberculosis </i> li>in Urine. Tuberculosis Research and Treatment, 2012, 2012, 1-7.	0.2	0
256	A Model of Tuberculosis Screening for Pregnant Women in Resource-Limited Settings Using Xpert MTB/RIF. Journal of Pregnancy, 2012, 2012, 1-5.	1.1	20
257	Opportunities for Improved Serodiagnosis of Human Tuberculosis, Bovine Tuberculosis, and Paratuberculosis. Veterinary Medicine International, 2012, 2012, 1-13.	0.6	33
258	CT screening for lung cancer: so near, yet so far. Thorax, 2012, 67, 651-652.	2.7	3
259	A Systematic Review of the Epidemiology, Immunopathogenesis, Diagnosis, and Treatment of Pleural TB in HIV- Infected Patients. Clinical and Developmental Immunology, 2012, 2012, 1-9.	3.3	12
260	Tuberculosis diagnostics: Challenges and opportunities. Lung India, 2012, 29, 259.	0.3	33
262	Risk factors associated with pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 2012, 18, 233-240.	1.2	60
263	High Diagnostic Yield of Tuberculosis From Screening Urine Samples From HIV-Infected Patients With Advanced Immunodeficiency Using The Xpert MTB/RIF Assay. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 289-294.	0.9	52
264	Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. Aids, 2012, 26, 2121-2133.	1.0	44
265	Tuberculosis diagnostics for children in high-burden countries: what is available and what is needed. Paediatrics and International Child Health, 2012, 32, 30-37.	0.3	25
266	Diagnosis of Tuberculosis by Trained African Giant Pouched Rats and Confounding Impact of Pathogens and Microflora of the Respiratory Tract. Journal of Clinical Microbiology, 2012, 50, 274-280.	1.8	34
267	Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. European Respiratory Journal, 2012, 39, 1425-1431.	3.1	135
268	Tuberculosis among adults starting antiretroviral therapy in South Africa: the need for routine case finding. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1252-1259.	0.6	31
269	Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. Aids, 2012, 26, 1635-1643.	1.0	53
270	Small Randomized Trial Among Low–birth-weight Children Receiving Bacillus Calmette-Guérin Vaccination at First Health Center Contact. Pediatric Infectious Disease Journal, 2012, 31, 306-308.	1.1	220
272	Diagnosis and Treatment of Multidrug-Resistant Tuberculosis in Developed and Developing Countries: Finally Towards Equality?. Current Respiratory Medicine Reviews, 2012, 8, 464-474.	0.1	2
273	Bridging the gap between PCR detection of <i>Mycobacterium tuberculosis</i> complex and tuberculosis diagnosis [Short communication]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 391-393.	0.6	1

#	Article	IF	CITATIONS
274	Will molecular diagnosis of drug-resistant tuberculosis improve patient outcomes? [Perspectives]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 4-5.	0.6	5
275	Rifampicin-resistant <1>Mycobacterium tuberculosis 1 : susceptibility to isoniazid and other anti-tuberculosis drugs [Short communication]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 355-357.	0.6	37
276	Laboratory diagnosis of tuberculosis in a large pediatric hospital in Cambodia. International Journal of Tuberculosis and Lung Disease, 2012, 16, 503-509.	0.6	4
277	Diagnostic accuracy of induced sputum LAM ELISA for tuberculosis diagnosis in sputum-scarce patients. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1108-1112.	0.6	22
278	Microscopy compared to culture for the diagnosis of tuberculosis in induced sputum samples: a systematic review [Review article]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 579-588.	0.6	54
279	¹⁸ F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1180-1185.	0.6	97
280	Effect of universal MODS access on pulmonary tuberculosis treatment outcomes in new patients in Peru. Public Health Action, 2012, 2, 162-167.	0.4	6
281	Clinical failures associated with <i>rpo</i> B mutations in phenotypically occult multidrug-resistant <i>Mycobacterium tuberculosis</i> . International Journal of Tuberculosis and Lung Disease, 2012, 16, 216-220.	0.6	95
282	Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis [Short communication]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 203-205.	0.6	53
283	The Colour Test for drug susceptibility testing of Mycobacterium tuberculosis strains. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1113-1118.	0.6	19
284	Tuberculosis in Pediatric Solid Organ and Hematopoietic Stem Cell Transplant Recipients. Pediatric Infectious Disease Journal, 2012, 31, 774-777.	1.1	21
285	The Diagnosis of Tuberculosis. Pediatric Infectious Disease Journal, 2012, 31, 302-305.	1.1	24
287	The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy. Aids, 2012, 26, 987-995.	1.0	70
288	The volatiles of pathogenic and nonpathogenic mycobacteria and related bacteria. Beilstein Journal of Organic Chemistry, 2012, 8, 290-299.	1.3	48
289	Tuberculosis in solid organ transplant patients. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2012, 30, 34-39.	0.3	9
290	Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet, The, 2012, 379, 1902-1913.	6.3	300
291	Diagnosis of tuberculous lymphadenitis using fine needle aspiration biopsy. Internal Medicine Journal, 2012, 42, 1029-1036.	0.5	22
292	Tuberculosis. Clinics in Laboratory Medicine, 2012, 32, 111-127.	0.7	7

#	Article	IF	CITATIONS
293	Immunodiagnosis of Tuberculosis: State of the Art. Medical Principles and Practice, 2012, 21, 4-13.	1.1	42
294	"Spoligoriftyping," a Dual-Priming-Oligonucleotide-Based Direct-Hybridization Assay for Tuberculosis Control with a Multianalyte Microbead-Based Hybridization System. Journal of Clinical Microbiology, 2012, 50, 3172-3179.	1.8	36
295	Promising directions in the diagnosis of childhood tuberculosis. Expert Review of Respiratory Medicine, 2012, 6, 385-395.	1.0	14
296	Is operational research delivering the goods? The journey to success in low-income countries. Lancet Infectious Diseases, The, 2012, 12, 415-421.	4.6	74
297	Multidrug-resistant tuberculosis in children can be treated. Lancet Infectious Diseases, The, 2012, 12, 425-426.	4.6	2
298	Perspectives on Introduction and Implementation of New Point-of-Care Diagnostic Tests. Journal of Infectious Diseases, 2012, 205, S181-S190.	1.9	57
299	TB or not TB: The role of immunodiagnosis. European Journal of Immunology, 2012, 42, 2840-2843.	1.6	2
300	Modelling the impacts of new diagnostic tools for tuberculosis in developing countries to enhance policy decisions. Health Care Management Science, 2012, 15, 239-253.	1.5	20
301	A simple and economical in-house phage technique for the rapid detection of rifampin, isoniazid, ethambutol, streptomycin, and ciprofloxacin drug resistance in Mycobacterium tuberculosis, directly on decontaminated sputum samples. International Journal of Infectious Diseases, 2012, 16, e332-e336.	1.5	4
302	Growth of Mycobacteria in Urine Determined by Isothermal Microcalorimetry: Implications for Urogenital Tuberculosis and Other Mycobacterial Infections. Urology, 2012, 80, 1163.e9-1163.e12.	0.5	15
303	Effectiveness of the BDProbeTec ET system for detection of Mycobacterium tuberculosis complex in sputum and bronchoalveolar lavage specimens. Brazilian Journal of Infectious Diseases, 2012, 16, 242-249.	0.3	3
304	Genotype MTBDRplus for Direct Detection of Mycobacterium tuberculosis and Drug Resistance in Strains from Gold Miners in South Africa. Journal of Clinical Microbiology, 2012, 50, 1189-1194.	1.8	35
305	Clinical Research and Development of Tuberculosis Diagnostics: Moving From Silos to Synergy. Journal of Infectious Diseases, 2012, 205, S159-S168.	1.9	30
306	European Union Standards for Tuberculosis Care. European Respiratory Journal, 2012, 39, 807-819.	3.1	188
307	Rapid molecular detection of tuberculosis and rifampicin drug resistance: retrospective analysis of a national UK molecular service over the last decade. Thorax, 2012, 67, 361-367.	2.7	21
308	Is Real-Time PCR Better than Conventional PCR for Mycobacterium tuberculosis Complex Detection in Clinical Samples?. Journal of Clinical Microbiology, 2012, 50, 2810-2813.	1.8	29
309	Transforming clinical microbiology with bacterial genome sequencing. Nature Reviews Genetics, 2012, 13, 601-612.	7.7	684
310	Pulmonary infections in HIV-infected patients: an update in the 21st century. European Respiratory Journal, 2012, 39, 730-745.	3.1	164

#	Article	IF	CITATIONS
311	The future of molecular diagnostics for drug-resistant tuberculosis. Expert Review of Molecular Diagnostics, 2012, 12, 395-405.	1.5	30
312	Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities. Journal of Infectious Diseases, 2012, 205, S147-S158.	1.9	154
313	The Unmet Need of Education in Genomic Medicine. American Journal of Medicine, 2012, 125, 5-6.	0.6	50
314	Converting Cancer Therapies into Cures: Lessons from Infectious Diseases. Cell, 2012, 148, 1089-1098.	13.5	159
315	Mycobacterium tuberculosis Population Structure Determines the Outcome of Genetics-Based Second-Line Drug Resistance Testing. Antimicrobial Agents and Chemotherapy, 2012, 56, 2420-2427.	1.4	53
316	Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infectious Diseases, 2012, 12, 103.	1.3	206
317	High yield of culture-based diagnosis in a TB-endemic setting. BMC Infectious Diseases, 2012, 12, 218.	1.3	10
318	Rapid and accurate detection of RMP- and INH- resistant Mycobacterium tuberculosisin spinal tuberculosis specimens by CapitalBioâ,,¢ DNA microarray: A prospective validation study. BMC Infectious Diseases, 2012, 12, 303.	1.3	41
319	Evaluation of microscopic observation drug susceptibility assay for diagnosis of multidrug-resistant Tuberculosis in Viet Nam. BMC Infectious Diseases, 2012, 12, 49.	1.3	14
320	Fine-needle aspiration for diagnosis of tuberculous lymphadenitis in children in Bangui, Central African Republic. BMC Pediatrics, 2012, 12, 191.	0.7	20
321	Diagnostic work-up and loss of tuberculosis suspects in Jogjakarta, Indonesia. BMC Public Health, 2012, 12, 132.	1.2	6
322	Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probe. Nature Chemistry, 2012, 4, 802-809.	6.6	154
323	A low cost point-of-care viscous sample preparation device for molecular diagnosis in the developing world; an example of microfluidic origami. Lab on A Chip, 2012, 12, 174-181.	3.1	158
324	Evaluation of Genetic Mutations Associated with Mycobacterium tuberculosis Resistance to Amikacin, Kanamycin and Capreomycin: A Systematic Review. PLoS ONE, 2012, 7, e33275.	1.1	219
325	Commercialization of microfluidic point-of-care diagnostic devices. Lab on A Chip, 2012, 12, 2118.	3.1	1,105
326	Confronting Multidrug-Resistant Tuberculosis. New England Journal of Medicine, 2012, 366, 2223-2224.	13.9	24
327	Enzyme-free signal amplification for electrochemical detection of Mycobacterium lipoarabinomannan antibody on a disposable chip. Biosensors and Bioelectronics, 2012, 38, 421-424.	5.3	27
328	An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagnostic Microbiology and Infectious Disease, 2012, 74, 207-209.	0.8	77

#	Article	IF	CITATIONS
330	HIV-associated tuberculosis. , 2012, , 325-347.		2
331	Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. European Respiratory Journal, 2012, 40, 442-447.	3.1	271
332	Transforming TB Diagnosis: Can Patients and Control Programs Afford to Wait?. American Journal of Tropical Medicine and Hygiene, 2012, 87, 202-204.	0.6	2
333	Economic analyses of diagnostics for tuberculosis: what's the point?. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 137-139.	0.7	3
334	Tuberculosis in Transplantation: Diagnosis, Prevention, and Treatment. Current Infectious Disease Reports, 2012, 14, 650-657.	1.3	9
335	Tuberculose : quelques certitudes et encore beaucoup d'inconnues. Revue Des Maladies Respiratoires Actualites, 2012, 4, 419-424.	0.0	1
336	Screening for tuberculosis in pregnancy. Expert Review of Obstetrics and Gynecology, 2012, 7, 387-395.	0.4	4
337	Diagnosis of extrapulmonary tuberculosis using the Xpert (sup) \hat{A}^{\otimes} (sup) MTB/RIF assay. Expert Review of Anti-Infective Therapy, 2012, 10, 631-635.	2.0	93
338	Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries. Expert Review of Molecular Diagnostics, 2012, 12, 687-701.	1.5	66
339	Current Approaches to Tuberculosis in the United States. JAMA - Journal of the American Medical Association, 2012, 308, 283-9.	3.8	18
340	Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa. PLoS ONE, 2012, 7, e31786.	1.1	17
341	Bead Array Direct rRNA Capture Assay (rCapA) for Amplification Free Speciation of Mycobacterium Cultures. PLoS ONE, 2012, 7, e32575.	1.1	2
342	The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE, 2012, 7, e36966.	1.1	126
343	Screening Strategies for Tuberculosis Prevalence Surveys: The Value of Chest Radiography and Symptoms. PLoS ONE, 2012, 7, e38691.	1.1	96
344	Leveraging Rapid Community-Based HIV Testing Campaigns for Non-Communicable Diseases in Rural Uganda. PLoS ONE, 2012, 7, e43400.	1.1	117
345	A Toolbox for Tuberculosis Diagnosis: An Indian Multicentric Study (2006-2008): Microbiological Results. PLoS ONE, 2012, 7, e43739.	1.1	12
346	A Diagnostic Accuracy Study of Xpert®MTB/RIF in HIV-Positive Patients with High Clinical Suspicion of Pulmonary Tuberculosis in Lima, Peru. PLoS ONE, 2012, 7, e44626.	1.1	32
347	Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy. PLoS ONE, 2012, 7, e46191.	1.1	190

#	Article	IF	Citations
348	Selection and Application of ssDNA Aptamers to Detect Active TB from Sputum Samples. PLoS ONE, 2012, 7, e46862.	1.1	57
349	Impact of Xpert MTB/RIF Testing on Tuberculosis Management and Outcomes in Hospitalized Patients in Uganda. PLoS ONE, 2012, 7, e48599.	1.1	68
350	Rapid Diagnostic Algorithms as a Screening Tool for Tuberculosis: An Assessor Blinded Cross-Sectional Study. PLoS ONE, 2012, 7, e49658.	1.1	9
351	The Impact of Expanded Testing for Multidrug Resistant Tuberculosis Using Geontype MTBDRplus in South Africa: An Observational Cohort Study. PLoS ONE, 2012, 7, e49898.	1.1	28
352	"Proof-Of-Concept―Evaluation of an Automated Sputum Smear Microscopy System for Tuberculosis Diagnosis. PLoS ONE, 2012, 7, e50173.	1.1	35
353	Performance of the 2007 WHO Algorithm to Diagnose Smear-Negative Pulmonary Tuberculosis in a HIV Prevalent Setting. PLoS ONE, 2012, 7, e51336.	1.1	28
354	Time to debate rapid molecular testing for tuberculosis?. BMJ, The, 2012, 345, e7814-e7814.	3.0	0
355	HIV and tuberculosis $\hat{a} \in \text{``science'}$ and implementation to turn the tide and reduce deaths. Journal of the International AIDS Society, 2012, 15, 17396.	1.2	49
356	Infectious diseases in Australia â€" the next decade. Medical Journal of Australia, 2012, 196, 292-293.	0.8	2
357	True facets of TB diagnosis in 2012: Hypes and realities. European Journal of Microbiology and Immunology, 2012, 2, 275-281.	1.5	4
358	Proportion of Multidrug-Resistant Tuberculosis in Human Immunodeficiency Virus/ <i>Mycobacterium tuberculosis</i> Co-Infected Patients in Korea. Journal of Korean Medical Science, 2012, 27, 1143.	1.1	4
359	Tuberculosis is Still a Major Challenge in Africa. , 0, , .		1
360	Detection of Mycobacterium tuberculosis and Drug Resistance: Opportunies and Challenges in Morocco. , 0, , .		0
361	Crohn's disease or TB - the perennial question and diagnostic pitfalls. BMJ Case Reports, 2012, 2012, bcr0120125620-bcr0120125620.	0.2	2
362	Mycobacterium intracellulare infection in non-HIV infected patient in a region with a high burden of tuberculosis. BMJ Case Reports, 2012, 2012, bcr0120125713-bcr0120125713.	0.2	4
363	APOPO's tuberculosis research agenda: achievements, challenges and prospects. Tanzania Health Research Bulletin, 2012, 14, 121-30.	0.5	6
364	Recent advances in the diagnosis of Mycobacterium tuberculosis. Germs, 2012, 2, 110-120.	0.5	12
365	Clinical Usefulness ofrpoBGene Sequence Analysis in Lymph Node Tuberculosis. Infection and Chemotherapy, 2012, 44, 357.	1.0	0

#	Article	IF	CITATIONS
366	Fast test for assessing the susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by real-time PCR. Memorias Do Instituto Oswaldo Cruz, 2012, 107, 903-908.	0.8	10
367	Discordance in <i>Mycobacterium tuberculosis</i> Rifampin Susceptibility. Emerging Infectious Diseases, 2012, 18, 537-539.	2.0	8
368	Advances in the Diagnosis, Treatment and Control of HIV Associated Tuberculosis. African Journal of Infectious Diseases, 2012, 6, 29-40.	0.5	0
369	High Prevalence of Multidrug-Resistant Tuberculosis, Swaziland, 2009–2010. Emerging Infectious Diseases, 2012, 18, 29-37.	2.0	60
370	Serological diagnosis of tuberculosis using proteins expressed from the region of difference 1 (RD1) and RD2 of mycobacterium tuberculosis as antigens. African Journal of Microbiology Research, 2012, 6, 6698-6703.	0.4	1
371	Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infectious Diseases, 2012, 12, 10.	1.3	63
373	Global tuberculosis control: lessons learnt and future prospects. Nature Reviews Microbiology, 2012, 10, 407-416.	13.6	199
374	Immunosensor towards low-cost, rapid diagnosis of tuberculosis. Lab on A Chip, 2012, 12, 1437.	3.1	56
375	Nonclinical Selection Criteria for Maximizing Yield of Nucleic Acid Amplification Tests in Tuberculosis Diagnosis. Journal of Clinical Microbiology, 2012, 50, 2592-2595.	1.8	1
376	Drug-Resistant Tuberculosisâ€"Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs. Journal of Infectious Diseases, 2012, 205, S228-S240.	1.9	140
377	Update in Tuberculosis and Nontuberculous Mycobacterial Disease 2011. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1266-1270.	2.5	12
378	Micro Total Analysis Systems for Cell Biology and Biochemical Assays. Analytical Chemistry, 2012, 84, 516-540.	3.2	237
379	Rapid Molecular Diagnosis of Pulmonary Tuberculosis in Children Using Nasopharyngeal Specimens. Clinical Infectious Diseases, 2012, 55, 1088-1095.	2.9	140
380	Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test. Journal of Visualized Experiments, 2012, , e3547.	0.2	26
381	Organ Donation, Discrimination After Death, Anti-Vaccination Sentiments, and Tuberculosis Management. Journal of Bioethical Inquiry, 2012, 9, 125-133.	0.9	0
382	Safety and tolerability of sputum induction in adolescents and adults with suspected pulmonary tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 529-537.	1.3	11
383	Overview of errors in the reference sequence and annotation of Mycobacterium tuberculosis H37Rv, and variation amongst its isolates. Infection, Genetics and Evolution, 2012, 12, 807-810.	1.0	6
384	Genetic diversity, population structure and drug resistance of Mycobacterium tuberculosis in Peru. Infection, Genetics and Evolution, 2012, 12, 577-585.	1.0	33

#	Article	IF	CITATIONS
385	Clinical tuberculosis. Medicine, 2012, 40, 340-345.	0.2	2
386	Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: AAmeta-analysis. Journal of Infection, 2012, 64, 580-588.	1.7	220
387	Scaling up Xpert MTB/RIF technology: the costs of laboratoryâ€vs. clinicâ€based rollâ€out in South Africa. Tropical Medicine and International Health, 2012, 17, 1142-1151.	1.0	54
388	Screening patients with Diabetes Mellitus for Tuberculosis in China. Tropical Medicine and International Health, 2012, 17, 1302-1308.	1.0	75
389	Translating basic science insight into public health action for multidrug―and extensively drug―resistant tuberculosis. Respirology, 2012, 17, 772-791.	1.3	14
390	Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice. EMBO Molecular Medicine, 2012, 4, 27-37.	3.3	61
391	Molecular Diagnosis of Diarrhea: Current Status and Future Potential. Current Infectious Disease Reports, 2012, 14, 41-46.	1.3	57
392	Management of drug-resistant spinal tuberculosis with a combination of surgery and individualised chemotherapy: a retrospective analysis of thirty-five patients. International Orthopaedics, 2012, 36, 277-283.	0.9	44
393	Establishing the diagnosis of tuberculous vertebral osteomyelitis. European Spine Journal, 2013, 22, 579-586.	1.0	83
394	Impact of a novel molecular TB diagnostic system in patients at high risk of TB mortality in rural South Africa (Uchwepheshe): study protocol for a cluster randomised trial. Trials, 2013, 14, 170.	0.7	6
395	Clinical and laboratory features of tuberculosis within a hospital population in Libreville, Gabon. Infection, 2013, 41, 737-739.	2.3	8
396	Comparative analysis of TB-Biochip, Xpert MTB/RIF, and GenoType MTBDRplus test systems for rapid determination of mutations responsible for drug resistance of M. tuberculosis complex (in sputum) Tj ETQq1 1 ().7 843 14 ı	gB T /Overloc
397	A dual molecular beacon approach for fast detection of Mycobacterium tuberculosis. Molecular Biology Reports, 2013, 40, 1883-1892.	1.0	2
398	Conditionally fluorescent molecular probes for detecting single base changes in double-stranded DNA. Nature Chemistry, 2013, 5, 782-789.	6.6	136
399	Diagnosing tuberculous meningitis – have we made any progress?. Tropical Medicine and International Health, 2013, 18, 783-793.	1.0	56
401	Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1409-1415.	1.3	22
402	Comparison of Xpert MTB/RIF with ProbeTec ET DTB and COBAS TaqMan MTB for direct detection of M. tuberculosis complex in respiratory specimens. BMC Infectious Diseases, 2013, 13, 280.	1.3	40
403	Factors associated with patient and health care system delay in diagnosis for tuberculosis in the province of Luanda, Angola. BMC Infectious Diseases, 2013, 13, 168.	1.3	48

#	Article	IF	CITATIONS
404	Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study. BMC Infectious Diseases, 2013, 13, 133.	1.3	66
405	Updated diagnosis and treatment of childhood tuberculosis. World Journal of Pediatrics, 2013, 9, 9-16.	0.8	13
406	Diagnostic tools and technologies for infectious and non-communicable diseases in low-and-middle-income countries. Health and Technology, 2013, 3, 271-281.	2.1	13
407	System for portable nucleic acid testing in low resource settings. , 2013, , .		6
408	Evaluation of Respiratory Disease. Clinics in Chest Medicine, 2013, 34, 191-204.	0.8	14
409	Multidrug-Resistant Tuberculosis: A Global Challenge. , 2013, , 89-119.		0
410	Decreased serum 5-oxoproline in TB patients is associated with pathological damage of the lung. Clinica Chimica Acta, 2013, 423, 5-9.	0.5	39
411	Tuberculose de l'adulte : Des progrès significatifs dans le diagnostic et le traitement. Revue Des Maladies Respiratoires Actualites, 2013, 5, 274-279.	0.0	0
412	A simple diagnostic aid for tuberculous meningitis in adults in Morocco by use of clinical and laboratory features. International Journal of Infectious Diseases, 2013, 17, e461-e465.	1.5	16
413	Immunogenicity of mycobacterial vesicles in humans: Identification of a new tuberculosis antibody biomarker. Tuberculosis, 2013, 93, 448-455.	0.8	33
414	Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial. Lancet Respiratory Medicine,the, 2013, 1, 471-478.	5.2	52
415	Algorithm for the diagnosis of smearâ€negative pulmonary tuberculosis in highâ€incidence resourceâ€constrained settings. Tropical Medicine and International Health, 2013, 18, 1222-1230.	1.0	6
416	Drug-Resistant Tuberculosis: Pediatric Guidelines. Current Infectious Disease Reports, 2013, 15, 356-363.	1.3	10
417	GeneXpert \hat{A}^{\otimes} for smear-negative pulmonary tuberculosis: does it play a role in low-burden countries?. Diagnostic Microbiology and Infectious Disease, 2013, 75, 325-326.	0.8	14
418	Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard. Journal of Clinical Microbiology, 2013, 51, 2633-2640.	1.8	216
419	Evaluation of Xpert MTB/RIF for Detection of Tuberculosis from Blood Samples of HIV-Infected Adults Confirms Mycobacterium tuberculosis Bacteremia as an Indicator of Poor Prognosis. Journal of Clinical Microbiology, 2013, 51, 2311-2316.	1.8	50
421	Identifying dynamic tuberculosis case-finding policies for HIV/TB coepidemics. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9457-9462.	3.3	34
422	Antibiotic resistanceâ€"the need for global solutions. Lancet Infectious Diseases, The, 2013, 13, 1057-1098.	4.6	3,184

#	Article	IF	Citations
423	Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry: a Fundamental Shift in the Routine Practice of Clinical Microbiology. Clinical Microbiology Reviews, 2013, 26, 547-603.	5.7	644
424	Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment. Journal of Antimicrobial Chemotherapy, 2013, 68, 2915-2920.	1.3	46
425	Point-of-Care Diagnostics on a Chip. Biological and Medical Physics Series, 2013, , .	0.3	22
426	Comparative study of diagnostic accuracy of established PCR assays and in-house developed sdaA PCR method for detection of Mycobacterium tuberculosis in symptomatic patients with pulmonary tuberculosis. Journal of Infection, 2013, 67, 399-407.	1.7	13
427	Utility of the REBA MTB-rifa \hat{A}^{\otimes} assay for rapid detection of rifampicin resistant Mycobacterium Tuberculosis. BMC Infectious Diseases, 2013, 13, 478.	1.3	9
428	Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infectious Diseases, 2013, 13, 407.	1.3	68
429	Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. BMC Infectious Diseases, 2013, 13, 352.	1.3	47
430	Molecular Bacteriology and Mycobacteriology. , 2013, , 733-779.		O
431	Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. , 2013, , CD009593.		283
432	Multidrug-resistant Tuberculosis. Medical Clinics of North America, 2013, 97, 553-579.	1.1	25
433	Infections of the Developing World. Critical Care Clinics, 2013, 29, 485-507.	1.0	12
434	Identification of mycobacteria based on spectroscopic analyses of mycolic acid profiles. Analyst, The, 2013, 138, 6774.	1.7	36
435	Evaluation of two microbiological diagnostic methods for pulmonary tuberculosis based on Bayes rule. Zeitschrift Fur Gesundheitswissenschaften, 2013, 21, 123-130.	0.8	2
436	Xpert MTB/RIF and pulmonary tuberculosis: time to delve deeper?. Thorax, 2013, 68, 987-988.	2.7	7
437	The Role of Technology in Translational Science. World Medical and Health Policy, 2013, 5, 389-394.	0.9	1
438	Electrolyte-free amperometric immunosensor using a dendritic nanotip. RSC Advances, 2013, 3, 4281.	1.7	15
439	Performance of Cepheid® Xpert MTB/RIF® and TB-Biochip® MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 735-743.	1.3	26
440	Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa. Journal of Infectious Diseases, 2013, 207, 9-17.	1.9	116

#	Article	IF	CITATIONS
441	The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends in Genetics, 2013, 29, 160-169.	2.9	165
442	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. European Respiratory Journal, 2013, 42, 252-271.	3.1	211
443	Single nucleotide polymorphisms in Mycobacterium tuberculosis and the need for a curated database. Tuberculosis, 2013, 93, 30-39.	0.8	43
444	Advances in the Diagnosis of Mycobacterium tuberculosis and Detection of Drug Resistance. , 2013, , 557-586.		0
445	Technical and Clinical Niches for Point of Care Molecular Devices. , 2013, , 619-626.		0
446	Interpretation and Relevance of Advanced Technique Results. , 2013, , 911-936.		1
447	Point-of-care assays for tuberculosis: Role of nanotechnology/microfluidics. Biotechnology Advances, 2013, 31, 438-449.	6.0	108
448	Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respiratory Medicine, the, 2013, 1, 462-470.	5.2	151
449	The role of drug susceptibility testing in M/XDR-TB. Too little and too late – Are we doing the right things?. International Journal of Mycobacteriology, 2013, 2, 191-193.	0.3	5
451	Tuberculosis, drug use and HIV infection in Central Asia: An urgent need for attention. Drug and Alcohol Dependence, 2013, 132, S32-S36.	1.6	24
452	Decentralisation of multidrug-resistant-tuberculosis care and management. Lancet Infectious Diseases, The, 2013, 13, 644-646.	4.6	12
453	Luciferase reporter phage phAE85 for rapid detection of rifampicin resistance in clinical isolates of Mycobacterium tuberculosis. Asian Pacific Journal of Tropical Medicine, 2013, 6, 728-731.	0.4	3
455	A simple, rapid and economic method for detecting multidrug-resistant tuberculosis. Brazilian Journal of Infectious Diseases, 2013, 17, 667-671.	0.3	7
456	Molecular Approaches and Biomarkers for Detection of Mycobacterium tuberculosis. Clinics in Laboratory Medicine, 2013, 33, 553-566.	0.7	10
457	Evaluation of Xpert MTB/RIF assay for rapid molecular diagnosis of tuberculosis in a two-year period in Croatia. International Journal of Mycobacteriology, 2013, 2, 179-182.	0.3	33
458	The Twin Epidemics of Tuberculosis and HIV. Current Infectious Disease Reports, 2013, 15, 77-84.	1.3	9
459	Cytometry-Based Antimicrobial Resistance Techniques. , 2013, , 75-85.		0
460	Tuberculosis. New England Journal of Medicine, 2013, 368, 745-755.	13.9	636

#	Article	IF	CITATIONS
461	Tuberculosis: Time for a new perspective?. Journal of Infection, 2013, 66, 299-302.	1.7	8
462	Pointâ€ofâ€care diagnosis of tuberculosis: Past, present and future. Respirology, 2013, 18, 217-232.	1.3	127
463	Scoring systems using chest radiographic features for the diagnosis of pulmonary tuberculosis in adults: a systematic review. European Respiratory Journal, 2013, 42, 480-494.	3.1	59
464	The Immune Response in Tuberculosis. Annual Review of Immunology, 2013, 31, 475-527.	9.5	1,108
465	Evidence-Based Point-of-Care Diagnostics: Current Status and Emerging Technologies. Annual Review of Analytical Chemistry, 2013, 6, 191-211.	2.8	90
466	Case 3-2013. New England Journal of Medicine, 2013, 368, 375-385.	13.9	3
467	Assessing new strategies for TB diagnosis in low- and middle-income countries. Brazilian Journal of Infectious Diseases, 2013, 17, 211-217.	0.3	6
468	Overview of the Microfluidic Diagnostics Commercial Landscape. Methods in Molecular Biology, 2013, 949, 65-83.	0.4	13
469	Rapid and Biosecure Diagnostic Test for Tuberculosis. Cell Biochemistry and Biophysics, 2013, 65, 173-179.	0.9	5
470	Economic evaluations of point of care testing strategies for active tuberculosis. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 313-325.	0.7	5
472	Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infectious Diseases, The, 2013, 13, 349-361.	4.6	385
473	HIV, Tuberculosis, Malaria and Streptococcus pneumoniae. , 2013, , 248-250.		0
474	Rapid detection of bacterial resistance to antibiotics using AFM cantilevers as nanomechanical sensors. Nature Nanotechnology, 2013, 8, 522-526.	15.6	296
476	Low-Cost Microdevices for Point-of-Care Testing. Biological and Medical Physics Series, 2013, , 3-21.	0.3	32
477	Is Passive Diagnosis Enough?. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 543-551.	2.5	103
478	Resistance profiles and rpoB gene mutations of Mycobacterium tuberculosis isolates in Taiwan. Journal of Microbiology, Immunology and Infection, 2013, 46, 266-270.	1.5	22
479	Screening for active tuberculosis: methodological challenges in implementation and evaluation [State of the art series. Active case finding/screening. Number 4 in the series]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 856-865.	0.6	23
480	Enhanced serodiagnostic utility of novel Mycobacterium tuberculosis polyproteins. Journal of Infection, 2013, 66, 366-375.	1.7	33

#	Article	IF	CITATIONS
481	Management of drug-resistant tuberculosis. Current Respiratory Care Reports, 2013, 2, 208-217.	0.6	9
482	Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. International Journal of Tuberculosis and Lung Disease, 2013, 17, 198-206.	0.6	7
483	Failure to Initiate Antiretroviral Therapy, Loss to Follow-up and Mortality Among HIV-Infected Patients During the Pre-ART Period in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, e64-e71.	0.9	80
484	Factors associated with delayed tuberculosis diagnosis in China. European Journal of Public Health, 2013, 23, 253-257.	0.1	17
485	Comparison of molecular and immunological methods for the rapid diagnosis of smear-negative tuberculosis. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1459-1465.	0.6	12
486	Tuberculosis and the military. Journal of the Royal Army Medical Corps, 2013, 159, 190-199.	0.8	7
488	GenoType® MTBDR <i>plus</i> assay detection of drug-resistant tuberculosis in routine practice in Korea. International Journal of Tuberculosis and Lung Disease, 2013, 17, 120-124.	0.6	29
489	Diagnostic accuracy of Xpert® MTB/RIF on bronchoscopy specimens in patients with suspected pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease, 2013, 17, 917-921.	0.6	65
490	Multidrug-resistant tuberculosis in children: evidence from global surveillance. European Respiratory Journal, 2013, 42, 701-707.	3.1	70
491	Detection of Mycobacterium tuberculosis in Blood by Use of the Xpert MTB/RIF Assay. Journal of Clinical Microbiology, 2013, 51, 2317-2322.	1.8	23
492	Selected culture and drug-susceptibility testing methods for drug-resistant <i>Mycobacterium tuberculosis</i> screening in resource-constrained settings. Expert Review of Molecular Diagnostics, 2013, 13, 247-249.	1.5	3
493	GeneXpert for TB diagnosis: planned and purposeful implementation. Global Health, Science and Practice, 2013, 1, 18-23.	0.6	63
494	Noninvasive Molecular Imaging of Tuberculosis-Associated Inflammation With Radioiodinated DPA-713. Journal of Infectious Diseases, 2013, 208, 2067-2074.	1.9	45
495	Differential Expression of Host Biomarkers in Saliva and Serum Samples from Individuals with Suspected Pulmonary Tuberculosis. Mediators of Inflammation, 2013, 2013, 1-10.	1.4	47
496	Utility of the Xpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis. PLoS Medicine, 2013, 10, e1001537.	3.9	13
497	ASSESSMENT OF DIAGNOSTIC TECHNIQUES OF URINARY TUBERCULOSIS. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013034.	0.5	17
498	Detection of Tuberculosis in HIV-Infected and -Uninfected African Adults Using Whole Blood RNA Expression Signatures: A Case-Control Study. PLoS Medicine, 2013, 10, e1001538.	3.9	314
499	Tuberculous Osteomyelitis of the Hyoid Bone: A Case Report. Case Reports in Otolaryngology, 2013, 2013, 1-3.	0.1	0

#	Article	IF	CITATIONS
500	Tuberculosis and HIV Coinfection. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 032-043.	0.8	60
501	Management of Multidrug Resistant Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 044-059.	0.8	34
502	Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bulletin of the World Health Organization, 2013, 91, 36-45.	1.5	133
503	Diagnostic Accuracy of Quantitative PCR (Xpert MTB/RIF) for Tuberculous Meningitis in a High Burden Setting: A Prospective Study. PLoS Medicine, 2013, 10, e1001536.	3.9	142
504	Rapid Diagnosis of Mycobacterium tuberculosis Infection and Drug Susceptibility Testing. Archives of Pathology and Laboratory Medicine, 2013, 137, 812-819.	1.2	27
505	Exploring Alternative Biomaterials for Diagnosis of Pulmonary Tuberculosis in HIV-Negative Patients by Use of the GeneXpert MTB/RIF Assay. Journal of Clinical Microbiology, 2013, 51, 4161-4166.	1.8	42
506	Performance Monitoring of Mycobacterium tuberculosis Dried Culture Spots for Use with the GeneXpert System within a National Program in South Africa. Journal of Clinical Microbiology, 2013, 51, 4018-4021.	1.8	10
507	Advances in the diagnosis and treatment of tuberculous meningitis. Current Opinion in Neurology, 2013, 26, 295-300.	1.8	62
508	Use of Colorimetric Culture Methods for Detection of Mycobacterium tuberculosis Complex Isolates from Sputum Samples in Resource-Limited Settings. Journal of Clinical Microbiology, 2013, 51, 2273-2279.	1.8	19
509	Modeling the Impact of Alternative Strategies for Rapid Molecular Diagnosis of Tuberculosis in Southeast Asia. American Journal of Epidemiology, 2013, 178, 1740-1749.	1.6	31
510	Cephalosporin Resistance in Neisseria gonorrhoeae Infections. JAMA - Journal of the American Medical Association, 2013, 309, 1989.	3.8	8
511	Aspiring to Zero Tuberculosis Deaths among Southern Africa's Miners: Is There a Way Forward?. International Journal of Health Services, 2013, 43, 651-664.	1.2	18
512	Diagnosis of pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 2013, 19, 280-288.	1.2	15
513	Direct Comparison of Xpert MTB/RIF Assay with Liquid and Solid Mycobacterial Culture for Quantification of Early Bactericidal Activity. Journal of Clinical Microbiology, 2013, 51, 1894-1898.	1.8	38
514	Multidrug resistant Mycobacterium tuberculosis in cutaneous tuberculosis in China. Annals of Nigerian Medicine, 2013, 7, 71.	0.0	1
515	Mobile Digital Fluorescence Microscopy for Diagnosis of Tuberculosis. Journal of Clinical Microbiology, 2013, 51, 1774-1778.	1.8	59
516	Multicenter Evaluation of Genechip for Detection of Multidrug-Resistant Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2013, 51, 1707-1713.	1.8	43
517	Diagnosis and management of miliary tuberculosis: current state and future perspectives. Therapeutics and Clinical Risk Management, 2013, 9, 9.	0.9	55

#	Article	lF	CITATIONS
518	The Changing Landscape of Diagnostic Services for Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 017-031.	0.8	27
519	Tuberculosis immunodiagnosis: delving below the surface. Thorax, 2013, 68, 204-206.	2.7	3
520	Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax, 2013, 68, 1043-1051.	2.7	93
521	Comparative performance of Thin Layer Agar and Löwenstein–Jensen culture for diagnosis of tuberculosis. Clinical Microbiology and Infection, 2013, 19, E502-E508.	2.8	7
522	Challenges to the global control of tuberculosis. Respirology, 2013, 18, 596-604.	1.3	43
523	Comparison of the Xpert MTB/RIF and Cobas TaqMan MTB Assays for Detection of Mycobacterium tuberculosis in Respiratory Specimens. Journal of Clinical Microbiology, 2013, 51, 3225-3227.	1.8	39
524	Integrating the Xpert MTB/RIF Assay into a Diagnostic Workflow for Rapid Detection of Mycobacterium tuberculosis in a Low-Prevalence Area. Journal of Clinical Microbiology, 2013, 51, 2396-2399.	1.8	23
525	Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis. BMC Infectious Diseases, 2013, 13, 507.	1.3	78
526	Multidrug-Resistant Tuberculosis Drug Susceptibility and Molecular Diagnostic Testing. American Journal of the Medical Sciences, 2013, 345, 143-148.	0.4	45
527	Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries. Expert Review of Molecular Diagnostics, 2013, 13, 763-767.	1.5	28
528	Immunological evaluation of a novel Mycobacterium tuberculosis antigen, Rv3117, absent in Mycobacterium bovis BCG. Molecular Medicine Reports, 2013, 8, 1587-1593.	1.1	0
529	Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation. BMC Medicine, 2013, 11, 190.	2.3	53
530	Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. European Respiratory Journal, 2013, 42, 708-720.	3.1	85
531	TIMEBOMB revisited 10 years later: can we sustain progress or are we losing the war? [Sir John Crofton Memorial Lecture]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1377-1382.	0.6	2
532	The utility of stool cultures for diagnosing tuberculosis in people living with the human immunodeficiency virus. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1023-1028.	0.6	19
533	Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1328-1335.	0.6	57
534	Cough officer' nurses in a general medical clinic successfully detect drug-susceptible and -resistant tuberculosis. Public Health Action, 2013, 3, 46-50.	0.4	6
535	Xpert \hat{A}^{\otimes} MTB/RIF under routine conditions in diagnosing pulmonary tuberculosis: a study in two hospitals in Pakistan [Short communication]. Public Health Action, 2013, 3, 20-22.	0.4	5

#	Article	IF	CITATIONS
536	Diagnostic and prognostic value of serum C-reactive protein for screening for HIV-associated tuberculosis. International Journal of Tuberculosis and Lung Disease, 2013, 17, 636-643.	0.6	54
537	Simple, direct drug susceptibility testing technique for diagnosis of drug-resistant tuberculosis in resource-poor settings. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1212-1216.	0.6	4
538	Point-of-Care Microdevices for Global Health Diagnostics of Infectious Diseases. , 2013, , 115-133.		0
539	Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda. Aids, 2013, 27, 2883-2892.	1.0	34
540	Clinical review: Tuberculosis on the intensive care unit. Critical Care, 2013, 17, 240.	2.5	41
542	Diagnosing Xpert MTB/RIF negative TB: Impact and cost of alternative algorithms for South Africa. South African Medical Journal, 2013, 103, 101.	0.2	27
543	Characteristics of patients with diabetes screened for tuberculosis in a tertiary care hospital in South India. Public Health Action, 2013, 3, 23-28.	0.4	35
544	Advances in tuberculosis. African Journal of Microbiology Research, 2013, 7, 73-81.	0.4	0
545	Rapid Clinical Bacteriology and Its Future Impact. Annals of Laboratory Medicine, 2013, 33, 14-27.	1.2	102
546	Increase in Multidrug-resistant Tuberculosis (MDR-TB) in Alberta Among Foreign-born Persons: Implications for Tuberculosis Management. Canadian Journal of Public Health, 2013, 104, e22-e27.	1.1	13
547	Early and Efficient Detection of Mycobacterium tuberculosis in Sputum by Microscopic Observation of Broth Cultures. PLoS ONE, 2013, 8, e57527.	1.1	21
548	Time to Treatment and Patient Outcomes among TB Suspects Screened by a Single Point-of-Care Xpert MTB/RIF at a Primary Care Clinic in Johannesburg, South Africa. PLoS ONE, 2013, 8, e65421.	1.1	76
549	The High Burden of Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) in a Large Zambian Prison: A Public Health Alert. PLoS ONE, 2013, 8, e67338.	1.1	55
550	Cost-Effectiveness Comparison of Genechip and Conventional Drug Susceptibility Test for Detecting Multidrug-Resistant Tuberculosis in China. PLoS ONE, 2013, 8, e69267.	1.1	12
551	Population-Level Impact of Same-Day Microscopy and Xpert MTB/RIF for Tuberculosis Diagnosis in Africa. PLoS ONE, 2013, 8, e70485.	1.1	22
552	Comparative Evaluation of GenoType MTBDRplus Line Probe Assay with Solid Culture Method in Early Diagnosis of Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Centre in India. PLoS ONE, 2013, 8, e72036.	1.1	61
553	Rapid Molecular Testing for TB to Guide Respiratory Isolation in the U.S.: A Cost-Benefit Analysis. PLoS ONE, 2013, 8, e79669.	1.1	35
554	Recent Advances in Tuberculosis and Nontuberculous Mycobacteria Lung Disease. Tuberculosis and Respiratory Diseases, 2013, 74, 251.	0.7	6

#	Article	IF	CITATIONS
555	Construction of an internal amplification control for Mycobacterium tuberculosis polymerase chain reaction (PCR) test. African Journal of Biotechnology, 2013, 12, 4277-4282.	0.3	0
556	Using Xpert MTB/RIF. Current Respiratory Medicine Reviews, 2013, 9, 187-192.	0.1	16
557	Improving the case detection of pulmonary tuberculosis by bleach microscopy method in the North West of Nigeria. Journal of Medical Laboratory and Diagnosis, 2013, 4, 34-37.	0.3	5
558	Molecular Detection of Fluoroquinolone Resistance in Multidrug-ResistantMycobacterium tuberculosisIsolates. Annals of Clinical Microbiology, 2014, 17, 80.	0.3	2
559	GeneXpert MTB/RIF Testing in the Management of Patients with Active Tuberculosis; A Real Life Experience from Saudi Arabia. Infection and Chemotherapy, 2014, 46, 30.	1.0	10
560	Tuberculous Pleurisy: An Update. Tuberculosis and Respiratory Diseases, 2014, 76, 153.	0.7	64
561	Potential Cost-Effectiveness of a New Infant Tuberculosis Vaccine in South Africa - Implications for Clinical Trials: A Decision Analysis. PLoS ONE, 2014, 9, e83526.	1.1	10
562	Semi-Automated, Occupationally Safe Immunofluorescence Microtip Sensor for Rapid Detection of Mycobacterium Cells in Sputum. PLoS ONE, 2014, 9, e86018.	1.1	8
563	A Reduction in Adult Blood Stream Infection and Case Fatality at a Large African Hospital following Antiretroviral Therapy Roll-Out. PLoS ONE, 2014, 9, e92226.	1.1	30
564	The Sensitivity and Specificity of Using a Computer Aided Diagnosis Program for Automatically Scoring Chest X-Rays of Presumptive TB Patients Compared with Xpert MTB/RIF in Lusaka Zambia. PLoS ONE, 2014, 9, e93757.	1.1	76
565	A Multi-Site Evaluation of Innovative Approaches to Increase Tuberculosis Case Notification: Summary Results. PLoS ONE, 2014, 9, e94465.	1.1	55
566	Availability and Use of Molecular Microbiological and Immunological Tests for the Diagnosis of Tuberculosis in Europe. PLoS ONE, 2014, 9, e99129.	1.1	31
567	Evaluation of Cepheid's Xpert MTB/RIF Test on Pleural Fluid in the Diagnosis of Pleural Tuberculosis in a High Prevalence HIV/TB Setting. PLoS ONE, 2014, 9, e102702.	1.1	33
568	A Comparison of Multidrug-Resistant Tuberculosis Treatment Commencement Times in MDRTBPlus Line Probe Assay and Xpert® MTB/RIF-Based Algorithms in a Routine Operational Setting in Cape Town. PLoS ONE, 2014, 9, e103328.	1.1	51
569	Manufacturer stands by Xpert tuberculosis test after India study questions its reliability. BMJ, The, 2014, 348, g3338-g3338.	3.0	2
570	Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - Report from a third world country. Pakistan Journal of Medical Sciences, 2014, 31, 105-10.	0.3	40
571	Rendimiento de la prueba Xpert MTB/RIF en muestras respiratorias en un escenario real de trabajo de un paÃs en desarrollo. Biomedica, 2014, 35, .	0.3	3
572	QUANTITATIVE REAL-TIME PCR (Q-PCR) FOR SPUTUM SMEAR DIAGNOSIS OF PULMONARY TUBERCULOSIS AMONG PEOPLE WITH HIV/AIDS. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2014, 56, 139-142.	0.5	7

#	Article	IF	CITATIONS
573	Diagnosis and treatment of pulmonary tuberculosis. Journal of the Korean Medical Association, 2014, 57, 19.	0.1	1
574	Diagnosis and treatment of multidrug-resistant tuberculosis. Journal of the Korean Medical Association, 2014, 57, 27.	0.1	4
575	Use of amplified Mycobacterium tuberculosis direct test in respiratory samples from HIV-infected patients in Brazil. Jornal Brasileiro De Pneumologia, 2014, 40, 148-154.	0.4	6
576	Antitubercular therapy in patients with cirrhosis: Challenges and options. World Journal of Gastroenterology, 2014, 20, 5760.	1.4	28
577	Clinical Features and Management of HIV/AIDS. , 2014, , 79-96.e6.		3
578	A Systematic Review on the Effectiveness of Detection of M. tuberculosisand Rifampin Resistance Using Xpert MTB/RIF. Annals of Clinical Microbiology, 2014, 17, 42.	0.3	0
580	Is Xpert MTB/RIF assay in gastric lavage aspirate useful for diagnosis of smear-negative childhood pulmonary tuberculosis?. Indian Pediatrics, 2014, 51, 1007-1011.	0.2	2
581	Evaluation of the modified colorimetric resazurin microtiter plate-based antibacterial assay for rapid and reliable tuberculosis drug susceptibility testing. BMC Microbiology, 2014, 14, 259.	1.3	15
582	Performance evaluation of the Xpert MTB/RIF assay according to its clinical application. BMC Infectious Diseases, 2014, 14, 589.	1.3	15
583	Specific capture of target bacteria onto sensor surfaces for infectious disease diagnosis. Journal of Micromechanics and Microengineering, 2014, 24, 045009.	1.5	3
584	Diagnosis of Childhood Tuberculosis and Host RNA Expression in Africa. New England Journal of Medicine, 2014, 370, 1712-1723.	13.9	324
585	Translating genomics research into control of tuberculosis: lessons learned and future prospects. Genome Biology, 2014, 15, 514.	3.8	2
586	A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 2259-2266.	1.3	12
587	Sensititre MYCOTB MIC Plate for Testing Mycobacterium tuberculosis Susceptibility to First- and Second-Line Drugs. Antimicrobial Agents and Chemotherapy, 2014, 58, 11-18.	1.4	86
588	Rifampicin resistance mutations in the 81Âbp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert®MTB/RIF in Kampala, Uganda: a retrospective study. BMC Infectious Diseases, 2014, 14, 481.	1.3	48
589	Operational modelling to guide implementation and scale-up of diagnostic tests within the health system: exploring opportunities for parasitic disease diagnostics based on example application for tuberculosis. Parasitology, 2014, 141, 1795-1802.	0.7	7
590	Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India. European Respiratory Journal, 2014, 44, 1090-1093.	3.1	53
591	Xpert MTB/RIF Assay Shortens Airborne Isolation for Hospitalized Patients With Presumptive Tuberculosis in the United States. Clinical Infectious Diseases, 2014, 59, 186-192.	2.9	55

#	Article	IF	CITATIONS
592	Initial experience with GeneXpert MTB/RIF assay in the Arkansas Tuberculosis Control Program. Australasian Medical Journal, 2014, 7, 203-207.	0.1	10
593	HIV-Associated Central Nervous System Tuberculosis. Seminars in Neurology, 2014, 34, 103-116.	0.5	18
594	Operational lessons drawn from pilot implementation of Xpert MTB/Rif in Brazil. Bulletin of the World Health Organization, 2014, 92, 613-617.	1.5	13
595	Drug-Resistant Tuberculosis. , 2014, , 1-20.		0
596	The Importance of Implementation Strategy in Scaling Up Xpert MTB/RIF for Diagnosis of Tuberculosis in the Indian Health-Care System: A Transmission Model. PLoS Medicine, 2014, 11, e1001674.	3.9	42
597	Cross-sectional studies of tuberculosis prevalence in Cambodia between 2002 and 2011. Bulletin of the World Health Organization, 2014, 92, 573-581.	1.5	40
598	PCR-Based Techniques for Leprosy Diagnosis: From the Laboratory to the Clinic. PLoS Neglected Tropical Diseases, 2014, 8, e2655.	1.3	90
599	Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial. PLoS Medicine, 2014, 11, e1001766.	3.9	107
600	Impact of the Xpert $<$ SUP $>$ $\hat{A}^{\otimes} <$ /SUP $>$ MTB/RIF molecular test on the late diagnosis of pulmonary tuberculosis [Short Communication]. International Journal of Tuberculosis and Lung Disease, 2014, 18, 435-437.	0.6	14
601	Fast and inexpensive detection of bacterial viability and drug resistance through metabolic monitoring. , 2014, , .		3
602	Performance of Xpert MTB/RIF in the Diagnosis of Tuberculous Mediastinal Lymphadenopathy by Endobronchial Ultrasound. Annals of the American Thoracic Society, 2014, 11, 392-396.	1.5	42
603	False-positive Xpert^{\hat{A}^{\otimes}} MTB/RIF assays in previously treated patients: need for caution in interpreting results. International Journal of Tuberculosis and Lung Disease, 2014, 18, 876-878.	0.6	65
604	Primary drug resistance among pulmonary treatment-na \tilde{A} ve tuberculosis patients in Amazonas State, Brazil. International Journal of Tuberculosis and Lung Disease, 2014, 18, 559-563.	0.6	12
605	Point-of-Care System for Detection of Mycobacterium tuberculosis and Rifampin Resistance in Sputum Samples. Journal of Clinical Microbiology, 2014, 52, 502-507.	1.8	44
606	Impact of three empirical anti-tuberculosis treatment strategies for people initiating antiretroviral therapy. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1340-1346.	0.6	2
607	Value of procalcitonin in differentiating pulmonary tuberculosis from other pulmonary infections: a meta-analysis. International Journal of Tuberculosis and Lung Disease, 2014, 18, 470-477.	0.6	19
608	Pyrosequencing for Rapid Detection of Extensively Drug-Resistant Mycobacterium tuberculosis in Clinical Isolates and Clinical Specimens. Journal of Clinical Microbiology, 2014, 52, 475-482.	1.8	69
609	Manual liquid culture on simple Middlebrook 7H9 or <scp>MGIT</scp> for the diagnosis of smearâ€negative pulmonary tuberculosis. Tropical Medicine and International Health, 2014, 19, 1500-1503.	1.0	5

#	Article	IF	CITATIONS
610	Classical and new assays for detecting drug resistance in tuberculosis. Biomarkers in Medicine, 2014, 8, 1105-1114.	0.6	6
611	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. European Respiratory Journal, 2014, 44, 23-63.	3.1	256
612	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. European Respiratory Journal, 2014, 43, 166-177.	3.1	30
613	Evaluation of the performance of the microscopic observation drug susceptibility assay for diagnosis of extrapulmonary tuberculosis in China: A preliminary study. Respirology, 2014, 19, 132-137.	1.3	6
614	Xpert MTB/RIF for diagnosis of tuberculous cervical lymphadenitis in HIV-infected patients. Laryngoscope, 2014, 124, 1382-1385.	1.1	11
615	Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment. Clinical Microbiology and Infection, 2014, 20, 536-541.	2.8	4
617	Clinical Insights: Tuberculosis Prevention., 2014,,.		0
619	Choosing algorithms for TB screening: a modelling study to compare yield, predictive value and diagnostic burden. BMC Infectious Diseases, 2014, 14, 532.	1.3	49
620	Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons. BMC Public Health, 2014, 14, 22.	1.2	38
621	Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon- \hat{l}^3 in a high burden setting: a prospective study. BMC Medicine, 2014, 12, 101.	2.3	75
622	Multidrug-resistant tuberculosis in Ethiopia: efforts to expand diagnostic services, treatment and care. Antimicrobial Resistance and Infection Control, 2014, 3, 31.	1.5	39
623	Diagnostic Accuracy of a Rapid Urine Lipoarabinomannan Test for Tuberculosis in HIV-Infected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 270-279.	0.9	70
624	Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals. Aids, 2014, 28, 1307-1314.	1.0	43
625	Evaluation of the Xpert MTB/RIF Assay in Gastric Lavage Aspirates for Diagnosis of Smear-negative Childhood Pulmonary Tuberculosis. Pediatric Infectious Disease Journal, 2014, 33, 1047-1051.	1.1	44
626	Diagnostic Delays and Clinical Decision Making With Centralized Xpert MTB/RIF Testing in Durban, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, e88-e93.	0.9	30
627	Rapid Diagnosis of Pediatric Mycobacterial Lymphadenitis Using Fine Needle Aspiration Biopsy. Pediatric Infectious Disease Journal, 2014, 33, 893-896.	1.1	22
628	Impact of GeneXpert MTB/RIF Assay on Triage of Respiratory Isolation Rooms for Inpatients With Presumed Tuberculosis: A Hypothetical Trial. Clinical Infectious Diseases, 2014, 59, 1353-1360.	2.9	40
629	Multiplex SNP detection in multiple codons for accurate drug therapy. Chemical Communications, 2014, 50, 14585-14588.	2.2	6

#	Article	IF	CITATIONS
630	Tuberculous uveitis: an update. Expert Review of Ophthalmology, 2014, 9, 125-137.	0.3	4
631	Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. The Lancet Global Health, 2014, 2, e581-e591.	2.9	55
632	Rifoligotyping assay: an alternative method for rapid detection of rifampicin resistance in \langle i \rangle Mycobacterium tuberculosis \langle i \rangle isolates from Morocco. Biotechnology and Biotechnological Equipment, 2014, 28, 1095-1102.	0.5	4
633	Editorial Commentary: Xpert MTB/RIF Testing for Individuals With Presumed Tuberculosis: Implications for Infection Control and Rapid Tuberculosis Detection in the United States. Clinical Infectious Diseases, 2014, 59, 1361-1363.	2.9	2
634	Pathogen-derived biomarkers for active tuberculosis diagnosis. Frontiers in Microbiology, 2014, 5, 549.	1.5	37
635	Causes and Determinants of Mortality in HIV-Infected Adults With Tuberculosis: An Analysis From the CAMELIA ANRS 1295-CIPRA KH001 Randomized Trial. Clinical Infectious Diseases, 2014, 59, 435-445.	2.9	39
636	Potential for Use of the Seegene Anyplex MTB/NTM Real-Time Detection Assay in a Regional Reference Laboratory. Journal of Clinical Microbiology, 2014, 52, 1708-1710.	1.8	27
637	The urgent need for clinical, diagnostic, and operational research for management of Buruli ulcer in Africa. Lancet Infectious Diseases, The, 2014, 14, 435-440.	4.6	31
638	Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2811-2814.	1.0	36
639	Tuberculosis of the eye in Italy: a forgotten extrapulmonary localization. Infection, 2014, 42, 335-342.	2.3	23
640	Extrapulmonary tuberculosis. Medicine, 2014, 42, 18-22.	0.2	28
641	A prospective audit of the use of diagnostic laparoscopy to establish the diagnosis of abdominal tuberculosis. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 1895-1901.	1.3	7
642	Evaluation of Fluorotype MTB for detection of Mycobacterium tuberculosis complex DNA in clinical specimens from a low-incidence country. BMC Infectious Diseases, 2014, 14, 59.	1.3	27
644	Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infectious Diseases, 2014, 14, 2.	1.3	144
645	Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. Journal of Infection and Public Health, 2014, 7, 75-91.	1.9	73
646	Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respiratory Medicine, the, 2014, 2, 321-338.	5.2	237
647	Comparison of Xpert MTB/RIF with Line Probe Assay for Detection of Rifampin-Monoresistant Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2014, 52, 1846-1852.	1.8	120
648	Evaluation of GeneXpert MTB/RIF for Diagnosis of Tuberculous Meningitis. Journal of Clinical Microbiology, 2014, 52, 226-233.	1.8	181

#	Article	IF	CITATIONS
649	Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis. Expert Review of Anti-Infective Therapy, 2014, 12, 633-647.	2.0	100
650	Diagnostic point-of-care tests in resource-limited settings. Lancet Infectious Diseases, The, 2014, 14, 239-249.	4.6	525
651	Diagnostic Accuracy of Xpert MTB/RIF for Extrapulmonary Tuberculosis Specimens: Establishing a Laboratory Testing Algorithm for South Africa. Journal of Clinical Microbiology, 2014, 52, 1818-1823.	1.8	93
653	Emerging technologies for hybridization based single nucleotide polymorphism detection. Analyst, The, 2014, 139, 353-370.	1.7	61
654	Automatic Tuberculosis Screening Using Chest Radiographs. IEEE Transactions on Medical Imaging, 2014, 33, 233-245.	5.4	403
655	Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet, The, 2014, 383, 424-435.	6.3	379
656	A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis, 2014, 94, 105-110.	0.8	103
657	Rapid Detection of Mycobacterium tuberculosis and Pyrazinamide Susceptibility Related to <i>pncA</i> Mutations in Sputum Specimens through an Integrated Gene-to-Protein Function Approach. Journal of Clinical Microbiology, 2014, 52, 260-267.	1.8	8
658	Pediatric and Adolescent Urologic Imaging. , 2014, , .		5
659	Serologic diagnosis of tuberculosis by combining Ig classes against selected mycobacterial targets. Journal of Infection, 2014, 69, 581-589.	1.7	45
660	Host RNA signatures for diagnostics: An example from paediatric tuberculosis inÂAfrica. Journal of Infection, 2014, 69, S28-S31.	1.7	16
661	Invasive Diagnostic Strategies in Immunosuppressed Patients with Acute Respiratory Distress Syndrome. Clinics in Chest Medicine, 2014, 35, 697-712.	0.8	5
662	Near-Infrared, Surface-Enhanced Fluorescence Using Silver Nanoparticle Aggregates in Solution. Plasmonics, 2014, 9, 27-34.	1.8	13
663	Tuberculosis: the problem of multiresistance. , 2014, , 199-211.		0
664	Xpert MTB/RIF: The newly endorsed TB diagnostic. Pediatric Infectious Disease, 2014, 6, 75-78.	0.1	1
665	An Automated Screening System for Tuberculosis. IEEE Journal of Biomedical and Health Informatics, 2014, 18, 855-862.	3.9	19
666	Mixed Mycobacterium tuberculosis Complex Infections and False-Negative Results for Rifampin Resistance by GeneXpert MTB/RIF Are Associated with Poor Clinical Outcomes. Journal of Clinical Microbiology, 2014, 52, 2422-2429.	1.8	114
667	Label-free Molecular Beacons for Biomolecular Detection. Analytical Chemistry, 2014, 86, 10864-10869.	3.2	73

#	Article	IF	CITATIONS
668	Economic challenges associated with tuberculosis diagnostic development. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 499-510.	0.7	4
669	On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resistance Updates, 2014, 17, 105-123.	6.5	33
670	Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand. BMC Microbiology, 2014, 14, 165.	1.3	54
671	Evaluation of a microcolony growth monitoring method for the rapid determination of ethambutol resistance in Mycobacterium tuberculosis. BMC Infectious Diseases, 2014, 14, 380.	1.3	3
672	Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa. BMC Infectious Diseases, 2014, 14, 442.	1.3	30
673	Delays in diagnosis and treatment of pulmonary tuberculosis in Wakiso and Mukono districts, Uganda. BMC Public Health, 2014, 14, 586.	1.2	49
674	Retrospective observational study of diagnostic accuracy of the Xpert® MTB/RIF assay on fiberoptic bronchoscopy sampling for early diagnosis of smear-negative or sputum-scarce patients with suspected tuberculosis. BMC Pulmonary Medicine, 2014, 14, 137.	0.8	45
675	Emerging Technologies for the Clinical Microbiology Laboratory. Clinical Microbiology Reviews, 2014, 27, 783-822.	5.7	236
676	Current Treatment Options in Tuberculosis. Current Treatment Options in Infectious Diseases, 2014, 6, 456-468.	0.8	0
677	ATS Core Curriculum 2014: Part I. Adult Pulmonary Medicine. Annals of the American Thoracic Society, 2014, 11, 1136-1144.	1.5	5
679	Update on Opportunistic Infections in the Era of Effective Antiretroviral Therapy. Infectious Disease Clinics of North America, 2014, 28, 501-518.	1.9	27
680	Xpert \hat{A}^{\otimes} MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Library, 2014, , CD009593.	1.5	660
681	Rapid Detection of Isoniazid Resistance in Mycobacterium tuberculosis Isolates by Use of Real-Time-PCR-Based Melting Curve Analysis. Journal of Clinical Microbiology, 2014, 52, 1644-1652.	1.8	35
682	Sequence analysis for detection of drug resistance in Mycobacterium tuberculosis complex isolates from the Central Region of Cameroon. BMC Microbiology, 2014, 14, 113.	1.3	17
683	Rapid optical determination of Î ² -lactamase and antibiotic activity. BMC Microbiology, 2014, 14, 84.	1.3	29
684	Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed hiv-infected adults: a prospective, clinic-based study. BMC Infectious Diseases, 2014, 14, 110.	1.3	37
685	MicrobiologÃa de la tuberculosis. Seminarios De La Fundaciâ^šâ‰¥n Espaâ^šÂ±ola De Reumatologâ^šâ‰a, 2014, 25-33.	15 0.1	1
686	Multicenter Feasibility Study To Assess External Quality Assessment Panels for Xpert MTB/RIF Assay in South Africa. Journal of Clinical Microbiology, 2014, 52, 2493-2499.	1.8	26

#	Article	IF	Citations
687	Impact of GeneXpert MTB/RIF on Patients and Tuberculosis Programs in a Low-Burden Setting. A Hypothetical Trial. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1551-1559.	2.5	37
688	Childhood tuberculosis in southern Taiwan, with emphasis on central nervous system complications. Journal of Microbiology, Immunology and Infection, 2014, 47, 503-511.	1.5	10
689	Evaluation of the AID TB Resistance Line Probe Assay for Rapid Detection of Genetic Alterations Associated with Drug Resistance in Mycobacterium tuberculosis Strains. Journal of Clinical Microbiology, 2014, 52, 940-946.	1.8	38
690	Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia. Tuberculosis, 2014, 94, 502-505.	0.8	30
691	Evaluation of the Indian TrueNAT micro RT-PCR device with GeneXpert for case detection of pulmonary tuberculosis. International Journal of Mycobacteriology, 2014, 3, 205-210.	0.3	54
692	Molecular Diagnosis of Tuberculosis and Drug Resistance. Clinics in Laboratory Medicine, 2014, 34, 297-314.	0.7	26
693	Evaluation of Two Line Probe Assays for Rapid Detection of Mycobacterium tuberculosis, Tuberculosis (TB) Drug Resistance, and Non-TB Mycobacteria in HIV-Infected Individuals with Suspected TB. Journal of Clinical Microbiology, 2014, 52, 1052-1059.	1.8	42
694	Evaluation of GeneXpert MTB/RIF for the detection of Mycobacterium tuberculosis and resistance to rifampin in clinical specimens. Journal of Infection, 2014, 68, 338-343.	1.7	44
695	Extensively drug-resistant tuberculosis: epidemiology and management. Clinical Epidemiology, 2014, 6, 111.	1.5	98
696	Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray. Journal of Visualized Experiments, 2014, , .	0.2	4
697	The Molecular Genetics of Fluoroquinolone Resistance in <i>Mycobacterium tuberculosis</i> Microbiology Spectrum, 2014, 2, MGM2-0009-2013.	1.2	28
698	Medical diagnosis – the promise. Diagnosis, 2014, 1, 5-9.	1.2	6
700	Sputum induction for tuberculosis diagnosis in an Arctic setting: a cost comparison. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1223-1230.	0.6	7
701	Rapid Detection of Mycobacterium tuberculosis Using a Novel Ultrafast Chip-Type Real-Time Polymerase Chain Reaction System. Chest, 2014, 146, 1319-1326.	0.4	10
702	Chest X-ray vs. Xpert® MTB/RIF assay for the diagnosis of sputum smear-negative tuberculosis in Uganda. International Journal of Tuberculosis and Lung Disease, 2014, 18, 216-219.	0.6	14
703	Diagnostic accuracy and clinical role of rapid C-reactive protein testing in HIV-infected individuals with presumed tuberculosis in South Africa. International Journal of Tuberculosis and Lung Disease, 2014, 18, 20-26.	0.6	42
704	Practical biosafety in the tuberculosis laboratory: containment at the source is what truly counts. International Journal of Tuberculosis and Lung Disease, 2014, 18, 885-889.	0.6	11
705	Patient costs for the diagnosis of tuberculosis in Brazil: comparison of Xpert $<$ SUP $>$ $\hat{A}^{\otimes}<$ /SUP $>$ MTB/RIF and smear microscopy. International Journal of Tuberculosis and Lung Disease, 2014, 18, 547-551.	0.6	10

#	Article	IF	CITATIONS
706	Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis. International Journal of Tuberculosis and Lung Disease, 2014, 18, 647-654.	0.6	11
707	Impact of changing diagnostic criteria for smear-positive tuberculosis: a cohort study in Malawi. International Journal of Tuberculosis and Lung Disease, 2014, 18, 843-846.	0.6	4
708	Comparable characteristics of tuberculous and non-tuberculous mycobacterial cavitary lung diseases. International Journal of Tuberculosis and Lung Disease, 2014, 18, 725-729.	0.6	24
709	High time to use rapid tests to detect multidrug resistance in sputum smear-negative tuberculosis in Belarus. Public Health Action, 2014, 4, 243-248.	0.4	7
710	Rollout of Xpert<SUP> \hat{A} & lt;/SUP> MTB/RIF in Northwest Cambodia for the diagnosis of tuberculosis among PLHA. Public Health Action, 2014, 4, 216-221.	0.4	7
711	Is introducing rapid culture into the diagnostic algorithm of smear-negative tuberculosis cost-effective?. International Journal of Tuberculosis and Lung Disease, 2014, 18, 541-546.	0.6	7
712	Xpert ^{\hat{A}^{\otimes}} MTB/RIF assay for tuberculosis diagnosis: evaluation in an Indian setting. International Journal of Tuberculosis and Lung Disease, 2014, 18, 958-960.	0.6	8
713	Mycobacteriumdiagnostics: from the primitive to the promising. British Journal of Biomedical Science, 2015, 72, 32-41.	1.2	9
714	Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana–findings from the DETECT HIV-TB study. BMC Infectious Diseases, 2015, 15, 407.	1.3	50
717	Drug-resistant tuberculosis in HIV-infected patients in a national referral hospital, Phnom Penh, Cambodia. Global Health Action, 2015, 8, 25964.	0.7	5
718	Evaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis. Journal of the Royal Society Interface, 2015, 12, 20150146.	1.5	9
719	Screening for Tuberculosis Among Adults Newly Diagnosed With HIV in Sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 83-90.	0.9	17
720	The 100 top-cited tuberculosis research studies. International Journal of Tuberculosis and Lung Disease, 2015, 19, 717-722.	0.6	26
721	The arrival of a true point-of-care molecular assayâ€"ready for global implementation?. The Lancet Global Health, 2015, 3, e663-e664.	2.9	33
722	Countrywide roll-out of Xpert^{\hat{A}^{\otimes}} MTB/RIF in Swaziland: the first three years of implementation. Public Health Action, 2015, 5, 140-146.	0.4	23
723	Xpert MTB/RIF assay can be used on archived gastric aspirate and induced sputum samples for sensitive diagnosis of paediatric tuberculosis. BMC Microbiology, 2015, 15, 191.	1.3	46
724	Assessing the effect of decentralisation of laboratory diagnosis for drug-resistant tuberculosis in Kenya. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1348-1353.	0.6	4
725	Tuberculous endocarditis in an immunocompetent host without miliary tuberculosis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1407-1408.	0.6	2

#	ARTICLE	IF	CITATIONS
726	Newer rapid TB diagnostic tests: why the uptake is low in India's private sector. Public Health Action, 2015, 5, 89-89.	0.4	1
727	Impact of intensified case-finding strategies on childhood TB case registration in Nepal. Public Health Action, 2015, 5, 93-98.	0.4	25
728	In reply. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1406-1407.	0.6	0
729	Characteristics of tuberculosis patients and the evaluation of compliance to the national TB management guidelines at clinics in a rural community from Mpumalanga province, South Africa. Southern African Journal of Infectious Diseases, 2015, 31, 135-137.	0.3	0
730	Current Trends in Point-of-Care Testing for Syphilis and Tuberculosis in Developing Countries. Point of Care, 2015, 14, 73-75.	0.5	0
731	Changes in Diagnostic Methods for Pulmonary Tuberculosis between 2005 and 2013. Tuberculosis and Respiratory Diseases, 2015, 78, 227.	0.7	4
732	Ensayo Xpert MTB/RIF en el diagn \tilde{A}^3 stico de tuberculosis. Revista Chilena De Enfermedades Respiratorias, 2015, 31, 127-131.	0.1	7
733	Applicability of Xpert MTB/RIF assay for routine diagnosis of tuberculosis: a four-year single-center experience. Turkish Journal of Medical Sciences, 2015, 45, 1329-1334.	0.4	11
734	Mycobacterium tuberculosis., 2015, , 2787-2818.e5.		20
735	Incremental detection of pulmonary tuberculosis among presumptive patients by GeneXpert MTB/RIF® over fluorescent microscopy in Mwanza, Tanzania: an operational study. Healthcare in Low-resource Settings, 2015, 3, .	0.0	3
736	Tuberculous Pleural Effusion. Turk Toraks Dergisi, 2015, 16, 1-9.	0.2	30
737	Review on convectional and advanced diagnostic techniques of human tuberculosis. Journal of Medical Laboratory and Diagnosis, 2015, 6, 9-16.	0.3	2
738	Diagnosis of Pulmonary Tuberculosis: Recent Advances and Diagnostic Algorithms. Tuberculosis and Respiratory Diseases, 2015, 78, 64.	0.7	152
739	Biomarker discovery for diagnosis and treatment of tuberculosis: a role for biobanking?. Journal of Biorepository Science for Applied Medicine, 2015, , 47.	0.2	1
740	Impact on Patients' Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial. PLoS ONE, 2015, 10, e0123252.	1.1	40
741	Validity of Antibodies in Lymphocyte Supernatant in Diagnosing Tuberculosis in Severely Malnourished Children Presenting with Pneumonia. PLoS ONE, 2015, 10, e0126863.	1.1	8
742	A Controlled Study of Tuberculosis Diagnosis in HIV-Infected and Uninfected Children in Peru. PLoS ONE, 2015, 10, e0120915.	1.1	12
743	Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a "Low-Level―rpoB Mutation L511P – Insights into a Mechanism of Resistance Escalation. PLoS ONE, 2015, 10, e0129207.	1.1	15

#	ARTICLE	IF	CITATIONS
744	Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis. PLoS ONE, 2015, 10, e0136861.	1.1	34
745	GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings. PLoS ONE, 2015, 10, e0137471.	1.1	47
746	Evaluating the Diagnostic Accuracy of Xpert MTB/RIF Assay in Pulmonary Tuberculosis. PLoS ONE, 2015, 10, e0141011.	1.1	97
747	Estimation of D-Arabinose by Gas Chromatography/Mass Spectrometry as Surrogate for Mycobacterial Lipoarabinomannan in Human Urine. PLoS ONE, 2015, 10, e0144088.	1.1	23
748	Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries. PLoS ONE, 2015, 10, e0144656.	1.1	44
749	The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa. PLoS ONE, 2015, 10, e0145796.	1.1	10
750	Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. PLoS ONE, 2015, 10, e0145380.	1.1	19
751	Comparison of Xpert MTB/RIF Assay and the Conventional Sputum Microscopy in DetectingMycobacterium tuberculosisin Northern Thailand. Tuberculosis Research and Treatment, 2015, 2015, 1-6.	0.2	24
752	A Rapid and Sensitive Diagnostic Screening Assay for Detection of Mycobacteria Including Mycobacterium tuberculosis Directly from Sputum without Extraction. International Journal of Bacteriology, 2015, 2015, 1-8.	1.0	2
753	Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies. Advances in Medicine, 2015, 2015, 1-10.	0.3	24
754	The Application of GeneXpert MTB/RIF for Smear-Negative TB Diagnosis as a Fee-Paying Service at a South Asian General Hospital. Tuberculosis Research and Treatment, 2015, 2015, 1-6.	0.2	14
755	Newer initiatives in revised national tuberculosis control programme and its current implementation status. Asian Journal of Medical Sciences, 2015, 6, 1-8.	0.0	1
756	The Effectiveness of Real-Time PCR Assay, Compared with Microbiologic Results for the Diagnosis of Pulmonary Tuberculosis. Tuberculosis and Respiratory Diseases, 2015, 78, 1.	0.7	4
757	Contemporary molecular approaches in the clinical microbiology laboratory: progress and pitfalls. Pathology, 2015, 47, 189-190.	0.3	0
758	Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients. Scientific Reports, 2015, 5, 8668.	1.6	62
7 59	Editorial Commentary: Contact Tracing in Children Exposed to an Index Case of Tuberculosis: The Need, the Challenge, and the Impact. Clinical Infectious Diseases, 2015, 60, 19-20.	2.9	1
760	Discovery, Innovation, and New Frontiers in Tuberculosis Diagnostics: Reflections and Expectations. Journal of Infectious Diseases, 2015, 211, S78-S80.	1.9	6
761	Biomarkers for Tuberculosis Based on Secreted, Species-Specific, Bacterial Small Molecules. Journal of Infectious Diseases, 2015, 212, 1827-1834.	1.9	20

#	Article	IF	CITATIONS
762	Amperometric immunosensor for rapid detection of <i>Mycobacterium tuberculosis</i> . Journal of Micromechanics and Microengineering, 2015, 25, 055013.	1.5	21
763	Simulation-guided DNA probe design for consistently ultraspecific hybridization. Nature Chemistry, 2015, 7, 545-553.	6.6	131
764	Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. Health Technology Assessment, 2015, 19, 1-188.	1.3	74
765	The Feasibility, Accuracy, and Impact of Xpert MTB/RIF Testing in a Remote Aboriginal Community in Canada. Chest, 2015, 148, 767-773.	0.4	10
766	Identification of miR $\hat{a} \in 93$ as a suitable miR for normalizing miRNA in plasma of tuberculosis patients. Journal of Cellular and Molecular Medicine, 2015, 19, 1606-1613.	1.6	36
767	Xpert [®] MTB/RIF and very low positive detection in bronchoalveolar lavage: diagnostic concerns. International Journal of Tuberculosis and Lung Disease, 2015, 19, 871-873.	0.6	1
768	Detection of Mycobacterium tuberculosis (MTB) in Fecal Specimens From Adults Diagnosed With Pulmonary Tuberculosis Using the Xpert MTB/Rifampicin Test. Open Forum Infectious Diseases, 2015, 2, ofv074.	0.4	25
769	Understanding the incremental value of novel diagnostic tests for tuberculosis. Nature, 2015, 528, S60-S67.	13.7	114
770	Urine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region: a prospective cohort study. BMJ Open, 2015, 5, e006833-e006833.	0.8	29
771	The channel capacity of a diagnostic test as a function of test sensitivity and test specificity. Statistical Methods in Medical Research, 2015, 24, 1044-1052.	0.7	8
772	Molecular detection of <l>Mycobacterium tuberculosis</l> from sputum transported in PrimeStore [®] from rural settings. International Journal of Tuberculosis and Lung Disease, 2015, 19, 552-557.	0.6	9
773	Structural measurements and cell line studies of the copper–PEG–Amikacin complex against Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5825-5830.	1.0	7
775	Routine use of Xpert ^{\hat{A}^{\otimes}} MTB/RIF in areas with different prevalences of HIV and drug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1078-1083.	0.6	8
776	Impact of point-of-care implementation of Xpert $\langle SUP \rangle \hat{A}^{\otimes} \langle SUP \rangle MTB/RIF$: product vs. process innovation. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1084-1090.	0.6	13
777	Assessment of terbium (III) as a luminescent probe for the detection of tuberculosis biomarkers. Analytica Chimica Acta, 2015, 896, 143-151.	2.6	3
778	Introducing new tuberculosis diagnostics: the impact of Xpert [®] MTB/RIF testing on case notifications in Nepal. International Journal of Tuberculosis and Lung Disease, 2015, 19, 545-551.	0.6	41
779	Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease. Tuberculosis, 2015, 95, 179-185.	0.8	20
780	Stemming the tide of drug-resistant Neisseria gonorrhoeae: the need for an individualized approach to treatment. Journal of Antimicrobial Chemotherapy, 2015, 70, 374-381.	1.3	41

#	Article	IF	CITATIONS
781	Detection of Mycobacterium tuberculosis Genome in Vitreous Fluid of Eyes with Multifocal Serpiginoid Choroiditis. Ophthalmology, 2015, 122, 840-850.	2.5	42
782	Antibody modified gold nano-mushroom arrays for rapid detection of alpha-fetoprotein. Biosensors and Bioelectronics, 2015, 68, 468-474.	5.3	77
783	A rapid amplification/detection assay for analysis of Mycobacterium tuberculosis using an isothermal and silicon bio-photonic sensor complex. Biosensors and Bioelectronics, 2015, 68, 390-396.	5.3	41
784	Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens. Microbiology and Molecular Biology Reviews, 2015, 79, 101-116.	2.9	183
786	Novel <i>katG</i> mutations causing isoniazid resistance in clinical <i>M. tuberculosis</i> livisolates. Emerging Microbes and Infections, 2015, 4, 1-9.	3.0	95
787	Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Lancet Respiratory Medicine.the. 2015. 3. 621-630.	5.2	40
788	Detection of Drug-Resistant Tuberculosis by Xpert MTB/RIF in Swaziland. New England Journal of Medicine, 2015, 372, 1181-1182.	13.9	146
789	Incubation time of Mycobacterium tuberculosis complex sputum cultures in BACTEC MGIT 960: 4weeks of negative culture is enough for physicians to consider alternative diagnoses. Diagnostic Microbiology and Infectious Disease, 2015, 83, 162-164.	0.8	9
790	Implementing a Large-Scale Systematic Tuberculosis Screening Program in Correctional Facilities in South Africa. Open Forum Infectious Diseases, 2015, 2, ofu121.	0.4	13
791	A rapid and non-invasive 2-step algorithm for diagnosing tuberculous peritonitis using a T cell-based assay on peripheral blood and peritoneal fluid mononuclear cells together with peritoneal fluid adenosine deaminase. Journal of Infection, 2015, 70, 356-366.	1.7	16
792	"Paper Machine―for Molecular Diagnostics. Analytical Chemistry, 2015, 87, 7595-7601.	3.2	260
793	Cost-effectiveness analysis of the Xpert MTB/RIF assay for rapid diagnosis of suspected tuberculosis in an intermediate burden area. Journal of Infection, 2015, 70, 409-414.	1.7	17
794	Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. The Lancet Global Health, 2015, 3, e450-e457.	2.9	179
795	The Xpert \hat{A}^{\otimes} MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania. Respiratory Medicine, 2015, 109, 1484-1489.	1.3	11
796	Development and evaluation of a rapid multiplex-PCR based system for Mycobacterium tuberculosis diagnosis using sputum samples. Journal of Microbiological Methods, 2015, 116, 37-43.	0.7	12
797	Xpert MTB/RIF and GenoType MTBDRplus assays for the rapid diagnosis of bone and joint tuberculosis. International Journal of Infectious Diseases, 2015, 36, 27-30.	1.5	60
798	Tuberculosis control and economic recession: longitudinal study of data from 21 European countries, 1991–2012. Bulletin of the World Health Organization, 2015, 93, 369-379.	1.5	25
799	Tuberculosis as a Force Health Protection Threat to the United States Military. Military Medicine, 2015, 180, 276-284.	0.4	8

#	Article	IF	Citations
800	Xpert MTB/RIF to diagnose tuberculosis in children. Lancet Respiratory Medicine, the, 2015, 3, 419-421.	5.2	3
801	Discordance between Xpert MTB/RIF Assay and Bactec MGIT 960 Culture System for Detection of Rifampin-Resistant Mycobacterium tuberculosis Isolates in a Country with a Low Tuberculosis (TB) Incidence. Journal of Clinical Microbiology, 2015, 53, 1351-1354.	1.8	43
802	A feasibility study of the Xpert MTB/RIF test at the peripheral level laboratory in China. International Journal of Infectious Diseases, 2015, 31, 41-46.	1.5	23
803	Implementing rapid testing for tuberculosis in Mozambique. Bulletin of the World Health Organization, 2015, 93, 125-130.	1.5	22
804	Improving the Sensitivity of the Xpert MTB/RIF Assay on Sputum Pellets by Decreasing the Amount of Added Sample Reagent: a Laboratory and Clinical Evaluation. Journal of Clinical Microbiology, 2015, 53, 1258-1263.	1.8	4
805	Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial. Trials, 2015, 16, 125.	0.7	13
806	Rapid electrochemical phenotypic profiling of antibiotic-resistant bacteria. Lab on A Chip, 2015, 15, 2799-2807.	3.1	90
807	A novel method for diagnosis of smear-negative tuberculosis patients by combining a random unbiased Phi29 amplification with a specific real-time PCR. Tuberculosis, 2015, 95, 411-414.	0.8	4
808	Integration of Published Information Into a Resistance-Associated Mutation Database for Mycobacterium tuberculosis. Journal of Infectious Diseases, 2015, 211, S50-S57.	1.9	32
809	Radioiodinated DPA-713 Imaging Correlates with Bactericidal Activity of Tuberculosis Treatments in Mice. Antimicrobial Agents and Chemotherapy, 2015, 59, 642-649.	1.4	53
810	Detection of drug resistance in Mycobacterium tuberculosis: Methods, principles and applications. Indian Journal of Tuberculosis, 2015, 62, 13-22.	0.3	7
811	A Novel Reporter Phage To Detect Tuberculosis and Rifampin Resistance in a High-HIV-Burden Population. Journal of Clinical Microbiology, 2015, 53, 2188-2194.	1.8	24
812	MTB-DR-RIF 9G membrane: a platform for multiplex SNP detection of multidrug-resistant TB. Analytical and Bioanalytical Chemistry, 2015, 407, 5739-5745.	1.9	2
813	Value of Urine Lipoarabinomannan Grade and Second Test for Optimizing Clinic-Based Screening for HIV-Associated Pulmonary Tuberculosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 274-280.	0.9	23
814	New tuberculosis diagnostics and rollout. International Journal of Infectious Diseases, 2015, 32, 81-86.	1.5	46
815	Ventilator associated pneumonia in the ICU. Current Opinion in Pulmonary Medicine, 2015, 21, 226-231.	1.2	22
816	A Microbiological Revolution Meets an Ancient Disease: Improving the Management of Tuberculosis with Genomics. Clinical Microbiology Reviews, 2015, 28, 523-539.	5.7	32
817	Impact of the Xpert MTB/RIF diagnostic test for tuberculosis in countries with a high burden of disease. Current Opinion in Pulmonary Medicine, 2015, 21, 304-308.	1.2	20

#	Article	IF	CITATIONS
818	MTB-DR-RIF 9G test: Detection and discrimination of tuberculosis andÂmulti-drug resistant tuberculosis strains. Tuberculosis, 2015, 95, 780-785.	0.8	3
819	Advances in the diagnosis of tuberculosis: current status and future prospects. International Journal of Tuberculosis and Lung Disease, 2015, 19, 504-516.	0.6	22
820	Host Protein Biomarkers Identify Active Tuberculosis in HIV Uninfected and Co-infected Individuals. EBioMedicine, 2015, 2, 1160-1168.	2.7	50
821	Stopping tuberculosis: a biosocial model for sustainable development. Lancet, The, 2015, 386, 2354-2362.	6.3	81
822	Evaluation of Xpert [®] MTB/RIF assay: diagnosis and treatment outcomes in rifampicin-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1216-1221.	0.6	19
823	Psychological distress and its relationship with non-adherence to TB treatment: a multicentre study. BMC Infectious Diseases, $2015, 15, 253$.	1.3	49
824	Genotype-independent association between profound vitamin D deficiency and delayed sputum smear conversion in pulmonary tuberculosis. BMC Infectious Diseases, 2015, 15, 275.	1.3	13
826	Advances in Diagnostic Assays for Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a017806.	2.9	13
827	How Next-Generation Sequencing and Multiscale Data Analysis Will Transform Infectious Disease Management. Clinical Infectious Diseases, 2015, 61, civ670.	2.9	32
828	Diagnostic accuracy of nucleic acid amplification tests in urine for pulmonary tuberculosis: a meta-analysis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1339-1347.	0.6	15
829	Pooling sputum from multiple individuals for Xpert< SUP> \hat{A} & & lt; /SUP> MTB/RIF testing: a strategy for screening high-risk populations. International Journal of Tuberculosis and Lung Disease, 2015, 19, 87-90.	0.6	12
830	Improved diagnosis of childhood tuberculous meningitis using more than one nucleic acid amplification test. International Journal of Tuberculosis and Lung Disease, 2015, 19, 74-80.	0.6	41
832	Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention. International Journal of Tuberculosis and Lung Disease, 2015, 19, 5-9.	0.6	20
833	The impact of Xpert [®] MTB/RIF in sparsely populated rural settings. International Journal of Tuberculosis and Lung Disease, 2015, 19, 392-398.	0.6	26
834	Diagnostic accuracy of the Xpert (sup > \hat{A} $^{\circ}$ (/sup > MTB/RIF assay for extra-pulmonary tuberculosis: a meta-analysis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 278-284.	0.6	83
835	Markers to differentiate between Kaposi's sarcoma and tuberculous pleural effusions in HIV-positive patients. International Journal of Tuberculosis and Lung Disease, 2015, 19, 144-150.	0.6	9
836	Transformative tools for tackling tuberculosis. Journal of Experimental Medicine, 2015, 212, 1759-1769.	4.2	37
837	Accuracy of the Xpert^{\hat{A}^{\otimes}} MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. International Journal of Tuberculosis and Lung Disease, 2015, 19, 81-86.	0.6	29

#	Article	IF	CITATIONS
838	False-positive Xpert< SUP> \hat{A} & & lt; /SUP> MTB/RIF assays and previous treatment. International Journal of Tuberculosis and Lung Disease, 2015, 19, 495-496.	0.6	6
839	Radiology of Infectious Diseases: Volume 2. , 2015, , .		1
840	Suboptimal specificity of Xpert MTB/RIF among treatment-experienced patients. European Respiratory Journal, 2015, 45, 1504-1506.	3.1	19
841	Extensively drug-resistant tuberculosis in a young child after travel to India. Lancet Infectious Diseases, The, 2015, 15, 1485-1491.	4.6	36
842	Structural measurements and cell line studies of the copper–PEG–Rifampicin complex against Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 451-458.	1.0	10
843	Clinical Immunology and Multiplex Biomarkers of Human Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a018515-a018515.	2.9	32
844	Comparison of Three Molecular Assays for the Detection of Rifampin Resistance in Mycobacterium tuberculosis. Journal of Clinical Laboratory Analysis, 2015, 29, 142-145.	0.9	4
845	Port Site Tuberculosis Presenting as Nonhealing Sinus After Laparoscopic Appendicectomy. Indian Journal of Surgery, 2015, 77, 735-737.	0.2	0
846	Dramatic reduction of culture time of Mycobacterium tuberculosis. Scientific Reports, 2014, 4, 4236.	1.6	57
848	Mycobacterium tuberculosis., 2015,, 1637-1653.		2
849	Evaluation of GeneXpert MTB/RIF assay for direct diagnosis of pulmonary tuberculosis. Journal of King Abdulaziz University, Islamic Economics, 2016, 37, 1076-1081.	0.5	13
850	T7 Phage Display Library a Promising Strategy to Detect Tuberculosis Specific Biomarkers. Mycobacterial Diseases: Tuberculosis & Leprosy, 2016, 6, .	0.1	7
851	Diagnostic Accuracy of Xpert MTB/RIF Assay in Diagnosis of Pulmonary Tuberculosis. Journal of Infectious Diseases and Treatment, 2016, 2, .	0.0	1
852	Tuberculosis Biomarkers: From Diagnosis to Protection. Gastroenterology Insights, 2016, 8, 6568.	0.7	129
853	Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. International Journal of Tuberculosis and Lung Disease, 2016, 20, 999-1003.	0.6	26
854	Accurate Detection of Rifampicin-Resistant Mycobacterium Tuberculosis Strains. Sensors, 2016, 16, 376.	2.1	2
855	Issues Related to the Updated 2014 Korean Guidelines for Tuberculosis. Tuberculosis and Respiratory Diseases, 2016, 79, 1.	0.7	8
856	Laboratory systems as an antibacterial resistance containment tool in Africa. African Journal of Laboratory Medicine, 2016, 5, 497.	0.2	8

#	Article	IF	Citations
857	The reliability analysis of Xpert-positive result for smear-negative and culture-negative specimen collected from bone and joint tuberculosis suspects. Journal of Thoracic Disease, 2016, 8, 1205-1209.	0.6	11
858	XPERT MYCOBACTERIUM TUBERCULOSIS/RIFAMPICIN ASSAY: A BOON IN TUBERCULOSIS DIAGNOSTICS. Asian Journal of Pharmaceutical and Clinical Research, 2016, 9, 225.	0.3	7
859	Assessment of Gene-Xpert MTB RIF Program Implementation and the Challenges For Enhanced Tuberculosis Diagnosis in Nigeria. SAARC Journal of Tuberculosis Lung Diseases and HIV/AIDS, 2016, 12, 1-7.	0.1	8
861	Utilisation du test GeneXpert pour le diagnostic de la tuberculose au service des maladies infectieuses du CHNU de Fann. Pan African Medical Journal, 2016, 23, .	0.3	5
862	Multi-Fluorescence Real-Time PCR Assay for Detection of RIF and INH Resistance of M. tuberculosis. Frontiers in Microbiology, 2016, 7, 618.	1.5	11
863	Sub-optimal Specificity of Modified Ziehl-Neelsen Staining for Quick Identification of Tuberculous Meningitis. Frontiers in Microbiology, 2016, 7, 2096.	1.5	6
864	Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda. BMC Health Services Research, 2016, 16, 563.	0.9	7
865	Discordance between MTB/RIF and Real-Time Tuberculosis-Specific Polymerase Chain Reaction Assay in Bronchial Washing Specimen and Its Clinical Implications. PLoS ONE, 2016, 11, e0164923.	1.1	13
866	Performance of the GeneXpert Ebola Assay for Diagnosis of Ebola Virus Disease in Sierra Leone: A Field Evaluation Study. PLoS Medicine, 2016, 13, e1001980.	3.9	67
867	Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB. PLoS ONE, 2016, 11, e0160062.	1.1	35
868	Mycobacterium tuberculosis: clinical and microbiological aspects. , 2016, , 153-166.		0
869	A Large Cohort Study on the Clinical Value of Simultaneous Amplification and Testing for the Diagnosis of Pulmonary Tuberculosis. Medicine (United States), 2016, 95, e2597.	0.4	18
871	Limited value of whole blood Xpert® MTB/RIF for diagnosing tuberculosis in children. Journal of Infection, 2016, 73, 326-335.	1.7	7
872	Field evaluation of a novel preservation medium to transport sputum specimens for molecular detection of <i>Mycobacterium tuberculosis</i> in a rural African setting. Tropical Medicine and International Health, 2016, 21, 776-782.	1.0	8
873	Diagnosis of Concurrent Pulmonary Tuberculosis and Tuberculous Otitis Media Confirmed by Xpert MTB/RIF in the United States. Infectious Diseases in Clinical Practice, 2016, 24, 180-182.	0.1	6
874	Dynamic IgG antibody response to immunodominant antigens of M. tuberculosis for active TB diagnosis in high endemic settings. Clinica Chimica Acta, 2016, 461, 25-33.	0.5	11
875	Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Scientific Reports, 2016, 6, 25330.	1.6	44
876	Assessing the utility of Xpert \hat{A}^{\otimes} MTB/RIF as a screening tool for patients admitted to medical wards in South Africa. Scientific Reports, 2016, 6, 19391.	1.6	19

#	Article	IF	Citations
877	Rapid Urine LAM Testing Improves Diagnosis of Expectorated Smear-Negative Pulmonary Tuberculosis in an HIV-endemic Region. Scientific Reports, 2016, 6, 19992.	1.6	26
878	A review on automatic tuberculosis screening using chest radiographs. , 2016, , .		2
879	Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan. BMC Medicine, 2016, 14, 187.	2.3	13
881	Point-of-Care Technologies for the Diagnosis of Active Tuberculosis. , 2016, , 556-579.		1
882	Diagnosing tuberculosis in the 21st century $\hat{a} \in \mathbb{C}$ Dawn of a genomics revolution?. International Journal of Mycobacteriology, 2016, 5, 384-391.	0.3	22
883	Clinical Impact and Cost-Effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients with Presumptive Pulmonary Tuberculosis in the United States. Clinical Infectious Diseases, 2017, 64, ciw803.	2.9	32
884	Use of Nucleic Acid Amplification Tests in Tuberculosis Patients in California, 2010–2013. Open Forum Infectious Diseases, 2016, 3, ofw230.	0.4	14
885	Pilot study of a rapid and minimally instrumented sputum sample preparation method for molecular diagnosis of tuberculosis. Scientific Reports, 2016, 6, 19541.	1.6	14
886	Polymorphisms in the PE35 and PPE68 antigens in Mycobacterium tuberculosis strains may affect strain virulence and reflect ongoing immune evasion. Molecular Medicine Reports, 2016, 13, 947-954.	1.1	13
887	Rifampin Resistance Mutations Are Associated with Broad Chemical Remodeling of Mycobacterium tuberculosis. Journal of Biological Chemistry, 2016, 291, 14248-14256.	1.6	64
888	BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers. Clinical Infectious Diseases, 2016, 62, S262-S267.	2.9	13
889	Outbreak of Multidrug-resistant Tuberculosis in Two Secondary Schools. Archivos De Bronconeumologia, 2016, 52, 70-75.	0.4	3
890	Scenario Analysis for Programmatic Tuberculosis Control in Western Province, Papua New Guinea. American Journal of Epidemiology, 2016, 183, 1138-1148.	1.6	17
891	Assessment of diagnostic accuracy of Gene Xpert MTB/RIF in diagnosis of suspected retreatment pulmonary tuberculosis patients. The Egyptian Journal of Chest Diseases and Tuberculosis, 2016, 65, 637-641.	0.1	12
892	Sensititre® MYCOTB MIC plate for drug susceptibility testing of <l>Mycobacterium tuberculosis</l> complex isolates. International Journal of Tuberculosis and Lung Disease, 2016, 20, 329-334.	0.6	18
893	Drug-Resistant Tuberculosis. Infectious Disease Clinics of North America, 2016, 30, 509-522.	1.9	82
894	High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana. International Journal of Mycobacteriology, 2016, 5, 226-230.	0.3	22
896	Remote monitoring of Xpert® MTB/RIF testing in Mozambique: results of programmatic implementation of GxAlert. International Journal of Tuberculosis and Lung Disease, 2016, 20, 335-341.	0.6	15

#	Article	IF	Citations
897	The implications of whole-genome sequencing in the control of tuberculosis. Therapeutic Advances in Infectious Disease, 2016, 3, 47-62.	1.1	28
898	Ten years of R&D and full automation in molecular diagnosis. Future Microbiology, 2016, 11, 403-425.	1.0	82
899	Diagnostic Accuracy of the Small Membrane Filtration Method for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Prevalence Setting. Journal of Clinical Microbiology, 2016, 54, 1520-1527.	1.8	8
900	Rapid Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis using TaqMan Allelic Discrimination. Osong Public Health and Research Perspectives, 2016, 7, 127-130.	0.7	4
902	Is duration of preoperative anti-tuberculosis treatment a risk factor for postoperative relapse or non-healing of spinal tuberculosis: response to comments by Li et al European Spine Journal, 2016, 25, 3008-3009.	1.0	0
903	Edge map analysis in chest X-rays for automatic pulmonary abnormality screening. International Journal of Computer Assisted Radiology and Surgery, 2016, 11, 1637-1646.	1.7	68
904	Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nature Genetics, 2016, 48, 544-551.	9.4	145
905	Tuberculosis in Older Adults. Clinics in Geriatric Medicine, 2016, 32, 479-491.	1.0	42
906	Antibody detection tests for early diagnosis in tuberculous meningitis. International Journal of Infectious Diseases, 2016, 48, 64-69.	1.5	12
907	Clinical tuberculosis. Medicine, 2016, 44, 384-389.	0.2	1
908	Added value of molecular assay Xpert MTB/RIF compared to sputum smear microscopy to assess the risk of tuberculosis transmission in a low-prevalence country. Clinical Microbiology and Infection, 2016, 22, 613-619.	2.8	41
909	Nontuberculous mycobacteria in fistula-in-ano: A new finding and its implications. International Journal of Mycobacteriology, 2016, 5, 276-279.	0.3	8
910	Highly sensitive sequence specific qPCR detection of Mycobacterium tuberculosis complex in respiratory specimens. Tuberculosis, 2016, 101, 114-124.	0.8	23
911	Propidium monoazide and Xpert MTB/RIF to quantify Mycobacterium tuberculosis cells. Tuberculosis, 2016, 101, 79-84.	0.8	14
914	The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosis. BMC Infectious Diseases, 2016, 16, 366.	1.3	41
915	High rate of drug resistance among tuberculous meningitis cases in Shaanxi province, China. Scientific Reports, 2016, 6, 25251.	1.6	20
916	Phenotypic Heterogeneity in <i>Mycobacterium tuberculosis</i> . Microbiology Spectrum, 2016, 4, .	1.2	55
917	Advances in Tuberculosis Medicinal Chemistry. , 2016, , .		0

#	Article	IF	Citations
918	Evaluation of Xpert® MTB/RIF and Ustar EasyNATâ,,¢ TB IAD for diagnosis of tuberculous lymphadenitis of children in Tanzania: a prospective descriptive study. BMC Infectious Diseases, 2016, 16, 246.	1.3	25
921	Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?. European Respiratory Journal, 2016, 48, 516-525.	3.1	239
922	Impact of rapid molecular diagnostic tests on time to treatment initiation and outcomes in patients with multidrug-resistant tuberculosis, Tamil Nadu, India. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 534-541.	0.7	23
923	Outcome of culture-confirmed isoniazid-resistant rifampicin-susceptible tuberculosis in children. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1469-1476.	0.6	11
924	Microfluidic cantilever detects bacteria and measures their susceptibility to antibiotics in small confined volumes. Nature Communications, 2016, 7, 12947.	5.8	134
925	Tuberculosis. Nature Reviews Disease Primers, 2016, 2, 16076.	18.1	830
926	HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nature Reviews Neurology, 2016, 12, 662-674.	4.9	166
927	Mixed impact of Xpert® MTB/RIF on tuberculosis diagnosis in Cambodia. Public Health Action, 2016, 6, 129-135.	0.4	7
928	Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert < sup > \hat{A}^{\otimes} < /sup > MTB/RIF in Zimbabwe. Public Health Action, 2016, 6, 122-128.	0.4	10
929	An observational study on the incidence of tuberculosis among a cohort of HIV infected adults in a setting with low prevalence of tuberculosis. HIV Clinical Trials, 2016, 17, 181-188.	2.0	4
930	Performance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: a retrospective case-control study of analytical and clinical samples from highand low-tuberculosis prevalence settings. BMC Infectious Diseases, 2016, 16, 764.	1.3	11
931	Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, e1-e7.	0.9	14
932	Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis. Open Forum Infectious Diseases, 2016, 3, ofw068.	0.4	42
933	Diagnostic Molecular Mycobacteriology in Regions With Low Tuberculosis Endemicity: Combining Real-time PCR Assays for Detection of Multiple Mycobacterial Pathogens With Line Probe Assays for Identification of Resistance Mutations. EBioMedicine, 2016, 9, 228-237.	2.7	32
934	Increased detection of smear-negative pulmonary tuberculosis by GeneXpert MTB/RIF® assay after bleach concentration. International Journal of Mycobacteriology, 2016, 5, 211-218.	0.3	20
935	Xpert [®] MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, Zimbabwe. International Journal of Tuberculosis and Lung Disease, 2016, 20, 882-889.	0.6	21
936	Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research. Clinical Infectious Diseases, 2016, 63, 370-375.	2.9	5
937	Utility of QuantiFERON-TB Gold In-Tube assay in adult, pulmonary and extrapulmonary, active tuberculosis diagnosis. International Journal of Infectious Diseases, 2016, 44, 25-30.	1.5	17

#	Article	IF	CITATIONS
938	Advances in addressing technical challenges of point-of-care diagnostics in resource-limited settings. Expert Review of Molecular Diagnostics, 2016, 16, 449-459.	1.5	103
939	Whole-genome sequencing of Mycobacterium tuberculosis for rapid diagnostics and beyond. Lancet Respiratory Medicine,the, 2016, 4, 6-8.	5 . 2	13
940	Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2016, 54, 727-733.	1.8	65
941	Xpert $<$ SUP $>$ \hat{A}^{\otimes} $<$ /SUP $>$ MTB/RIF for smear-negative presumptive TB: impact on case notification in DR Congo. International Journal of Tuberculosis and Lung Disease, 2016, 20, 240-246.	0.6	12
942	Update on the diagnosis and treatment of pulmonary tuberculosis. Revista Clínica Espanõla, 2016, 216, 76-84.	0.3	0
943	Systematic review: Comparison of Xpert MTB/RIF, LAMP and SAT methods for the diagnosis of pulmonary tuberculosis. Tuberculosis, 2016, 96, 75-86.	0.8	54
944	Rapid diagnosis of childhood TB: Can we meet pediatric TB requirements?. Pediatric Infectious Disease, 2016, 8, 91-97.	0.1	0
945	Evaluation and Diagnosis of HIV-Associated Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 199-213.	0.8	9
946	Mycobacterial Lung Disease Complicating HIV Infection. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 230-242.	0.8	8
947	The role of novel molecular techniques for tuberculosis diagnostics in the WHO European Region. Journal of Public Health, 2016, 38, fdv200.	1.0	0
948	Use of Xpert (sup) \hat{A}^{\otimes} (sup) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. International Journal of Tuberculosis and Lung Disease, 2016, 20, 448-455.	0.6	29
949	Personalized medicine for patients with MDR-TB: TableÂ1 Journal of Antimicrobial Chemotherapy, 2016, 71, 852-855.	1.3	31
950	GeneXpert assay for rapid detection of Mycobacterium tuberculosis complex in respiratory specimens from a high TB endemic area of Pakistan. Microbial Pathogenesis, 2016, 95, 82-85.	1.3	6
951	Editorial Commentary: 1, 2, 3 (Years)â€^â€\â€^â€^and You're Out: The End of a 123-year Historic Era. Clinical Infectious Diseases, 2016, 62, 1089-1091.	2.9	1
952	Indoor environmental control of tuberculosis and other airborne infections. Indoor Air, 2016, 26, 79-87.	2.0	47
953	Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?. Clinical Infectious Diseases, 2016, 62, 995-1001.	2.9	112
954	Double staining of bacilli and antigen Ag85B improves the accuracy of the pathological diagnosis of pulmonary tuberculosis. Journal of Clinical Pathology, 2016, 69, 600-606.	1.0	15
955	Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making. International Journal of Infectious Diseases, 2016, 42, 17-23.	1.5	54

#	Article	IF	CITATIONS
956	Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clinical Infectious Diseases, 2016, 62, 1081-1088.	2.9	68
957	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e119-e126.	0.9	26
958	Pulmonary Complications of HIV Infection. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 145-146.	0.8	2
959	Extensively Drug-Resistant Tuberculosis. Mayo Clinic Proceedings, 2016, 91, 482-495.	1.4	21
960	Genetic Determinants of Drug Resistance in <i>Mycobacterium tuberculosis</i> and Their Diagnostic Value. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 621-630.	2.5	131
961	Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children. Clinical Infectious Diseases, 2016, 62, 1161-1168.	2.9	67
962	The changing landscape in drug resistant-tuberculosis: an analysis of recent advances. Expert Review of Respiratory Medicine, 2016, 10, 603-606.	1.0	5
963	Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 509-521.	1.5	62
964	Sample-to-result molecular infectious disease assays: clinical implications, limitations and potential. Expert Review of Molecular Diagnostics, 2016, 16, 323-341.	1.5	14
965	Accuracy of Xpert [®] MTB/RIF assay compared with AdvanSureâ,,¢ TB/NTM real-time PCR using bronchoscopy specimens. International Journal of Tuberculosis and Lung Disease, 2016, 20, 115-120.	0.6	13
966	Performance characteristics of the new Abbott Real Time MTB assay for detection of Mycobacterium tuberculosis complex in respiratory specimens. Diagnostic Microbiology and Infectious Disease, 2016, 84, 212-214.	0.8	13
967	Brote de tuberculosis multirresistente en dos colegios de educaci \tilde{A}^3 n secundaria. Archivos De Bronconeumologia, 2016, 52, 70-75.	0.4	1
968	Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa. Clinical Biochemistry, 2016, 49, 22-31.	0.8	49
969	Multicenter Evaluation of Anyplex Plus MTB/NTM MDR-TB Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Multidrug-Resistant Isolates in Pulmonary and Extrapulmonary Specimens. Journal of Clinical Microbiology, 2016, 54, 59-63.	1.8	44
970	Actualizaci \tilde{A}^3 n en el diagn \tilde{A}^3 stico y tratamiento de la tuberculosis pulmonar. Revista Clinica Espanola, 2016, 216, 76-84.	0.2	12
971	Transmission and Institutional Infection Control of Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a018192.	2.9	62
972	Polymeric-Based In Vitro Diagnostic Devices. , 2016, , 15-58.		1
973	In-Vitro Diagnostic Devices. , 2016, , .		3

#	Article	IF	Citations
974	RAIRS2 a new expert system for diagnosing tuberculosis with real-world tournament selection mechanism inside artificial immune recognition system. Medical and Biological Engineering and Computing, 2016, 54, 385-399.	1.6	11
975	Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data. Journal of Infectious Diseases, 2016, 213, 287-294.	1.9	62
976	Pulmonary Complications of HIV Infection. , 2016, , 1583-1611.e31.		0
977	Microbiologic Diagnosis of Lung Infection. , 2016, , 278-298.e7.		1
978	Nanotools and molecular techniques to rapidly identify and fight bacterial infections. Journal of Microbiological Methods, 2017, 138, 72-81.	0.7	20
979	High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China. BMC Infectious Diseases, 2017, 17, 15.	1.3	18
980	Tuberculosis testing for healthcare workers in South Africa: A health service analysis using Porter's Five Forces Framework. International Journal of Healthcare Management, 2017, 10, 49-56.	1.2	4
981	Rapid Sputum Multiplex Detection of the M. tuberculosis Complex (MTBC) and Resistance Mutations for Eight Antibiotics by Nucleotide MALDI-TOF MS. Scientific Reports, 2017, 7, 41486.	1.6	17
982	Evaluation of rapid GeneXpert MTB/RIF method using DNA tissue specimens of vertebral bones in patients with suspected spondylitis TB. Journal of Orthopaedics, 2017, 14, 189-191.	0.6	11
983	Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study. BMC Research Notes, 2017, 10, 8.	0.6	43
984	Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nature Genetics, 2017, 49, 395-402.	9.4	258
986	Diagnosis and treatment of paediatric tuberculosis: An insight review. Critical Reviews in Microbiology, 2017, 43, 466-480.	2.7	59
987	Trends in Testing for Mycobacterium tuberculosis Complex From US Public Health Laboratories, 2009–2013. Public Health Reports, 2017, 132, 56-64.	1.3	7
989	Tuberculosis is changing. Lancet Infectious Diseases, The, 2017, 17, 359-361.	4.6	49
990	Agents of change: The role of healthcare workers in the prevention of nosocomial and occupational tuberculosis. Presse Medicale, 2017, 46, e53-e62.	0.8	41
991	The cursed duet today: Tuberculosis and HIV-coinfection. Presse Medicale, 2017, 46, e23-e39.	0.8	50
992	Association of high serum vitamin D concentrations with active pulmonary TB in an HIV co-endemic setting, Harare, Zimbabwe. BMC Infectious Diseases, 2017, 17, 142.	1.3	8
993	Three year evaluation of Xpert MTB/RIF in a low prevalence tuberculosis setting: AÂScottish perspective. Journal of Infection, 2017, 74, 466-472.	1.7	12

#	Article	IF	CITATIONS
994	Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali. Clinical Microbiology and Infection, 2017, 23, 408.e1-408.e6.	2.8	6
995	Multiplex detection of extensively drug resistant tuberculosis using binary deoxyribozyme sensors. Biosensors and Bioelectronics, 2017, 94, 176-183.	5.3	29
996	Clinical evaluation of the Abbott RealTi me MTB Assay for direct detection of Mycobacterium tuberculosis -complex from respiratory and non-respiratory samples. Tuberculosis, 2017, 104, 65-69.	0.8	15
997	Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru. Epidemiology and Infection, 2017, 145, 1107-1117.	1.0	12
998	Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	8
999	Wild-Type Gyrase A Genotype of Neisseria gonorrhoeae Predicts In Vitro Susceptibility to Ciprofloxacin: A Systematic Review of the Literature and Meta-Analysis. Sexually Transmitted Diseases, 2017, 44, 261-265.	0.8	35
1000	Early detection of the growth of Mycobacterium tuberculosis using magnetophoretic immunoassay in liquid culture. Biosensors and Bioelectronics, 2017, 96, 68-76.	5.3	41
1001	Drug-Resistant Tuberculosis., 2017,, 263-286.		O
1002	Fullerene-doped polyaniline as new redox nanoprobe and catalyst in electrochemical aptasensor for ultrasensitive detection of Mycobacterium tuberculosis MPT64 antigen in human serum. Biomaterials, 2017, 133, 11-19.	5.7	96
1003	Droplet-based non-faradaic impedance sensors for assessment of susceptibility of Escherichia coli to ampicillin in 60 min. Biomedical Microdevices, 2017, 19, 27.	1.4	8
1004	Mycobacterium tuberculosis Whole Genome Sequences From Southern India Suggest Novel Resistance Mechanisms and the Need for Region-Specific Diagnostics. Clinical Infectious Diseases, 2017, 64, 1494-1501.	2.9	76
1005	Diagnostic performance of Anyplex II MTB/MDR/XDR for detection of resistance to first and second line drugs in Mycobacterium tuberculosis. Journal of Microbiological Methods, 2017, 139, 74-78.	0.7	7
1006	Diagnostic accuracy of the Xpert $\sup \hat{A}^{\otimes}$ (sup > MTB/RIF cycle threshold level to predict smear positivity: a meta-analysis. International Journal of Tuberculosis and Lung Disease, 2017, 21, 493-502.	0.6	25
1007	Utility of urine lipoarabinomannan (LAM) in diagnosing tuberculosis and predicting mortality with and without HIV: prospective TB cohort from the Thailand Big City TB Research Network. International Journal of Infectious Diseases, 2017, 59, 96-102.	1.5	37
1008	Molecular diagnosis of central nervous system opportunistic infections and mortality in HIV-infected adults in Central China. AIDS Research and Therapy, 2017, 14, 24.	0.7	21
1009	Use of GeneXpert Remnants for Drug Resistance Profiling and Molecular Epidemiology of Tuberculosis in Libreville, Gabon. Journal of Clinical Microbiology, 2017, 55, 2105-2115.	1.8	17
1010	Immune Reconstitution Inflammatory Syndrome (IRIS): What pathologists should know. Seminars in Diagnostic Pathology, 2017, 34, 340-351.	1.0	20
1011	Mitigation of Discordant Rifampicin-Susceptibility Results Obtained by Xpert <i>Mycobacterium tuberculosis/</i> Rifampicin and Mycobacterium Growth Indicator Tube. Microbial Drug Resistance, 2017, 23, 1045-1052.	0.9	12

#	Article	IF	CITATIONS
1012	Comparison of sputum collection methods for tuberculosis diagnosis: a systematic review and pairwise and network meta-analysis. The Lancet Global Health, 2017, 5, e760-e771.	2.9	58
1013	Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand. Clinical Infectious Diseases, 2017, 64, S171-S178.	2.9	14
1014	Diagnosis of opportunistic infections. Current Opinion in HIV and AIDS, 2017, 12, 129-138.	1.5	31
1015	Diagnosis of Tuberculosis in <scp>HIV</scp> Coâ€infected Individuals: Current Status, Challenges and Opportunities for the Future. Scandinavian Journal of Immunology, 2017, 86, 76-82.	1.3	37
1016	Potential of multi-component antigens for tuberculosis diagnosis. Biologicals, 2017, 48, 109-113.	0.5	8
1017	Evaluation of the MTBDRplus 2.0 assay for the detection of multidrug resistance among persons with presumptive pulmonary TB in China. Scientific Reports, 2017, 7, 3364.	1.6	14
1018	Performance of the Abbott RealTi <i>m</i> e MTB and MTB RIF/INH Assays in a Setting of High Tuberculosis and HIV Coinfection in South Africa. Journal of Clinical Microbiology, 2017, 55, 2491-2501.	1.8	29
1020	A novel automatic molecular test for detection of multidrug resistance tuberculosis in sputum specimen: A case control study. Tuberculosis, 2017, 105, 9-12.	0.8	3
1021	Management of Tuberculosis in Special Populations. , 2017, , 141-190.		1
1022	The Influence of HIV on the Evolution of Mycobacterium tuberculosis. Molecular Biology and Evolution, 2017, 34, 1654-1668.	3.5	27
1023	GeneXpert: A momentous innovation that needs a touch of prudence. Indian Journal of Tuberculosis, 2017, 64, 69-71.	0.3	0
1024	Bacterial Resistance Against Antibiotics. , 2017, , 171-192.		6
1025	Fluorescent quantitative PCR detection of <i>Mycobacterium tuberculosis </i> in tissue sections from granulomatous lesions retrieved using EDTA. Journal of Clinical Pathology, 2017, 70, 390-394.	1.0	2
1026	Handbook of Tuberculosis. , 2017, , .		3
1027	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases, 2017, 64, e1-e33.	2.9	501
1028	Performance evaluation of Xpert MTB/RIF in a moderate tuberculosis incidence compared with TaqMan MTB and TRCRapid M.TB. Journal of Infection and Chemotherapy, 2017, 23, 101-106.	0.8	4
1029	Point-of-Care Diagnostics: Recent Developments in a Connected Age. Analytical Chemistry, 2017, 89, 102-123.	3.2	386
1030	Detection of ESAT-6 by a label free miniature immuno-electrochemical biosensor as a diagnostic tool for tuberculosis. Materials Science and Engineering C, 2017, 74, 465-470.	3.8	28

#	Article	IF	CITATIONS
1031	The Burden and Clinical Presentation of Pulmonary Tuberculosis in Adults With Severe Respiratory Illness in a High Human Immunodeficiency Virus Prevalence Setting, 2012–2014. Open Forum Infectious Diseases, 2017, 4, ofx116.	0.4	6
1032	Bacteriological diagnosis of childhood TB: a prospective observational study. Scientific Reports, 2017, 7, 11808.	1.6	8
1033	Improved performance of the artus Mycobacterium tuberculosis RG PCR kit in a low incidence setting: a retrospective monocentric study. Scientific Reports, 2017, 7, 14127.	1.6	3
1034	Tuberculous pyelonephritis in children: three case reports. Paediatrics and International Child Health, 2017, 37, 292-297.	0.3	9
1035	Genetic Mimetics of Mycobacterium tuberculosis and Methicillin-Resistant Staphylococcus aureus as Verification Standards for Molecular Diagnostics. Journal of Clinical Microbiology, 2017, 55, 3384-3394.	1.8	6
1036	The New Xpert MTB/RIF Ultra: Improving Detection of <i>Mycobacterium tuberculosis</i> Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. MBio, 2017, 8, .	1.8	431
1037	Challenges in pleural tuberculosis diagnosis: existing reference standards and nucleic acid tests. Future Microbiology, 2017, 12, 1201-1218.	1.0	32
1038	Identification of antibiotics in wastewater: current state of extraction protocol and future perspectives. Journal of Water and Health, 2017, 15, 982-1003.	1.1	17
1039	Mycothiol acetyltransferase (Rv0819) of <i>Mycobacterium tuberculosis </i> is a potential biomarker for direct diagnosis of tuberculosis using patient serum specimens. Letters in Applied Microbiology, 2017, 65, 504-511.	1.0	3
1040	Tuberculosis Meningitis. Current Infectious Disease Reports, 2017, 19, 39.	1.3	34
1041	Diagnosis of Tuberculosis Using Colorimetric Gold Nanoparticles on a Paper-Based Analytical Device. ACS Sensors, 2017, 2, 1345-1354.	4.0	119
1043	Direct detection of Mycobacterium tuberculosis and drug resistance in respiratory specimen using Abbott Realti m e MTB detection and RIF/INH resistance assay. Diagnostic Microbiology and Infectious Disease, 2017, 89, 118-124.	0.8	18
1044	Misdiagnosis of tuberculosis associated with some species of nontuberculous mycobacteria by GeneXpert MTB/RIF assay. Infection, 2017, 45, 677-681.	2.3	14
1045	GeneXpert MTB/RIF assay in the diagnosis of urinary tuberculosis from urine specimens. Scientific Reports, 2017, 7, 6181.	1.6	36
1046	Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. Clinical Infectious Diseases, 2017, 65, 1364-1370.	2.9	17
1047	Differential diagnosis of granulomatous lung disease: clues and pitfalls. European Respiratory Review, 2017, 26, 170012.	3.0	95
1048	Mycobacterium canettii , une mycobactérie du complexe tuberculosis. Revue Francophone Des Laboratoires, 2017, 2017, 47-59.	0.0	0
1049	Evolution of Phenotypic and Molecular Drug Susceptibility Testing. Advances in Experimental Medicine and Biology, 2017, 1019, 221-246.	0.8	28

#	Article	IF	CITATIONS
1050	Mathematical Models for the Epidemiology and Evolution of Mycobacterium tuberculosis. Advances in Experimental Medicine and Biology, 2017, 1019, 281-307.	0.8	1
1051	Mycobacterial genomic DNA from used Xpert MTB/RIF cartridges can be utilised for accurate second-line genotypic drug susceptibility testing and spoligotyping. Scientific Reports, 2017, 7, 14854.	1.6	11
1052	Establishment of a rapid and sensitive method based on recombinase polymerase amplification to detect mts90, a new molecular target of Mycobacterium tuberculosis. RSC Advances, 2017, 7, 49895-49902.	1.7	7
1053	Selection of a new Mycobacterium tuberculosis H37Rv aptamer and its application in the construction of a SWCNT/aptamer/Au-IDE MSPQC H37Rv sensor. Biosensors and Bioelectronics, 2017, 98, 261-266.	5. 3	30
1054	Selective Deamination of Mutagens by a Mycobacterial Enzyme. Journal of the American Chemical Society, 2017, 139, 10762-10768.	6.6	5
1055	Detection of Mycobacterium tuberculosis from paraffin-embedded tissues by GeneXpert MTB/RIF. Tuberculosis, 2017, 106, 53-55.	0.8	12
1056	Treatment delay and fatal outcomes of pulmonary tuberculosis in advanced age: a retrospective nationwide cohort study. BMC Infectious Diseases, 2017, 17, 449.	1.3	33
1057	Evaluation of gene xpert for routine diagnosis of HIV-associated tuberculosis in Nigeria: A prospective cohort study. BMC Pulmonary Medicine, 2017, 17, 87.	0.8	18
1058	Self-tests for influenza: an empirical ethics investigation. BMC Medical Ethics, 2017, 18, 33.	1.0	6
1059	Remembering the basics: interventions to improve sputum collection for tuberculosis diagnosis. The Lancet Global Health, 2017, 5, e728-e729.	2.9	2
1060	Acerca de la tuberculosis extrapulmonar. Repertorio De Medicina Y Cirugia, 2017, 26, 90-97.	0.0	4
1061	Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring. Infection, 2017, 45, 269-276.	2.3	32
1062	Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use. Journal of Clinical Microbiology, 2017, 55, 183-198.	1.8	47
1063	Molecular characterization of Isoniazid and Rifampicin target genes in multi-drug resistant Mycobacterium tuberculosis isolates from southwest of Iran. Gene Reports, 2017, 6, 19-25.	0.4	3
1065	Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clinical Microbiology and Infection, 2017, 23, 167-172.	2.8	72
1066	Mycobacterium tuberculosis and whole genome sequencing: a practical guide and online tools available for the clinical microbiologist. Clinical Microbiology and Infection, 2017, 23, 69-72.	2.8	26
1067	Tuberculosis: Just the FAQs. MBio, 2017, 8, .	1.8	17
1068	What We Know About Tuberculosis Transmission: An Overview. Journal of Infectious Diseases, 2017, 216, S629-S635.	1.9	193

#	Article	IF	Citations
1069	Evaluation of the TB-LAMP assay for the rapid diagnosis of pulmonary tuberculosis in Northern India. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1150-1153.	0.6	25
1070	Laboratory Diagnosis of Tuberculosis: Advances in Technology and Drug Susceptibility Testing. Indian Journal of Medical Microbiology, 2017, 35, 323-331.	0.3	28
1071	Phenotypic Heterogeneity in <i>Mycobacterium tuberculosis </i> ., 0, , 671-697.		1
1072	Evaluation of XpertMTB/Rif performance for diagnosis of tuberculosis among HIV positive patients in northern Tanzania. Tanzania Journal of Health Research, 2017, 19, .	0.1	O
1073	TUBERCULOSIS: A LITERATURE REVIEW. International Research Journal of Pharmacy, 2017, 8, 9-16.	0.0	0
1075	Genotypic distribution of multidrug-resistant and extensively drug-resistant tuberculosis in northern Thailand. Infection and Drug Resistance, 2017, Volume 10, 167-174.	1.1	9
1076	Rifampicin-resistant Mycobacterium tuberculosis among tuberculosis-presumptive cases at University of Gondar Hospital, northwest Ethiopia. Infection and Drug Resistance, 2017, Volume 10, 185-192.	1.1	34
1077	Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis. Journal of Clinical Medicine, 2017, 6, 78.	1.0	8
1078	Rapid and Sensitive Detection of Bacteria Response to Antibiotics Using Nanoporous Membrane and Graphene Quantum Dot (GQDs)-Based Electrochemical Biosensors. Materials, 2017, 10, 603.	1.3	33
1079	Tuberculosis, Public Health Aspects. , 2017, , 252-266.		1
1080	An evaluation of false-positive rifampicin resistance on the Xpert MTB/RIF. Memorias Do Instituto Oswaldo Cruz, 2017, 112, 756-759.	0.8	10
1081	Integrated Polymerase Chain Reaction Technologies (Sample-to-Answer Technologies). , 2017, , 59-78.		3
1082	Current Nucleic Acid Extraction Methods and Their Implications to Point-of-Care Diagnostics. BioMed Research International, 2017, 2017, 1-13.	0.9	199
1083	The Feasibility of Xpert MTB/RIF Testing to Detect Rifampicin Resistance among Childhood Tuberculosis for Prevalence Surveys in Northern China. BioMed Research International, 2017, 2017, 1-10.	0.9	9
1084	Missed opportunities for earlier diagnosis of rifampicin-resistant tuberculosis despite access to Xpert® MTB/RIF. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1100-1105.	0.6	7
1085	<i>FAST</i> implementation in Bangladesh: high frequency of unsuspected tuberculosis justifies challenges of scale-up. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1020-1025.	0.6	23
1086	Peripheral clinic versus centralized laboratory-based Xpert MTB/RIF performance: Experience gained from a pragmatic, stepped-wedge trial in Botswana. PLoS ONE, 2017, 12, e0183237.	1.1	18
1087	Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting. PLoS ONE, 2017, 12, e0186139.	1.1	33

#	Article	IF	CITATIONS
1088	Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. International Journal of Tuberculosis and Lung Disease, 2017, 21, 670-676.	0.6	22
1089	Preservation of sputum samples with cetylpyridinium chloride (CPC) for tuberculosis cultures and Xpert MTB/RIF in a low-income country. BMC Infectious Diseases, 2017, 17, 542.	1.3	16
1090	Treatment Outcome of Drug Resistance Tuberculosis From a Centre of Eastern Region, Nepal. Birat Journal of Health Sciences, 2017, 1, 20-26.	0.1	0
1091	The Impact of Tuberculosis among Immigrants: Epidemiology and Strategies of Control in High-Income Countries—Current Data and Literature Review. , 0, , .		O
1092	Molecular Testing for Diseases Associated with Bacterial Infections. , 2017, , 139-150.		2
1093	PERFORMANCE OF XPERT MTB/RIF ASSAY FOR DETECTION OF M.TB IN PULMONARY AND EXTRA-PULMONARY SAMPLES IN INDIAN PATIENTS. SAARC Journal of Tuberculosis Lung Diseases and HIV/AIDS, 2017, 14, 7-13.	0.1	1
1095	Effect of previous treatment and sputum quality on diagnostic accuracy of Xpert® MTB/RIF. International Journal of Tuberculosis and Lung Disease, 2017, 21, 389-397.	0.6	10
1096	Molecular Characterization of Mycobacterium bovis and its Significance: Role for Control of Zoonotic Tuberculosis in Africa. Journal of Medical Diagnostic Methods, 2017, 06, .	0.0	3
1097	Molecular Diagnosis of TB in the HIV Positive Population. Annals of Global Health, 2018, 80, 476.	0.8	24
1098	TB diagnosis from the Dark Ages to fluorescence. Nature Microbiology, 2018, 3, 268-269.	5.9	8
1099	Prevalence of Mycoplasma genitalium and Azithromycin-resistant Infections Among Remnant Clinical Specimens, Los Angeles. Sexually Transmitted Diseases, 2018, 45, 632-635.	0.8	10
1100	Genotypic drug resistance using whole-genome sequencing of Mycobacterium tuberculosis clinical isolates from North-western Tanzania. Tuberculosis, 2018, 109, 97-101.	0.8	18
1101	Impact of diagnostic test Xpert MTB/RIF® on health outcomes for tuberculosis. The Cochrane Library, 2018, , .	1.5	6
1102	The Immune Response to <i>Mycobacterium tuberculosis</i> in HIV-1-Coinfected Persons. Annual Review of Immunology, 2018, 36, 603-638.	9.5	85
1103	Performance of the TB-LAMP diagnostic assay in reference laboratories: Results from a multicentre study. International Journal of Infectious Diseases, 2018, 68, 44-49.	1.5	21
1104	Evaluating the diagnostic accuracy of the Xpert MTB/RIF assay on bronchoalveolar lavage fluid: A retrospective study. International Journal of Infectious Diseases, 2018, 71, 14-19.	1.5	20
1105	Experimental platform utilising melting curve technology for detection of mutations in Mycobacterium tuberculosis isolates. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1273-1279.	1.3	3
1106	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017Âupdate. European Respiratory Journal, 2018, 51, 1702678.	3.1	50

#	Article	IF	CITATIONS
1107	The impact of repeated NALC/NaOH- decontamination on the performance of Xpert MTB/RIF assay. Tuberculosis, 2018, 110, 56-58.	0.8	5
1108	Drugâ€resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology, 2018, 23, 656-673.	1.3	159
1109	Optimal Management of Drug-Resistant Tuberculosis and Human Immunodeficiency Virus: an Update. Current Treatment Options in Infectious Diseases, 2018, 10, 90-106.	0.8	0
1110	Dramatic shortening of the diagnosis of multidrug-resistant tuberculosis by the detection of rifampicin resistance using a genotypic method: GeneXpert MTB/RIF assay. Comparative Clinical Pathology, 2018, 27, 583-588.	0.3	1
1111	High genetic diversity among Mycobacterium tuberculosis strains in Tehran, Iran. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2018, 11, 1-6.	0.6	18
1112	Comparing different technologies for active TB case-finding among the homeless: a transmission-dynamic modelling study. Scientific Reports, 2018, 8, 1433.	1.6	7
1113	Mycobacterium Nontuberculosis Species. , 2018, , 806-812.e4.		3
1114	Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria. Clinical Microbiology Reviews, 2018, 31, .	5.7	175
1115	Rapid molecular diagnostics for multi-drug resistant tuberculosis in India. Expert Review of Anti-Infective Therapy, 2018, 16, 197-204.	2.0	12
1116	Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics. Open Forum Infectious Diseases, 2018, 5, ofx269.	0.4	7
1117	Automated Chest X-Ray Screening: Can Lung Region Symmetry Help Detect Pulmonary Abnormalities?. IEEE Transactions on Medical Imaging, 2018, 37, 1168-1177.	5.4	124
1118	Clinical Evaluation of a Blood Assay to Diagnose Paucibacillary Tuberculosis via Bacterial Antigens. Clinical Chemistry, 2018, 64, 791-800.	1.5	28
1119	Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. Journal of Antimicrobial Chemotherapy, 2018, 73, 1138-1151.	1.3	219
1120	Koch's postulates – Pitfalls and relevance in the 21st century. Indian Journal of Tuberculosis, 2018, 65, 6-7.	0.3	0
1121	A novel isothermal amplification-based method to detect Mycobacterium tuberculosis complex. Journal of Microbiological Methods, 2018, 145, 59-65.	0.7	6
1122	Detection of Apparent Cell-free M. tuberculosis DNA from Plasma. Scientific Reports, 2018, 8, 645.	1.6	26
1123	Delays in the diagnosis and treatment of bone and joint tuberculosis in the United Kingdom. Bone and Joint Journal, 2018, 100-B, 119-124.	1.9	47
1124	The role for rapid molecular diagnostic tests for infectious diseases in precision medicine. Expert Review of Precision Medicine and Drug Development, 2018, 3, 69-77.	0.4	7

#	Article	IF	CITATIONS
1125	Simultaneous detections of genetic fragment and single nucleotide mutation with a three-tiered output for tuberculosis diagnosis. Analytica Chimica Acta, 2018, 1007, 1-9.	2.6	2
1126	Loss-to-follow-up and delay to treatment initiation in Pakistan's national tuberculosis control programme. BMC Public Health, 2018, 18, 335.	1.2	14
1127	Diagnostic usefulness of bronchoalveolar lavage fluid xpert MTB/RIF in pauci-bacillary pulmonary tuberculosis. Infectious Diseases, 2018, 50, 725-727.	1.4	9
1128	Molecular recognition strategy for detection and antimicrobial susceptibility testing of Staphylococcus aureus by utilizing teicoplanin and porcine IgG as indicator molecules. Sensors and Actuators B: Chemical, 2018, 267, 51-57.	4.0	9
1129	Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. Journal of Infection and Public Health, 2018, 11, 605-610.	1.9	125
1130	GeneXpert MTB/RIF for rapid diagnosis and rifampin resistance detection of endobronchial tuberculosis. Respirology, 2018, 23, 950-955.	1.3	20
1131	Antimicrobial susceptibility testing by using virulent phages to evaluate bacterial viability. Analytical Methods, 2018, 10, 1799-1804.	1.3	3
1132	Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods. European Respiratory Journal, 2018, 51, 1702189.	3.1	12
1133	A high throughput methodology for susceptibility testing of Mycobacterium tuberculosis isolates. Journal of Microbiological Methods, 2018, 146, 64-67.	0.7	2
1134	Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study. Journal of Clinical Microbiology, 2018, 56, .	1.8	9
1135	Dissecting whole-genome sequencing-based online tools for predicting resistance in Mycobacterium tuberculosis: can we use them for clinical decision guidance?. Tuberculosis, 2018, 110, 44-51.	0.8	25
1136	Use of a Single Xpert MTB/RIF Assay to Determine the Duration of Airborne Isolation in Hospitalized Patients With Suspected Pulmonary Tuberculosis. Infection Control and Hospital Epidemiology, 2018, 39, 590-595.	1.0	13
1137	Tag Array gene chip rapid diagnosis anti-tuberculosis drug resistance in pulmonary tuberculosis -a feasibility study. Tuberculosis, 2018, 110, 96-103.	0.8	6
1138	Tuberculosis pulmonar del adulto. EMC - Tratado De Medicina, 2018, 22, 1-9.	0.0	1
1139	Evaluation of Xpert MTB/RIF assay in children with presumed pulmonary tuberculosis in Papua New Guinea. Paediatrics and International Child Health, 2018, 38, 97-105.	0.3	9
1140	Application of molecular, microbiological, and immunological tests for the diagnosis of bone and joint tuberculosis. Journal of Clinical Laboratory Analysis, 2018, 32, .	0.9	19
1141	Characteristics of Mycobacterium Tuberculosis Positive Patients Screened for Drug-Resistant Tuberculosis at a Tertiary Health Facility in Lagos, Nigeria. Journal of the National Medical Association, 2018, 110, 88-91.	0.6	8
1143	Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB/RIF in Wuhan, China: A Retrospective Study. Microbial Drug Resistance, 2018, 24, 675-679.	0.9	22

#	Article	IF	CITATIONS
1144	Molecular epidemiology of multi- and extensively-drug-resistant Mycobacterium tuberculosis in Ireland, 2001–2014. Journal of Infection, 2018, 76, 55-67.	1.7	12
1145	The reliability of rifampicin resistance as a proxy for multidrug-resistant tuberculosis: a systematic review of studies from Iran. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 9-14.	1.3	20
1146	Mechanisms and Detection of Antimicrobial Resistance. , 2018, , 1467-1478.e4.		6
1147	Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infectious Diseases, The, 2018, 18, 76-84.	4.6	474
1148	Rapid Microarray-Based Detection of Rifampin, Isoniazid, and Fluoroquinolone Resistance in Mycobacterium tuberculosis by Use of a Single Cartridge. Journal of Clinical Microbiology, 2018, 56, .	1.8	10
1149	DNA variants in <i>DHFR</i> gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol. Pharmacogenomics, 2018, 19, 105-112.	0.6	11
1150	What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	83
1151	Gene detection: An essential process to precision medicine. Biosensors and Bioelectronics, 2018, 99, 625-636.	5.3	15
1152	A single-tube approach for in vitro diagnostics using diatomaceous earth and optical sensor. Biosensors and Bioelectronics, 2018, 99, 443-449.	5.3	24
1153	What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?. F1000Research, 2018, 7, 1011.	0.8	33
1154	Diagnosis of lymph node tuberculosis using the GeneXpert MTB/RIF in Bangladesh. Mediscope, 2018, 6, 19-23.	0.0	0
1155	Key Issues in the Management of Multi-Drug Resistant Tuberculosis: A Case Report. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 1282-1288.	0.1	0
1156	Wavelet-domain elastic net for clustering on genomes strains. Genetics and Molecular Biology, 2018, 41, 884-892.	0.6	3
1157	Identification of rpoB, gyrA and embB Gene Mutations in Mycobacterium Tuberculosis Isolates from Retreatment Tuberculosis Patients in Nepal. SAARC Journal of Tuberculosis Lung Diseases and HIV/AIDS, 2018, 14, 39-50.	0.1	0
1158	Has TB CARE I sputum transport improved access to culture services for retreatment tuberculosis patients in Zimbabwe?. Public Health Action, 2018, 8, 66-71.	0.4	4
1159	Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria. African Health Sciences, 2018, 18, 472.	0.3	27
1160	Study on challenges in diagnosis of TB and MDR TB by Gene-Xpert in Bangladesh. SAARC Journal of Tuberculosis Lung Diseases and HIV/AIDS, 2018, 14, 1-11.	0.1	0
1161	Xpert < sup > \hat{A}^{\otimes} < /sup > MTB/RIF associated with improved treatment initiation among patients with smear-negative tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1475-1480.	0.6	13

#	Article	IF	CITATIONS
1162	Has the utilisation of Xpert ^{\hat{A}^{\otimes}} MTB/RIF in Manicaland Province, Zimbabwe, improved with new guidance on whom to test?. Public Health Action, 2018, 8, 124-129.	0.4	10
1163	Prevalence of rifampicin resistance by automated Genexpert rifampicin assay in patients with pulmonary tuberculosis in Yenagoa, Nigeria. Pan African Medical Journal, 2018, 29, 204.	0.3	20
1164	The World Health Organization Recommended TB Diagnostic Tools. , 0, , .		5
1165	Effects of Xpert ^{\hat{A}^{\otimes}} MTB/RIF testing and GxAlert on MDR-TB diagnosis and linkage to care in Mozambique. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1358-1365.	0.6	4
1166	Advances in the Diagnosis of Mycobacterium tuberculosis Infection. , 2018, , 101-135.		0
1167	Interpretation and Relevance of Advanced Technique Results. , 2018, , 711-740.		0
1168	Challenges and Progress with Diagnosing Pulmonary Tuberculosis in Low- and Middle-Income Countries. Diagnostics, 2018, 8, 78.	1.3	45
1169	Recent Developments in the Rapid Diagnosis of MDR-TB. Journal of Bacteriology & Parasitology, 2018, 09, .	0.2	O
1170	Diagnosis of HIV-associated tuberculosis. Current Opinion in HIV and AIDS, 2018, 13, 462-468.	1.5	6
1171	How can integrated care and research assist in achieving the SDG targets for diabetes, tuberculosis and HIV/AIDS?. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1117-1126.	0.6	11
1172	Prevalence of tuberculosis and multidrug resistant tuberculosis in the Middle East Region. Expert Review of Anti-Infective Therapy, 2018, 16, 709-721.	2.0	22
1173	Microfluidic Devices for Label-Free DNA Detection. Chemosensors, 2018, 6, 43.	1.8	38
1175	Effectiveness of Tuberculosis Screening Technology in the Initiation of Correct Diagnosis of Pulmonary Tuberculosis at a Tertiary Care Hospital in Thailand: Comparative Analysis of Xpert MTB/RIF Versus Sputum AFB Smear. Asia-Pacific Journal of Public Health, 2018, 30, 542-550.	0.4	4
1176	Recent Advances in Tuberculosis Immunodiagnostics. , 2018, , 23-40.		O
1177	Polymerase Chain Reaction (PCR) as a Potential Point of Care Laboratory Test for Leprosy Diagnosis—A Systematic Review. Tropical Medicine and Infectious Disease, 2018, 3, 107.	0.9	23
1178	Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTi <i>m</i> e MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. Journal of Clinical Microbiology, 2018, 56, .	1.8	49
1179	Using simultaneous amplification and testing method for evaluating the treatment outcome of pulmonary tuberculosis. BMC Infectious Diseases, 2018, 18, 512.	1.3	6
1180	Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study. Lancet Infectious Diseases, The, 2018, 18, 1350-1359.	4.6	118

#	Article	IF	CITATIONS
1181	Bacteriophages and Rapid Detection of Bacterial Pathogens: A Novel Approach., 2018,,.		2
1182	Outbreak of Tuberculosis and Multidrug-Resistant Tuberculosis, Mbuji-Mayi Central Prison, Democratic Republic of the Congo. Emerging Infectious Diseases, 2018, 24, 2029-2035.	2.0	21
1183	Comparison of GeneXpert against Light-Emitting Diode Fluorescent Microscopy for the Diagnosis of Pulmonary Tuberculosis in Addis Ababa, Ethiopia. Journal of Microbial & Biochemical Technology, 2018, 10, .	0.2	2
1184	Evaluation of Xpert MTB/RIF assay for detection of Mycobacterium tuberculosis in stool samples of adults with pulmonary tuberculosis. PLoS ONE, 2018, 13, e0203063.	1.1	20
1185	Direct Detection of Rifampin-Resistant Mycobacterium tuberculosis in Respiratory Specimens Using Quantamatrix Multiplexed Assay Platform (QMAP) System: A Multicenter Study in Korea. Frontiers in Microbiology, 2018, 9, 1804.	1.5	2
1186	Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology, 2018, 23, 1098-1113.	1.3	62
1187	Potential role for Rv2026c- and Rv2421c- specific antibody responses in diagnosing active tuberculosis. Clinica Chimica Acta, 2018, 487, 369-376.	0.5	7
1188	Upfront Xpert MTB/RIF testing on various specimen types for presumptive infant TB cases for early and appropriate treatment initiation. PLoS ONE, 2018, 13, e0202085.	1.1	10
1190	Association of Radiological Findings with the Xpert MTB/RIF Test in Patients with Suspected Pulmonary Tuberculosis. Lung, 2018, 196, 755-760.	1.4	4
1191	Perspectives for personalized therapy for patients with multidrugâ€resistant tuberculosis. Journal of Internal Medicine, 2018, 284, 163-188.	2.7	33
1192	Droplet microfluidics for highâ€sensitivity and highâ€throughput detection and screening of disease biomarkers. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2018, 10, e1522.	3.3	60
1193	Why Can't We Just Use PCR? The Role of Genotypic versus Phenotypic Testing for Antimicrobial Resistance Testing. Clinical Microbiology Newsletter, 2018, 40, 87-95.	0.4	51
1194	Comparison of GeneXpert MTB/RIF assay and LED-FM microscopy for the diagnosis of extra pulmonary tuberculosis in Khyber Pakhtunkhwa, Pakistan. Brazilian Journal of Microbiology, 2018, 49, 909-913.	0.8	19
1195	Molecular insight into multiple RpoB clinical mutants of Mycobacterium tuberculosis: An attempt to probe structural variations in rifampicin binding site underlying drug resistance. International Journal of Biological Macromolecules, 2018, 120, 2200-2214.	3.6	5
1196	The clinical utility of cycle of threshold value of GeneXpert MTB/RIF (CBNAAT) and its diagnostic accuracy in pulmonary and extra-pulmonary samples at a tertiary care center in India. Indian Journal of Tuberculosis, 2018, 65, 296-302.	0.3	11
1197	Evaluation of the Xpert MTB/RIF Ultra Assay for Direct Detection of Mycobacterium tuberculosis Complex in Smear-Negative Extrapulmonary Samples. Journal of Clinical Microbiology, 2018, 56, .	1.8	80
1198	Direct Detection of Mycobacterium tuberculosis in Clinical Specimens Using Nucleic Acid Amplification Tests. Clinical Microbiology Newsletter, 2018, 40, 107-112.	0.4	2
1199	Nucleobase deaminases: a potential enzyme system for new therapies. RSC Advances, 2018, 8, 23567-23577.	1.7	10

#	Article	IF	Citations
1200	Management of Multidrug-Resistant Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 310-324.	0.8	32
1201	Molecular Diagnosis of Tuberculosis. Chonnam Medical Journal, 2018, 54, 1.	0.5	41
1202	Blood transcriptomic markers of <i>Mycobacterium tuberculosis</i> load in sputum. International Journal of Tuberculosis and Lung Disease, 2018, 22, 950-958.	0.6	7
1203	Rapid molecular assays for detection of tuberculosis. Pneumonia (Nathan Qld), 2018, 10, 4.	2.5	60
1204	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clinical Microbiology Reviews, 2018, 31, .	5.7	353
1205	Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF. PLoS ONE, 2018, 13, e0200523.	1.1	11
1206	Combined IFN- \hat{l}^3 and TNF- \hat{l}_\pm release assay for differentiating active tuberculosis from latent tuberculosis infection. Journal of Infection, 2018, 77, 314-320.	1.7	16
1207	The implementation of Xpert MTB/RIF assay for diagnosis of tuberculosis in Nepal: A mixed-methods analysis. PLoS ONE, 2018, 13, e0201731.	1.1	20
1208	Diagnostic evaluation of an in-house developed single-tube, duplex, nested IS6110 real-time PCR assay for rapid pulmonary tuberculosis diagnosis. Tuberculosis, 2018, 112, 120-125.	0.8	8
1209	An Electroacoustic Analysis for Determining the Effect of Amoxicillin on Microbial Cells. Biophysics (Russian Federation), 2018, 63, 375-380.	0.2	4
1210	Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital. JAMA Internal Medicine, 2018, 178, 1380.	2.6	22
1211	Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. JAMA Neurology, 2018, 75, 1546.	4.5	247
1212	How has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2018, 112, 285-293.	0.7	3
1213	Impact of involvement of non-formal health providers on TB case notification among migrant slum-dwelling populations in Odisha, India. PLoS ONE, 2018, 13, e0196067.	1.1	15
1214	Correlation of microbiological yield with radiographic activity on chest computed tomography in cases of suspected pulmonary tuberculosis. PLoS ONE, 2018, 13, e0201748.	1.1	3
1215	Differential diagnosis of inflammatory bowel disease: imitations and complications. The Lancet Gastroenterology and Hepatology, 2018, 3, 644-653.	3.7	88
1216	Discordance in Xpert® MTB/RIF assay results among low bacterial load clinical specimens in Bangladesh. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1056-1062.	0.6	14
1217	Incremental cost-effectiveness of the second Xpert MTB/RIF assay to detect Mycobacterium tuberculosis. Journal of Thoracic Disease, 2018, 10, 1689-1695.	0.6	10

#	Article	IF	CITATIONS
1218	Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert® MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis. Applied Health Economics and Health Policy, 2018, 16, 537-548.	1.0	10
1219	Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil. PLoS ONE, 2018, 13, e0193988.	1.1	9
1220	A rapid culture system uninfluenced by an inoculum effect increases reliability and convenience for drug susceptibility testing of Mycobacterium tuberculosis. Scientific Reports, 2018, 8, 8651.	1.6	7
1221	A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection. Nature Communications, 2018, 9, 2308.	5.8	142
1222	Applications of genomics to slow the spread of multidrugâ€resistant <i>Neisseria gonorrhoeae</i> Annals of the New York Academy of Sciences, 2019, 1435, 93-109.	1.8	31
1223	Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in Rural Malawi: A Cluster Randomized Trial (Chepetsa). Clinical Infectious Diseases, 2019, 68, 1176-1183.	2.9	21
1224	Molecular Diagnostics for <i>Mycobacterium tuberculosis</i> Infection. Annual Review of Medicine, 2019, 70, 77-90.	5.0	23
1225	Stochastic DNA Walkers in Droplets for Superâ€Multiplexed Bacterial Phenotype Detection. Angewandte Chemie - International Edition, 2019, 58, 15448-15454.	7.2	79
1226	Whole-genome sequencing for rapid, reliable and routine investigation of Mycobacterium tuberculosis transmission in local communities. New Microbes and New Infections, 2019, 31, 100582.	0.8	21
1227	Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis. BMC Microbiology, 2019, 19, 177.	1.3	22
1228	Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: A meta-analysis of findings. Journal of Infection, 2019, 79, 349-356.	1.7	15
1229	Stochastic DNA Walkers in Droplets for Superâ€Multiplexed Bacterial Phenotype Detection. Angewandte Chemie, 2019, 131, 15594-15600.	1.6	29
1230	Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India. Scientific Reports, 2019, 9, 10283.	1.6	32
1231	Cartridge-based nucleic acid amplification test: a novel rapid diagnostic tool to study the burden of tuberculosis from a tertiary care hospital. Tropical Doctor, 2019, 49, 274-281.	0.2	4
1232	Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia. BMC Infectious Diseases, 2019, 19, 641.	1.3	31
1233	Rifampicin resistance among notified pulmonary tuberculosis (PTB) cases in South-Southern Nigeria. Heliyon, 2019, 5, e02096.	1.4	13
1234	Management of Advanced HIV Disease. Infectious Disease Clinics of North America, 2019, 33, 743-767.	1.9	7
1235	Advances in Directly Amplifying Nucleic Acids from Complex Samples. Biosensors, 2019, 9, 117.	2.3	27

#	Article	IF	CITATIONS
1236	Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. Journal of Infectious Diseases, 2019, 220, S116-S125.	1.9	33
1237	HIV and tuberculosis co-infection in East Asia and the Pacific from 1990 to 2017: results from the Global Burden of Disease Study 2017. Journal of Thoracic Disease, 2019, 11, 3822-3835.	0.6	4
1238	Tuberculosis diagnosis and treatment under uncertainty. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22990-22997.	3.3	9
1239	Monitoring quality indicators for the Xpert MTB/RIF molecular assay in Ethiopia. PLoS ONE, 2019, 14, e0225205.	1.1	13
1240	Evaluation of a membrane hybridization array for detection of Mycobacterium tuberculosis complex and resistance to isoniazid and rifampin in sputum specimens, mycobacterial liquid cultures, and clinical isolates. Kaohsiung Journal of Medical Sciences, 2019, 35, 615-623.	0.8	2
1241	Comparative Performance of Modified Kenneth Jones Criteria Scoring, World Health Organization Criteria, and Antibodies in Lymphocyte Supernatant for Diagnosing Tuberculosis in Severely Malnourished Children Presenting With Pneumonia. Frontiers in Pediatrics, 2019, 7, 406.	0.9	1
1242	WGS more accurately predicts susceptibility of Mycobacterium tuberculosis to first-line drugs than phenotypic testing. Journal of Antimicrobial Chemotherapy, 2019, 74, 2605-2616.	1.3	27
1243	Sandwich antibody-based biosensor system for identification of <i>Mycobacterium tuberculosis</i> complex and nontuberculous mycobacteria. Journal of Immunoassay and Immunochemistry, 2019, 40, 590-604.	0.5	9
1244	Comparison of GeneXpert MTB to Mycobacterium tuberculosis culture in children with tuberculosis. Paediatrica Indonesiana, 2019, 59, 113-8.	0.0	3
1245	Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia. Canadian Journal of Infectious Diseases and Medical Microbiology, 2019, 2019, 1-8.	0.7	21
1246	Development and Clinical Validation of Multiple Cross Displacement Amplification Combined With Nanoparticles-Based Biosensor for Detection of Mycobacterium tuberculosis: Preliminary Results. Frontiers in Microbiology, 2019, 10, 2135.	1.5	18
1247	Zoonotic Tuberculosis in Humans: Control, Surveillance, and the One Health Approach. Epidemiologic Reviews, 2019, 41, 130-144.	1.3	14
1248	Accuracy of Determine TB-LAM Ag to detect TB in HIV infected patients associated with diagnostic methods used in Brazilian public health units. PLoS ONE, 2019, 14, e0221038.	1.1	2
1249	Cost minimization analysis of line probe assay for detection of multidrug-resistant tuberculosis in Arkhangelsk region of Russian Federation. PLoS ONE, 2019, 14, e0211203.	1.1	8
1250	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. The Lancet Global Health, 2019, 7, e191-e199.	2.9	53
1251	Retrospective Analysis of False-Positive and Disputed Rifampin Resistance Xpert MTB/RIF Assay Results in Clinical Samples from a Referral Hospital in Hunan, China. Journal of Clinical Microbiology, 2019, 57, .	1.8	15
1252	The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study. PLoS ONE, 2019, 14, e0211355.	1.1	8
1253	<p>Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients</p> . Infection and Drug Resistance, 2019, Volume 12, 1265-1276.	1.1	13

#	Article	IF	CITATIONS
1254	Diagnostic value of Xpert MTB/RIF Ultra for osteoarticular tuberculosis. Journal of Infection, 2019, 79, 153-158.	1.7	34
1256	Evaluation of the tuberculosis culture color plate test for rapid detection of drug susceptible and drug-resistant Mycobacterium tuberculosis in a resource-limited setting, Addis Ababa, Ethiopia. PLoS ONE, 2019, 14, e0215679.	1.1	10
1257	Comparison of Quantamatrix Multiplexed Assay Platform and GenoType MTBDR Assay Using Smear-Positive Sputum Specimens From Patients With Multidrug- Resistant/Extensively Drug-Resistant Tuberculosis in South Korea. Frontiers in Microbiology, 2019, 10, 1075.	1.5	7
1258	Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet Infectious Diseases, The, 2019, 19, 852-861.	4.6	159
1259	Clinical Characteristics and Treatment Outcomes of Definitive versus Standard Anti-Tuberculosis Therapy in Patients with Tuberculous Lymphadenitis. Journal of Clinical Medicine, 2019, 8, 813.	1.0	4
1260	Advances in Molecular Diagnostic Approaches for Biothreat Agents. , 2019, , 281-310.		3
1261	GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions. Nature Communications, 2019, 10, 2128.	5.8	111
1262	Clinical Validation of the QMAC-DST System for Testing the Drug Susceptibility of Mycobacterium tuberculosis to First- and Second-Line Drugs. Frontiers in Microbiology, 2019, 10, 706.	1.5	4
1263	Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study. PLoS ONE, 2019, 14, e0216901.	1.1	11
1264	The incremental value of bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in a high-burden urban setting. Journal of Infection, 2019, 79, 24-29.	1.7	9
1265	Surveillance of Rifampicin Resistance With GeneXpert MTB/RIF in the National Reference Laboratory for Tuberculosis at the Institut Pasteur in Bangui, 2015–2017. Open Forum Infectious Diseases, 2019, 6, ofz075.	0.4	12
1266	Assessment of eight nucleic acid amplification technologies for potential use to detect infectious agents in low-resource settings. PLoS ONE, 2019, 14, e0215756.	1.1	26
1267	Comparative evaluation of Xpert MTB/RIF and the new Xpert MTB/RIF ultra with respiratory and extra-pulmonary specimens for tuberculosis case detection in a low incidence setting. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 15, 100094.	0.6	25
1268	Sonography to Rule Out Tuberculosis in Sub-Saharan Africa: A Prospective Observational Study. Open Forum Infectious Diseases, 2019, 6, ofz154.	0.4	15
1269	Evaluation of a manual identification system for detection of <i>Mycobacterium tuberculosis</i> in a primary tuberculosis laboratory in China. Journal of International Medical Research, 2019, 47, 2666-2673.	0.4	7
1270	Prednisone for Prevention of Paradoxical Tuberculosis-Associated IRIS. New England Journal of Medicine, 2019, 380, 1780-1781.	13.9	1
1271	Defense Against Biological Attacks. , 2019, , .		2
1272	rpoB Mutations Causing Discordant Rifampicin Susceptibility in Mycobacterium tuberculosis: Retrospective Analysis of Prevalence, Phenotypic, Genotypic, and Treatment Outcomes. Open Forum Infectious Diseases, 2019, 6, ofz065.	0.4	19

#	ARTICLE	IF	CITATIONS
1273	The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection. Clinical Microbiology and Infection, 2019, 25, 1370-1376.	2.8	75
1274	HIV-related tuberculosis: mortality risk in persons without vs. with culture-confirmed disease. International Journal of Tuberculosis and Lung Disease, 2019, 23, 306-314.	0.6	10
1275	Evaluation of two tuberculosis <scp>PCR</scp> assays for routine use in a clinical setting of low population and low tuberculosis prevalence. Apmis, 2019, 127, 462-467.	0.9	4
1276	How Can Operational Research Help to Eliminate Tuberculosis in the Asia Pacific Region?. Tropical Medicine and Infectious Disease, 2019, 4, 47.	0.9	7
1277	The changing treatment landscape for MDR/XDR-TB â€" Can current clinical trials revolutionise and inform a brave new world?. International Journal of Infectious Diseases, 2019, 80, S23-S28.	1.5	18
1278	Further evidence of Mycobacterium tuberculosis in the sputum of culture-negative pulmonary tuberculosis suspects using an ultrasensitive molecular assay. Tuberculosis, 2019, 116, 1-7.	0.8	1
1279	Genomic analysis of the emergence of drug-resistant strains of Mycobacterium tuberculosis in the Middle East. Scientific Reports, 2019, 9, 4474.	1.6	9
1280	Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts. PLoS Medicine, 2019, 16, e1002780.	3.9	36
1281	Detection of Mycobacterium tuberculosis in paucibacillary sputum: performances of the Xpert MTB/RIF ultra compared to the Xpert MTB/RIF, and IS6110 PCR. Diagnostic Microbiology and Infectious Disease, 2019, 94, 365-370.	0.8	25
1282	Evaluation of a gene-by-gene approach for prospective whole-genome sequencing-based surveillance of multidrug resistant Mycobacterium tuberculosis. Tuberculosis, 2019, 115, 81-88.	0.8	10
1283	Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infectious Diseases, The, 2019, 19, 298-307.	4.6	45
1284	Genomic prediction of tuberculosis drug-resistance: benchmarking existing databases and prediction algorithms. BMC Bioinformatics, 2019, 20, 68.	1.2	20
1285	Detection of <i>Mycobacterium tuberculosis</i> in AFB smear-negative sputum specimens through MTB culture and GeneXpert [®] MTB/RIF assay. International Journal of Immunopathology and Pharmacology, 2019, 33, 205873841982717.	1.0	44
1286	Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF–identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012–2017: A Retrospective Province-Wide Cohort Study. Clinical Infectious Diseases, 2019, 69, 1278-1287.	2.9	16
1287	Lab-on-a-Film disposable for genotyping multidrug-resistant <i>Mycobacterium tuberculosis</i> from sputum extracts. Lab on A Chip, 2019, 19, 1217-1225.	3.1	18
1288	Xpert MTB/RIF performance to diagnose tuberculosis and rifampicin resistance in a reference centre in southern Brazil. ERJ Open Research, 2019, 5, 00043-2019.	1.1	11
1289	Improving the diagnostics of tuberculosis and drug resistance with Xpert MTB/RIF in a district general hospital in Sierra Leone: a quality improvement project. BMJ Open Quality, 2019, 8, e000478.	0.4	4
1290	Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis. BMJ Open, 2019, 9, e031663.	0.8	8

#	Article	IF	CITATIONS
1293	<p>Efficacy Of Line Probe Assay In Detection Of Drug-Resistant Pulmonary Tuberculosis In Comparison With GeneXpert And Phenotypic Methods In Iran And Genetic Analysis Of Isolates By MIRU-VNTR</p> . Infection and Drug Resistance, 2019, Volume 12, 3585-3593.	1.1	12
1294	Isolation and deisolation of patients admitted with presumptive pulmonary tuberculosis. Journal of King Abdulaziz University, Islamic Economics, 2019, 40, 1008-1012.	0.5	2
1296	Rapid Tuberculosis Diagnosis Using Reporter Enzyme Fluorescence. Journal of Clinical Microbiology, 2019, 57, .	1.8	10
1298	Evaluation of GeneXpert MTB/RIF system performances in the diagnosis of extrapulmonary tuberculosis. BMC Infectious Diseases, 2019, 19, 1069.	1.3	47
1299	Low diagnostic accuracy of Xpert MTB/RIF assay for extrapulmonary tuberculosis: A multicenter surveillance. Scientific Reports, 2019, 9, 18515.	1.6	32
1300	Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial. BMC Infectious Diseases, 2019, 19, 1058.	1.3	6
1301	Reprogramming of Small Noncoding RNA Populations in Peripheral Blood Reveals Host Biomarkers for Latent and Active Mycobacterium tuberculosis Infection. MBio, 2019, 10, .	1.8	28
1302	The Many Roads to an Ideal Paper-based Device. , 2019, , 171-201.		1
1303	Evaluation of the culture-enhanced Xpert MTB/RIF assay for the diagnosis of smear-negative tuberculosis. MÃ@decine Et Maladies Infectieuses, 2019, 49, 467-470.	5.1	1
1304	Implications of Tuberculosis Sputum Culture Test Sensitivity on Accuracy of Other Diagnostic Modalities. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 664-664.	2.5	7
1305	Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings. Lancet Infectious Diseases, The, 2019, 19, e89-e95.	4.6	41
1306	Transmission of drug-resistant tuberculosis in HIV-endemic settings. Lancet Infectious Diseases, The, 2019, 19, e77-e88.	4.6	47
1307	The Global Landscape of Tuberculosis Therapeutics. Annual Review of Medicine, 2019, 70, 105-120.	5.0	24
1308	Six versus 12 Months of Anti Tubercular Therapy in Patients With Biopsy Proven Spinal Tuberculosis. Spine, 2019, 44, E1-E6.	1.0	15
1309	Added Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting. Journal of Clinical Microbiology, 2019, 57, .	1.8	53
1310	The performance and yield of tuberculosis testing algorithms using microscopy, chest x-ray, and Xpert MTB/RIF. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 14, 1-6.	0.6	12
1311	Respiratory Isolation Based on Rapid Molecular Testing in an Intermediate Tuberculosis-Burden Country. JAMA Internal Medicine, 2019, 179, 124.	2.6	0
1312	CB-NAAT MTB/RIF assay and histopathology correlation in diagnosis of osteoarticular tuberculosis using culture as reference standard. Journal of Clinical Orthopaedics and Trauma, 2019, 10, S53-S56.	0.6	1

#	Article	IF	CITATIONS
1313	Interference Disturbance Analysis Enables Single-Cell Level Growth and Mobility Characterization for Rapid Antimicrobial Susceptibility Testing. Nano Letters, 2019, 19, 643-651.	4.5	8
1314	Paper-based Diagnostics., 2019, , .		6
1315	Accuracy of the color plate micro-colony detection for the diagnosis of Mycobacterium tuberculosis complex in Northwest Ethiopia. Tuberculosis, 2019, 114, 54-60.	0.8	4
1316	Advances in the molecular diagnosis of tuberculosis: From probes to genomes. Infection, Genetics and Evolution, 2019, 72, 93-112.	1.0	46
1317	Diagnostic Microbiology. , 2019, , 1-1.		1
1318	Rifampin-resistant Tuberculosis in the United States, 1998–2014. Clinical Infectious Diseases, 2020, 70, 1596-1605.	2.9	15
1319	Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: A preliminary systematic review and meta-analysis. International Journal of Infectious Diseases, 2020, 90, 35-45.	1.5	41
1320	Critically III Patients With HIV. Chest, 2020, 157, 293-309.	0.4	26
1321	Multicenter Study of the Accuracy of the BD MAX Multidrug-resistant Tuberculosis Assay for Detection of Mycobacterium tuberculosis Complex and Mutations Associated With Resistance to Rifampin and Isoniazid. Clinical Infectious Diseases, 2020, 71, 1161-1167.	2.9	29
1322	Multidrug-Resistant Tuberculosis in Patients with Human Immunodeficiency Virus. Management Considerations within High-resourced Settings. Annals of the American Thoracic Society, 2020, 17, 16-23.	1.5	6
1323	Sensitivity and Specificity of Gene Xpert in the Diagnosis of Spinal Tuberculosis: A Prospective Controlled Clinical Study. Global Spine Journal, 2020, 10, 553-558.	1.2	15
1324	The technological imperative in tuberculosis care and prevention in Vietnam. Global Public Health, 2020, 15, 307-320.	1.0	1
1325	A pre-clinical validation plan to evaluate analytical sensitivities of molecular diagnostics such as BD MAX MDR-TB, Xpert MTB/Rif Ultra and FluoroType MTB. PLoS ONE, 2020, 15, e0227215.	1.1	10
1326	Tuberculosis: a focused review for the emergency medicine clinician. American Journal of Emergency Medicine, 2020, 38, 1014-1022.	0.7	12
1327	Comparison of Lowenstein-Jensen medium and MGIT culture system for recovery of Mycobacterium tuberculosis from abscess samples. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114969.	0.8	14
1329	Sputum culture and drug sensitivity testing outcome among X-pert Mycobacterium tuberculosis/rifampicin-positive, rifampicin-resistant sputum: A retrospective study — Not all rifampicin resistance is multi-drug resistant. Journal of Global Antimicrobial Resistance, 2020, 21, 434-438.	0.9	10
1330	Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infectious Diseases, The, 2020, 20, 299-307.	4.6	90
1331	Point-of-Care Testing in Microbiology: A Mechanism for Improving Patient Outcomes. Clinical Chemistry, 2020, 66, 124-137.	1.5	13

#	Article	IF	CITATIONS
1332	Performance of conventional histopathology and GeneXpert MTB/RIF in the diagnosis of spinal tuberculosis from bone specimens: A prospective clinical study. Clinical Biochemistry, 2020, 85, 33-37.	0.8	12
1333	Usefulness of Xpert MTB/RIF Ultra to Rapidly Diagnose Sputum Smear-Negative Pulmonary Tuberculosis Using Bronchial Washing Fluid. Frontiers in Microbiology, 2020, 11, 588963.	1.5	5
1334	Discordant line probe genotypic testing vs culture-based drug susceptibility phenotypic testing in TB endemic KwaZulu-Natal: Impact on bedside clinical decision making. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 20, 100176.	0.6	9
1335	Low-Cost Quantitative Photothermal Genetic Detection of Pathogens on a Paper Hybrid Device Using a Thermometer. Analytical Chemistry, 2020, 92, 14830-14837.	3.2	53
1336	Performance of the Xpert® MTB/RIF assay in the rapid diagnosis of tracheobronchial tuberculosis using bronchial washing fluid. Journal of International Medical Research, 2020, 48, 030006052092164.	0.4	0
1337	Identification of candidate host serum and saliva biomarkers for a better diagnosis of active and latent tuberculosis infection. PLoS ONE, 2020, 15, e0235859.	1.1	13
1338	Granulomatous lung disease: clinical aspects. Expert Review of Respiratory Medicine, 2020, 14, 1045-1063.	1.0	11
1339	Genomic Analysis Identifies Mutations Concerning Drug-Resistance and Beijing Genotype in Multidrug-Resistant Mycobacterium tuberculosis Isolated From China. Frontiers in Microbiology, 2020, 11, 1444.	1.5	13
1340	Precision global health: a roadmap for augmented action. Journal of Public Health and Emergency, 0, 4, 5-5.	4.4	5
1341	Oetection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs Among Mycobacterium tuberculosis by a Reverse Dot Blot Hybridization Assay. Infection and Drug Resistance, 2020, Volume 13, 4091-4104.	1.1	3
1342	GeneXpert assay – A cutting-edge tool for rapid tissue diagnosis of tuberculous lymphadenitis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 21, 100204.	0.6	3
1343	Performance of Xpert® MTB/RIF in diagnosing tuberculous pleuritis using thoracoscopic pleural biopsy. BMC Infectious Diseases, 2020, 20, 840.	1.3	12
1344	Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study. Clinical Infectious Diseases, 2021, 73, 298-303.	2.9	32
1345	<p>Factors Associated with Health-Seeking Preference Among People Who Were Supposed to Cough for More Than 2 Weeks: A Cross-Sectional Study in Southeast China</p> . Patient Preference and Adherence, 2020, Volume 14, 1173-1183.	0.8	2
1346	Discrepancies in Xpert tuberculosis testing. Lancet Microbe, The, 2020, 1, e47-e48.	3.4	2
1347	Carbon nanotube-based thin-film resistive sensor for point-of-care screening of tuberculosis. Biomedical Microdevices, 2020, 22, 50.	1.4	11
1348	Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility Testing. Open Forum Infectious Diseases, 2020, 7, ofaa279.	0.4	18
1349	Evolution Control for parallel ANN-assisted simulation-based optimization application to Tuberculosis Transmission Control. Future Generation Computer Systems, 2020, 113, 454-467.	4.9	6

#	Article	IF	CITATIONS
1350	Strain-level epidemiology of microbial communities and the human microbiome. Genome Medicine, 2020, 12, 71.	3.6	75
1351	Integrated nucleic acid testing system to enable TB diagnosis in peripheral settings. Lab on A Chip, 2020, 20, 4071-4081.	3.1	9
1352	Rapid detection of tuberculosis in remote Alaska. International Journal of Circumpolar Health, 2020, 79, 1827786.	0.5	0
1353	Association of Xpert MTB/RIF Cycle Threshold Values with Tuberculosis Treatment Outcomes. Lung, 2020, 198, 985-989.	1.4	7
1354	Cross-Population Train/Test Deep Learning Model: Abnormality Screening in Chest X-Rays., 2020,,.		15
1355	Upfront Xpert MTB/RIF for diagnosis of pediatric TBâ€"Does it work? Experience from India. PLoS ONE, 2020, 15, e0236057.	1.1	7
1356	Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries?. Frontiers in Public Health, 2020, 8, 443.	1.3	5
1357	<p>Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal</p> . Infection and Drug Resistance, 2020, Volume 13, 2911-2919.	1.1	10
1358	Performances and usefulness of Xpert MTB/RIF assay in low-incidence settings: not that bad?. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1645-1649.	1.3	1
1360	Culture-free proof of Mycobacterium tuberculosis - a new assay for viable bacteria. EBioMedicine, 2020, 62, 103117.	2.7	4
1361	A pilot study on the genetic diversity of Mycobacterium tuberculosis complex strains from tuberculosis patients in the Littoral region of Cameroon. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 21, 100182.	0.6	0
1362	The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance. PLoS ONE, 2020, 15, e0233500.	1.1	16
1363	Challenges in the diagnosis of tuberculous meningitis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 20, 100164.	0.6	22
1364	Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. Lancet Microbe, The, 2020, 1, e74-e83.	3.4	35
1365	Cost-Effectiveness Analysis of Xpert MTB/RIF for Multi-Outcomes of Patients With Presumptive Pulmonary Tuberculosis in Thailand. Value in Health Regional Issues, 2020, 21, 264-271.	0.5	1
1366	Pneumonia caused by Mycobacterium tuberculosis. Microbes and Infection, 2020, 22, 278-284.	1.0	30
1367	Endobronchial tuberculosis polyps. Respirology Case Reports, 2020, 8, e00595.	0.3	1
1368	Antibiotic sensitivity of Mycobacterium tuberculosis isolates; a retrospective study from a Saudi tertiary hospital. Journal of Taibah University Medical Sciences, 2020, 15, 142-147.	0.5	1

#	Article	IF	CITATIONS
1369	Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study. Lancet Respiratory Medicine, the, 2020, 8, 407-419.	5.2	86
1370	Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort. PLoS ONE, 2020, 15, e0229875.	1.1	9
1371	Diagnostic performance of nucleic acid tests in tuberculous pleurisy. BMC Infectious Diseases, 2020, 20, 242.	1.3	10
1372	Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis. Molecular Biology Reports, 2020, 47, 4065-4075.	1.0	109
1373	Evaluation of Xpert MTB/RIF Ultra assay for rapid diagnosis of pulmonary and extra-pulmonary tuberculosis in an Italian center. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1597-1600.	1.3	8
1374	Current and future treatments for tuberculosis. BMJ, The, 2020, 368, m216.	3.0	43
1375	Evaluation of Xpert MTB/RIF for the Diagnosis of Lymphatic Tuberculosis. BioMed Research International, 2020, 2020, 1-11.	0.9	2
1376	Drugs against Mycobacterium tuberculosis. , 2020, , 139-170.		1
1377	Xpert Mycobacterium tuberculosis/Rifampicin–Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications. Clinical Infectious Diseases, 2020, 73, e362-e370.	2.9	11
1378	Head-to-head comparison of the diagnostic accuracy of Xpert MTB/RIF and Xpert MTB/RIF Ultra for tuberculosis: a meta-analysis. Infectious Diseases, 2020, 52, 763-775.	1.4	16
1379	Genome sequencing of Mycobacterium tuberculosis clinical isolates revealed isoniazid resistance mechanisms undetected by conventional molecular methods. International Journal of Antimicrobial Agents, 2020, 56, 106068.	1.1	5
1380	A Self-Calibrating Surface-Enhanced Raman Scattering-Active System for Bacterial Phenotype Detection. Analytical Chemistry, 2020, 92, 4491-4497.	3.2	25
1381	Whole genome enrichment approach for rapid detection of Mycobacterium tuberculosis and drug resistance-associated mutations from direct sputum sequencing. Tuberculosis, 2020, 121, 101915.	0.8	21
1382	High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemporary Clinical Trials, 2020, 90, 105938.	0.8	36
1383	Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil. Respiratory Medicine, 2020, 162, 105876.	1.3	7
1384	New Machine, Old Cough: Technology and Tuberculosis in Patna. Frontiers in Sociology, 2020, 5, 18.	1.0	4
1385	Ultrasensitive enzyme-linked immunosorbent assay for the detection of MPT64 secretory antigen to evaluate Mycobacterium tuberculosis viability in sputum. International Journal of Infectious Diseases, 2020, 96, 244-253.	1.5	17
1386	High-resolution melt curve analysis for rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a single-centre study in Iran. New Microbes and New Infections, 2020, 35, 100665.	0.8	12

#	Article	IF	CITATIONS
1387	Multi-parameter flow cytometry immunophenotyping distinguishes different stages of tuberculosis infection. Journal of Infection, 2020, 81, 57-71.	1.7	26
1388	Pharmacologic management of <i>Mycobacterium ulcerans </i> Pharmacology, 2020, 13, 391-401.	1.3	16
1389	Accuracy of a reverse dot blot hybridization assay for simultaneous detection of the resistance of four anti-tuberculosis drugs in Mycobacterium tuberculosis isolated from China. Infectious Diseases of Poverty, 2020, 9, 38.	1.5	14
1390	Cost-effectiveness analysis of Xpert in detecting Mycobacterium tuberculosis: A systematic review. International Journal of Infectious Diseases, 2020, 95, 98-105.	1.5	8
1391	Diagnosis of Tuberculosis Using Gastric Aspirates in Pediatric Patients in Haiti. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 22-26.	0.6	3
1392	Probe A shown in the GeneXpert MTB/RIF assay during the detection ofÂMycobacterium intracellular infections. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115243.	0.8	1
1393	Comparison of the CapitalBioâ,,¢Mycobacterium RT-PCR detection test and Xpert MTB/RIF assay for diagnosis of renal tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 559-563.	1.3	1
1394	Prevalence and associated risk factors of drugâ€resistant tuberculosis in Thailand: results from the fifth national antiâ€tuberculosis drug resistance survey. Tropical Medicine and International Health, 2021, 26, 45-53.	1.0	8
1395	Pulmonary tuberculosis: Evaluation of current diagnostic strategy. Infectious Diseases Now, 2021, 51, 273-278.	0.7	5
1396	Value of Xpert MTB/RIF Using Bronchoalveolar Lavage Fluid for the Diagnosis of Pulmonary Tuberculosis: a Systematic Review and Meta-analysis. Journal of Clinical Microbiology, 2021, 59, .	1.8	6
1397	"l got tested at home, the help came to me― acceptability and feasibility of homeâ€based TB testing of household contacts using portable molecular diagnostics in South Africa. Tropical Medicine and International Health, 2021, 26, 343-354.	1.0	11
1398	Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum. Journal of Clinical Microbiology, 2021, 59, .	1.8	43
1399	Diagnostic accuracy of Xpert MTB/RIF ultra for detection of Mycobacterium tuberculosis in children: a prospective cohort study. Letters in Applied Microbiology, 2021, 72, 225-230.	1.0	6
1400	Rifampicin resistance among <i>Mycobacterium tuberculosis</i> â€infected individuals using GeneXpert MTB/RIF ultra: a hospitalâ€based study. Tropical Medicine and International Health, 2021, 26, 159-165.	1.0	2
1401	Comparison of first-line tuberculosis treatment outcomes between previously treated and new patients: a retrospective study in Machakos subcounty, Kenya. International Health, 2021, 13, 272-280.	0.8	8
1402	Precision Global Health. , 2021, , 1-32.		0
1403	Rapid detection of Mycobacterium tuberculosis in pus samples of suspected cases of extrapulmonary tuberculosis by GeneXpert MTB/RIF assay and its comparison with conventional methods. Journal of Indira Gandhi Institute of Medical Sciences, 2021, 7, 43.	0.1	0
1404	Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases. Open Forum Infectious Diseases, 2021, 8, ofab034.	0.4	2

#	Article	IF	CITATIONS
1405	Monitoring Tuberculosis (TB) Treatment Adherence Using eCompliance Digital Tool by Community Healthcare Workers., 2021,, 231-241.		1
1406	EasyNAT MTC assay: A simple, rapid, and low-cost cross-priming amplification method for the detection of mycobacterium tuberculosis suitable for point-of-care testing. Emerging Microbes and Infections, 2021, 10, 1530-1535.	3.0	10
1407	Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Library, 2021, 2021, CD012768.	1.5	63
1408	Diagnostic yield of endoscopic ultrasound–guided fine-needle aspiration of tubercular lymphadenitis using combination of cytology and Gene Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) genes. Indian Journal of Gastroenterology, 2021, , 1.	0.7	4
1409	Cost-effectiveness of Xpert®MTB/RIF in the diagnosis of tuberculosis: pragmatic study. Revista Da Sociedade Brasileira De Medicina Tropical, 2021, 54, e07552020.	0.4	2
1410	Precision Global Health. , 2021, , 1667-1698.		0
1411	Implementing New Approaches to Tuberculosis Control. China CDC Weekly, 2021, 3, 256-259.	1.0	1
1412	Role of GeneXpert or CBNAAT in diagnosing tuberculosis: Present scenario. Medical Journal of Dr D Y Patil Vidyapeeth, 2022, 15, 14.	0.0	O
1413	Performance Comparison of GeneXpert MTB/RIF and ProbeTec ET Tests for Rapid Molecular Diagnosis of Extrapulmonary Tuberculosis in a Low TB/MDR-TB Incidence Country. Medical Principles and Practice, 2021, 30, 277-284.	1.1	4
1414	Recent trends in smartphone-based detection for biomedical applications: a review. Analytical and Bioanalytical Chemistry, 2021, 413, 2389-2406.	1.9	93
1415	Performance Evaluation of Xpert MTB/RIF Assay and Prevalence of rpoB Gene Mutation in Mycobacterium Tuberculosis in Clinical Isolates Quetta, Pakistan: A Cross Sectional Retrospective Cohort Study. Asian Journal of Pharmacy Nursing and Medical Sciences, 2021, 9, .	0.1	0
1416	Epidemiology of molecular probes in Xpert MTB/RIF assay in Khyber Pakhtunkhwa, Pakistan. Archives of Microbiology, 2021, 203, 2249-2256.	1.0	O
1417	Utility of GeneXpert MTB/RIF assay for the diagnosis of pulmonary and extra-pulmonary tuberculosis, A report from Egypt. Novel Research in Microbiology Journal, 2021, 5, 1146-1161.	1.2	1
1418	GCâ€MS metabolomics identifies novel biomarkers to distinguish tuberculosis pleural effusion from malignant pleural effusion. Journal of Clinical Laboratory Analysis, 2021, 35, e23706.	0.9	9
1419	Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. The Cochrane Library, 2021, 2021, CD009593.	1.5	58
1420	Phenotypic and genotypic drug sensitivity profiles of Mycobacterium tuberculosis infection and associated factors in northeastern Ethiopia. BMC Infectious Diseases, 2021, 21, 261.	1.3	8
1421	Role of GeneXpertMTB/RIF in the diagnosis of cutaneous tuberculosis. Indian Journal of Tuberculosis, 2022, 69, 42-47.	0.3	1
1422	Performance Assessment of Xpert MTB/RIF Assay for Detecting Pulmonary Tuberculosis and Rifampin Resistance in a Tertiary Care Hospital in Korea. Japanese Journal of Infectious Diseases, 2021, 74, 537-542.	0.5	2

#	Article	IF	CITATIONS
1423	Analysis of Port Site Complications & Measures to Prevent them. International Journal of Healthcare Education & Medical Informatics, 2021, 07, 1-5.	0.2	0
1424	Rifampin resistance among individuals with extrapulmonary tuberculosis: 4 years of experience from a reference laboratory. New Microbes and New Infections, 2021, 40, 100841.	0.8	5
1425	Challenges in morphological diagnosis of tuberculosis. Biomedical Update, 2021, , 28-35.	0.1	0
1426	Disease of consumption to extensively drug resistance tuberculosis: Race of techniques to enhance diagnosis. Asia-Pacific Journal of Molecular Biology and Biotechnology, 0, , 73-81.	0.2	0
1427	Comparative performance of Line Probe Assay (version 2) and Xpert® MTB/RIF assay for early diagnosis of rifampicin resistant pulmonary tuberculosis. Tuberculosis and Respiratory Diseases, 2021, 84, 237-244.	0.7	6
1428	Commentary title: COVID-19 research, Africa, and global health. Journal of Virus Eradication, 2021, 7, 100030.	0.3	1
1429	Nanomotion Detection-Based Rapid Antibiotic Susceptibility Testing. Antibiotics, 2021, 10, 287.	1.5	20
1430	The value of GeneXpert MTB/RIF in bronchoalveolar lavage fluid in the diagnosis of smear-negative pulmonary tuberculosis. Investigacion Clinica, 2021, 62, 28-36.	0.0	1
1431	Visualizing the dynamics of tuberculosis pathology using molecular imaging. Journal of Clinical Investigation, 2021, 131, .	3.9	12
1432	Gap to End-TB targets in eastern China: A joinpoint analysis from population-based notification data in Zhejiang Province, China, 2005–2018. International Journal of Infectious Diseases, 2021, 104, 407-414.	1.5	12
1433	Case Report: Therapeutic Threshold for Rifampicin-Resistant Tuberculosis in a Patient from Maputo, Mozambique. American Journal of Tropical Medicine and Hygiene, 2021, 104, 1317-1320.	0.6	2
1434	Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda. Open Forum Infectious Diseases, 2021, 8, ofab173.	0.4	1
1435	Point-of-care diagnostics for infectious diseases: From methods to devices. Nano Today, 2021, 37, 101092.	6.2	276
1436	Drug resistant tuberculosis: Current scenario and impending challenges. Indian Journal of Tuberculosis, 2022, 69, 227-233.	0.3	3
1437	Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012–2019: Are We on the Right Track?. International Journal of Environmental Research and Public Health, 2021, 18, 4685.	1.2	2
1438	Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018. International Journal of Environmental Research and Public Health, 2021, 18, 4663.	1.2	13
1439	Diagnostic performance of the Xpert MTB/RIF assay in BAL fluid samples from patients under clinical suspicion of pulmonary tuberculosis: a tertiary care experience in a high-tuberculosis-burden area. Jornal Brasileiro De Pneumologia, 2021, 47, e20200581.	0.4	1
1440	Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra-pulmonary tuberculosis, one year of use in a multi-centric hospital laboratory in Brussels, Belgium. PLoS ONE, 2021, 16, e0249734.	1.1	21

#	Article	IF	CITATIONS
1441	Sensitive and Feasible Specimen Collection and Testing Strategies for Diagnosing Tuberculosis in Young Children. JAMA Pediatrics, 2021, 175, e206069.	3.3	29
1442	Diagnostic accuracy of the Xpert MTB/RIF assay for tuberculous pericarditis: A protocol of systematic review and meta-analysis. PLoS ONE, 2021, 16, e0252109.	1.1	6
1443	Clinical and CT characteristics of Xpert MTB/RIF-negative pulmonary tuberculosis. PLoS ONE, 2021, 16, e0250616.	1.1	3
1444	Sampling strategy for bacteriological diagnosis of intrathoracic tuberculosis. Respiratory Medicine and Research, 2021, 79, 100825.	0.4	2
1445	Specific and rapid reverse assaying protocol for detection and antimicrobial susceptibility testing of Pseudomonas aeruginosa based on dual molecular recognition. Scientific Reports, 2021, 11, 11101.	1.6	2
1446	A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays. European Respiratory Journal, 2021, 58, 2100526.	3.1	33
1447	Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis. The Cochrane Library, 2021, 2021, CD012972.	1.5	16
1448	Diagnostic utility of GeneXpert MTB/RIF assay versus conventional methods for diagnosis of pulmonary and extra-pulmonary tuberculosis. BMC Microbiology, 2021, 21, 144.	1.3	19
1449	Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in a clinical practice setting of China. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115306.	0.8	11
1450	The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis. European Respiratory Journal, 2021, 58, 2100266.	3.1	28
1451	Practical Guidance for Clinical Microbiology Laboratories: Diagnosis of Ocular Infections. Clinical Microbiology Reviews, 2021, 34, e0007019.	5.7	16
1452	Evaluation of screening strategies for pulmonary tuberculosis among hospitalized patients in a low-burden setting: cost-effectiveness of GeneXpert MTB/RIF compared to smear microscopy. Infection Control and Hospital Epidemiology, 2021, , 1-6.	1.0	0
1453	A Retrospective Cross-Sectional Study of the Utility of Cartridge-Based Nucleic Acid Amplification Test in Diagnosis of Pulmonary and Extrapulmonary Tuberculosis in People Living with HIV in Second Highest HIV Prevalent State in India. International Journal of Recent Surgical and Medical Sciences, 0, ,	0.1	0
1454	Access to quality diagnosis and rational treatment for tuberculosis: real-world evidence from China–Gates Tuberculosis Control Project Phase III. Infectious Diseases of Poverty, 2021, 10, 92.	1.5	3
1455	The diagnostic impact of implementing a molecular-based algorithm to standard mycobacterial screening at a reference laboratory with an intermediate prevalence for non-respiratory samples. Saudi Journal of Biological Sciences, 2021, 28, 4103-4108.	1.8	3
1456	Prevalence of isoniazid resistance in cases of rifampicin resistance detected on GeneXpert MTB/RIF assay. Medical Journal Armed Forces India, 2021, , .	0.3	0
1457	Revised guidelines for Australian laboratories performing mycobacteriology testing. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	2
1458	Computer-aided interpretation of chest radiography reveals the spectrum of tuberculosis in rural South Africa. Npj Digital Medicine, 2021, 4, 106.	5.7	29

#	Article	IF	Citations
1459	Additional drug resistance for Mycobacterium tuberculosis during turnaround time for drug-susceptibility testing in China: A multicenter observational cohort study. International Journal of Infectious Diseases, 2021, 108, 81-88.	1.5	8
1460	Utility of interferon gamma/tumor necrosis factor alpha FluoroSpot assay in differentiation between active tuberculosis and latent tuberculosis infection: a pilot study. BMC Infectious Diseases, 2021, 21, 651.	1.3	2
1461	Evaluation of the diagnostic performance of laboratory-based c-reactive protein as a triage test for active pulmonary tuberculosis. PLoS ONE, 2021, 16, e0254002.	1.1	13
1462	Aptamer-Based Diagnostic Systems for the Rapid Screening of TB at the Point-of-Care. Diagnostics, 2021, 11, 1352.	1.3	9
1463	Rifampicin resistance in Mycobacterium tuberculosis in Iran: a two-centre study. New Microbes and New Infections, 2021, 42, 100909.	0.8	5
1464	Tuberculous otitis media in Vietnam: Clinical features and diagnostic difficulties. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2021, 138, 467-469.	0.4	3
1465	Molecular detection of Mycobacterium tuberculosis in blood stained sputum samples using GeneXpert PCR assay. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115363.	0.8	6
1466	Challenging Mimickers in the Diagnosis of Sarcoidosis: A Case Study. Diagnostics, 2021, 11, 1240.	1.3	9
1467	Advancing sensing technology with CRISPR: From the detection of nucleic acids to a broad range of analytes $\hat{a} \in A$ review. Analytica Chimica Acta, 2021, 1185, 338848.	2.6	45
1468	Neoteric advancements in TB diagnostics and its future frame. Indian Journal of Tuberculosis, 2021, 68, 313-320.	0.3	0
1469	GeneXpert on patients with human immunodeficiency virus and smear-negative pulmonary tuberculosis. PLoS ONE, 2021, 16, e0253961.	1.1	6
1470	Time to Detection of Growth for Mycobacterium tuberculosis in a Low Incidence Area. Frontiers in Cellular and Infection Microbiology, 2021, 11, 704169.	1.8	9
1471	Diagnostic Efficacy of Xpert MTB/RIF Assay in Bronchoalveolar Lavage Fluid for Tracheobronchial Tuberculosis: A Retrospective Analysis. Frontiers in Medicine, 2021, 8, 682107.	1.2	7
1472	ETIOLOGY OF LYMPHADENOPTHY AMONG SOUTH INDIAN POPULTION, 2021,, 53-55.		0
1473	Effectiveness of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis at various stand-alone laboratories in Delhi. Indian Journal of Tuberculosis, 2021, , .	0.3	0
1474	Interaction of Host Pattern Recognition Receptors (PRRs) with <i>Mycobacterium Tuberculosis </i> Ayurvedic Management of Tuberculosis: A Systemic Approach. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	1
1475	Increased Detection of Mycobacterium tuberculosis Disease Using a Tissue-Based Laboratory-Developed Polymerase Chain Reaction Assay Compared to Standard Diagnostics. American Journal of Tropical Medicine and Hygiene, 2021, 105, 1657-1661.	0.6	0
1476	Comparison of LAMP, GeneXpert, Mycobacterial Culture, Smear Microscopy, TSPOT.TB, TBAg/PHA Ratio for Diagnosis of Pulmonary Tuberculosis. Current Medical Science, 2021, 41, 1023-1028.	0.7	8

#	Article	IF	CITATIONS
1477	Molecular Methods and Culture in Diagnosis of Tuberculous Meningitis in Children. Journal of Microbiology and Infectious Diseases, 0, , 140-146.	0.1	0
1478	SARS-CoV-2 Supply Shortages and Tuberculosis Diagnostics: Current Issues Requiring Immediate Solutions. Journal of Clinical Microbiology, 2021, 59, e0077821.	1.8	4
1479	Tuberculosis in Cirrhosis – A Diagnostic and Management Conundrum. Journal of Clinical and Experimental Hepatology, 2022, 12, 278-286.	0.4	8
1480	Comparative analysis of five inspection techniques for the application in the diagnosis and treatment of osteoarticular tuberculosis. International Journal of Infectious Diseases, 2021, 112, 258-263.	1.5	7
1481	Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin. BMC Infectious Diseases, 2021, 21, 979.	1.3	0
1482	Diagnostic accuracy of the Xpert MTB/RIF assay for tuberculous pericarditis: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0257220.	1.1	9
1483	Combining protein and RNA quantification to evaluate promoter activity by using dual-color fluorescent reporting systems. Bioscience Reports, 2021, 41, .	1.1	2
1484	Retrospective Diagnostic Accuracy Study of Abbott RealTi m e MTB against Xpert MTB/RIF Ultra and Xpert MTB/RIF for the Diagnosis of Pulmonary Tuberculosis and Susceptibility to Rifampin and Isoniazid Treatment. Microbiology Spectrum, 2021, 9, e0013221.	1.2	0
1486	Homogeneous electrochemical analysis of \hat{l}^2 -glycosidase and pathogenic bacteria in clinical sample assisted by click chemistry and enzyme-free catalytic hairpin assembly. Sensors and Actuators B: Chemical, 2021, 347, 130628.	4.0	6
1487	Tuberculosis: A Medical Mirage. Global Perspectives on Health Geography, 2021, , 143-157.	0.2	0
1488	Performance of GeneXpert MTB/RIF for Diagnosing Tuberculosis Among Symptomatic Household Contacts of Index Patients in South Africa. Open Forum Infectious Diseases, 2021, 8, ofab025.	0.4	3
1489	Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Library, 2019, 6, CD009593.	1.5	144
1490	Detection of rpoB Gene Mutations Using Helicase-Dependent Amplification. Methods in Molecular Biology, 2013, 1039, 89-98.	0.4	2
1491	Mycobacterial Infections., 2016,, 779-789.		1
1492	Tuberculosis (Mycobacterium tuberculosis). , 2011, , 996-1011.e1.		5
1493	Mechanisms and Detection of Antimicrobial Resistance. , 2012, , 1421-1433.e7.		3
1494	Bronchoscopic techniques in the management of patients with tuberculosis. International Journal of Infectious Diseases, 2017, 64, 27-37.	1.5	57
1495	Nanoporous layer fiber biosensing platform for real time culture- and separation-free detecting bacterial pathogens and measuring their susceptibility to antibiotics. Sensors and Actuators B: Chemical, 2020, 325, 128748.	4.0	10

#	Article	IF	CITATIONS
1496	Whole blood mRNA expression-based targets to discriminate active tuberculosis from latent infection and other pulmonary diseases. Scientific Reports, 2020, 10, 22072.	1.6	10
1497	Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology, 2017, 66, 412-418.	0.7	32
1498	Rapid diagnosis of extrapulmonary tuberculosis with Xpert Mycobacterium tuberculosis/rifampicin assay. Journal of Medical Microbiology, 2017, 66, 910-914.	0.7	21
1499	Laboratory tools for tuberculosis control in a setting with a high burden of HIV/AIDS. Journal of Medical Microbiology, 2019, 68, 1622-1628.	0.7	3
1500	Automated detection of bacterial growth on 96-well plates for high-throughput drug susceptibility testing of Mycobacterium tuberculosis. Microbiology (United Kingdom), 2018, 164, 1522-1530.	0.7	21
1505	Methodology of mycobacteria tuberculosis bacteria detection by Raman spectroscopy. , 2018, , .		2
1507	Susceptibility Test Methods: Mycobacteria, Nocardia, and Other Actinomycetes., 0,, 1356-1378.		9
1508	The Molecular Genetics of Fluoroquinolone Resistance in <i>Mycobacterium tuberculosis</i> ., 0, , 455-478.		2
1509	Surprising pathological and clinical manifestations of miliary tuberculosis. BMJ Case Reports, 2018, 2018, bcr-2017-223360.	0.2	1
1510	Microbiology of Mycobacterium tuberculosis and a new diagnostic test for TB., 2012, , 1-13.		4
1511	Evolution of the strategies for control and elimination of tuberculosis., 0,, 36-61.		3
1512	Multiple microbiologic tests for tuberculosis improve diagnostic yield of bronchoscopy in medically complex patients. AAS Open Research, 2019, 2, 25.	1.5	6
1513	Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. Gates Open Research, 2017, 1, 9.	2.0	22
1514	Can improved diagnostics reduce mortality from Tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. Wellcome Open Research, 0, 3, 64.	0.9	5
1515	Tuberculous meningitis diagnosis and outcomes during the Xpert MTB/Rif era: a 6.5-year cohort study in Uganda. Wellcome Open Research, 2018, 3, 64.	0.9	20
1516	Evaluation of GeneXpert MTB/RIF and line probe assay for rapid diagnosis of Mycobacterium tuberculosis in Sudanese pulmonary TB patients. Asian Pacific Journal of Tropical Disease, 2017, 7, 426-429.	0.5	7
1517	Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. PLoS Medicine, 2015, 12, e1001880.	3.9	236
1518	Trade-offs between cost and accuracy in active case finding for tuberculosis: A dynamic modelling analysis. PLoS Medicine, 2020, 17, e1003456.	3.9	2

#	Article	IF	CITATIONS
1519	Evaluation of the 2007 WHO Guideline to Improve the Diagnosis of Tuberculosis in Ambulatory HIV-Positive Adults. PLoS ONE, 2011, 6, e18502.	1.1	32
1520	Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assayâ€"A Clinical Validation Study. PLoS ONE, 2011, 6, e20458.	1.1	140
1521	Factors Associated with Negative Direct Sputum Examination in Asian and African HIV-Infected Patients with Tuberculosis (ANRS 1260). PLoS ONE, 2011, 6, e21212.	1.1	9
1522	Can Interferon-Gamma or Interferon-Gamma-Induced-Protein-10 Differentiate Tuberculosis Infection and Disease in Children of High Endemic Areas?. PLoS ONE, 2011, 6, e23733.	1.1	33
1523	Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Identification of Mycobacteria in Routine Clinical Practice. PLoS ONE, 2011, 6, e24720.	1.1	152
1524	Analytical Performance of the Roche LightCycler \hat{A}^{\otimes} Mycobacterium Detection Kit for the Diagnosis of Clinically Important Mycobacterial Species. PLoS ONE, 2011, 6, e24789.	1.1	11
1525	Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India. PLoS ONE, 2011, 6, e28066.	1.1	71
1526	Thoracic Empyema: A 12-Year Study from a UK Tertiary Cardiothoracic Referral Centre. PLoS ONE, 2012, 7, e30074.	1.1	86
1527	High Prevalence of Tuberculosis and Serious Bloodstream Infections in Ambulatory Individuals Presenting for Antiretroviral Therapy in Malawi. PLoS ONE, 2012, 7, e39347.	1,1	26
1528	Use of Multiplex Allele-Specific Polymerase Chain Reaction (MAS-PCR) to Detect Multidrug-Resistant Tuberculosis in Panama. PLoS ONE, 2012, 7, e40456.	1.1	23
1529	Performance Characteristics of the Cepheid Xpert MTB/RIF Test in a Tuberculosis Prevalence Survey. PLoS ONE, 2012, 7, e43307.	1.1	51
1530	Application of Hyperbranched Rolling Circle Amplification for Direct Detection of Mycobacterium Tuberculosis in Clinical Sputum Specimens. PLoS ONE, 2013, 8, e64583.	1.1	5
1531	Effect of Diagnostic and Treatment Delay on the Risk of Tuberculosis Transmission in Shenzhen, China: An Observational Cohort Study, 1993–2010. PLoS ONE, 2013, 8, e67516.	1.1	55
1532	Simple System for Isothermal DNA Amplification Coupled to Lateral Flow Detection. PLoS ONE, 2013, 8, e69355.	1.1	7 3
1533	Mycobacterium tuberculosis Bacteremia in a Cohort of HIV-Infected Patients Hospitalized with Severe Sepsis in Uganda–High Frequency, Low Clinical Sand Derivation of a Clinical Prediction Score. PLoS ONE, 2013, 8, e70305.	1.1	62
1534	The Diagnostic Performance of a Single GeneXpert MTB/RIF Assay in an Intensified Tuberculosis Case Finding Survey among HIV-Infected Prisoners in Malaysia. PLoS ONE, 2013, 8, e73717.	1.1	58
1535	The Conservation and Application of Three Hypothetical Protein Coding Gene for Direct Detection of Mycobacterium tuberculosis in Sputum Specimens. PLoS ONE, 2013, 8, e73955.	1.1	8
1536	Diagnostic Accuracy and Turnaround Time of the Xpert MTB/RIF Assay in Routine Clinical Practice. PLoS ONE, 2013, 8, e77456.	1.1	49

#	Article	IF	Citations
1537	Mycobacterium Tuberculosis-Specific TNF-α Is a Potential Biomarker for the Rapid Diagnosis of Active Tuberculosis Disease in Chinese Population. PLoS ONE, 2013, 8, e79431.	1.1	24
1538	High Tuberculosis Prevalence in a South African Prison: The Need for Routine Tuberculosis Screening. PLoS ONE, 2014, 9, e87262.	1.1	61
1539	Feasibility of Decentralised Deployment of Xpert MTB/RIF Test at Lower Level of Health System in India. PLoS ONE, 2014, 9, e89301.	1.1	63
1540	Correlation between Genotypic and Phenotypic Testing for Resistance to Rifampin in Mycobacterium tuberculosis Clinical Isolates in Haiti: Investigation of Cases with Discrepant Susceptibility Results. PLoS ONE, 2014, 9, e90569.	1.1	94
1541	Quantiferon-TB Gold: Performance for Ruling out Active Tuberculosis in HIV-Infected Adults with High CD4 Count in CÃ te d'Ivoire, West Africa. PLoS ONE, 2014, 9, e107245.	1,1	7
1542	The Burden of MDR/XDR Tuberculosis in Coastal Plains Population of China. PLoS ONE, 2015, 10, e0117361.	1.1	16
1543	Household Contact Screening Adherence among Tuberculosis Patients in Northern Ethiopia. PLoS ONE, 2015, 10, e0125767.	1.1	19
1544	A High Burden Human Immunodeficiency Virus and Tuberculosis Resource Limited Setting, Gains from Including Xpert MTB/RIF in the Diagnostic Algorithm of Fluid Specimens Submitted for Exclusion of Lymphoma by Immunophenotypic Analysis. PLoS ONE, 2015, 10, e0134404.	1.1	4
1545	Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial. PLoS ONE, 2015, 10, e0138149.	1.1	41
1546	Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population. PLoS ONE, 2015, 10, e0140375.	1.1	32
1547	Outcomes and Diagnostic Processes in Outpatients with Presumptive Tuberculosis in Zomba District, Malawi. PLoS ONE, 2015, 10, e0141414.	1.1	10
1548	Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial. PLoS ONE, 2015, 10, e0141623.	1.1	19
1549	Locked Nucleic Acid Probe-Based Real-Time PCR Assay for the Rapid Detection of Rifampin-Resistant Mycobacterium tuberculosis. PLoS ONE, 2015, 10, e0143444.	1.1	22
1550	Genotypic, Phenotypic and Clinical Validation of GeneXpert in Extra-Pulmonary and Pulmonary Tuberculosis in India. PLoS ONE, 2016, 11, e0149258.	1.1	53
1551	Xpert®MTB/RIF for the Diagnosis of Tuberculosis in a Remote Arctic Setting: Impact on Cost and Time to Treatment Initiation. PLoS ONE, 2016, 11, e0150119.	1.1	10
1552	Comparative Yield of Different Diagnostic Tests for Tuberculosis among People Living with HIV in Western Kenya. PLoS ONE, 2016, 11, e0152364.	1.1	12
1553	Comparison of Xpert MTB/RIF Assay and GenoType MTBDRplus DNA Probes for Detection of Mutations Associated with Rifampicin Resistance in Mycobacterium tuberculosis. PLoS ONE, 2016, 11, e0152694.	1.1	58
1554	The Sensitivity and Specificity of Loop-Mediated Isothermal Amplification (LAMP) Assay for Tuberculosis Diagnosis in Adults with Chronic Cough in Malawi. PLoS ONE, 2016, 11, e0155101.	1.1	42

#	Article	IF	CITATIONS
1555	Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis. PLoS ONE, 2016, 11, e0157554.	1.1	9
1556	Detection and Quantification of Mycobacterium tuberculosis in the Sputum of Culture-Negative HIV-infected Pulmonary Tuberculosis Suspects: A Proof-of-Concept Study. PLoS ONE, 2016, 11, e0158371.	1.1	6
1557	Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in the International epidemiologic Databases to Evaluate AIDS (IeDEA) program. PLoS ONE, 2017, 12, e0171384.	1.1	26
1558	Field evaluation of a blood based test for active tuberculosis in endemic settings. PLoS ONE, 2017, 12, e0173359.	1.1	23
1559	Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF. PLoS ONE, 2017, 12, e0176186.	1.1	55
1560	Performance of TaqMan array card to detect TB drug resistance on direct specimens. PLoS ONE, 2017, 12, e0177167.	1.1	11
1561	Sputum quality and diagnostic performance of GeneXpert MTB/RIF among smear-negative adults with presumed tuberculosis in Uganda. PLoS ONE, 2017, 12, e0180572.	1,1	37
1562	Implementing an isoniazid preventive therapy program for people living with HIV in Thailand. PLoS ONE, 2017, 12, e0184986.	1.1	7
1563	Comparison between the diagnostic validities of Xpert MTB/RIF and interferon- \hat{l}^3 release assays for tuberculous pericarditis using pericardial tissue. PLoS ONE, 2017, 12, e0188704.	1.1	31
1564	Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area. PLoS ONE, 2018, 13, e0189531.	1.1	11
1565	Accelerating access to quality TB care for pediatric TB cases through better diagnostic strategy in four major cities of India. PLoS ONE, 2018, 13, e0193194.	1.1	24
1566	TNF-α blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines. PLoS ONE, 2018, 13, e0194430.	1.1	35
1567	Accuracy of different Xpert MTB/Rif implementation strategies in programmatic settings at the regional referral hospitals in Uganda: Evidence for country wide roll out. PLoS ONE, 2018, 13, e0194741.	1.1	4
1568	EVALUATION OF CARTRIDGE BASED NUCLEIC ACID AMPLIFICATION TEST IN DIAGNOSIS OF PULMONARY TUBERCULOSIS. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 5281-5286.	0.1	5
1569	Study of CBNAAT and Anti-MPT64 Detection in Cytological and Histopathological Material for Early Diagnosis of TB Lymphadenitis. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 3540-3544.	0.1	2
1570	Agar de capa delgada: Una opción costoefectiva para el diagnóstico rápido de tuberculosis multirresistente. Revista De Salud Publica, 2014, 16, 101-113.	0.0	2
1573	Avaliação da utilidade clÃnica de novos testes diagnósticos em tuberculose: o papel dos ensaios clÃnicos pragmáticos. Jornal Brasileiro De Pneumologia, 2012, 38, 237-245.	0.4	9
1575	Pulmoner ve ekstrapulmoner $\tilde{A}\P$ rneklerde $\tilde{t}^{1/4}$ berk $\tilde{A}^{1/4}$ lozun erken tan $\ddot{A}\pm s\ddot{A}\pm v$ e rifampisin direncinin tespiti i \tilde{A} sin geneXpert MTB/RIF testinin de \ddot{A} verlendirilmesi. $\tilde{A}\pm v$ ukurova \tilde{A} ceniversitesi T $\tilde{A}\pm v$ Fak $\tilde{A}^{1/4}$ ltesi Dergisi, 0, , 548-553.	0.0	4

#	Article	IF	CITATIONS
1576	Diagnostic Role of Cartridge Based Nucleic Acid Amplification Test in Diagnosing Tuberculosis in Patients Co-infected with Human Immunodeficiency Virus. Journal of Medical Science and Clinical Research, 2017, 05, 21841-21848.	0.0	3
1577	Use of GeneXpert Mycobacterium tuberculosis/rifampicin for rapid detection of rifampicin resistant Mycobacterium tuberculosis strains of clinically suspected multi-drug resistance tuberculosis cases. Annals of Translational Medicine, 2016, 4, 168-168.	0.7	22
1578	The Application of Xpert Mycobacterium tuberculosis/Rifampicin, Quantitative Polymerase Chain Reaction and High Resolution Melting Curve in the Diagnosis of Superficial Lymph Node TB Current Pharmaceutical Biotechnology, 2019, 20, 1044-1054.	0.9	5
1579	The Situation of HIV/M. tuberculosis Co-Infection in Europe. The Open Infectious Diseases Journal, 2011, 5, 21-35.	0.6	3
1580	Role of gene Xpert MTB/ RIF assay in diagnosis of Tubercular Pleural Effusion. International Journal of Current Research in Medical Sciences, 2017, 3, 105-110.	0.3	4
1581	Detection of Rifampicin Resistance in HIV Seropositive Individuals with Suspected Pulmonary Tuberculosis by Using CBNAAT. Journal of Pure and Applied Microbiology, 2017, 11, 387-392.	0.3	3
1582	Diagnostic Performance of Xpert MTB /RIF in Comparison with LED Fluorescence Microscopy and Culture in Suspected Cases of Pulmonary Tuberculosis. Journal of Pure and Applied Microbiology, 2019, 13, 1461-1465.	0.3	1
1583	The diagnosis of pulmonary tuberculosis: a Korean perspective. Precision and Future Medicine, 2017, 1, 77-87.	0.5	8
1584	Tuberculosis control in China: use of modelling to develop targets and policies. Bulletin of the World Health Organization, 2015, 93, 790-798.	1.5	38
1585	The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa. Bulletin of the World Health Organization, 2017, 95, 554-563.	1.5	27
1586	Laboratory diagnosis of paediatric tuberculosis in the European Union/European Economic Area: analysis of routine laboratory data, 2007 to 2011. Eurosurveillance, 2014, 19, .	3.9	11
1587	Utility of Xpert MTB/RIF Assay for Diagnosis of Pediatric Tuberculosis Under Programmatic Conditions in India. Journal of Epidemiology and Global Health, 2020, 10, 153.	1.1	2
1588	Molecular Beacons in Diagnostics. F1000 Medicine Reports, 2012, 4, 10.	2.9	20
1589	Cost and affordability analysis of TB-LAMP and Xpert MTB/RIF assays as routine diagnostic tests in peripheral laboratories in Malawi and Vietnam. Journal of Global Health Science, $0,1,\ldots$	1.7	2
1591	Global evidence directing regional preventive strategies in Southeast Asia for fighting TB/HIV. Journal of Infection in Developing Countries, 2013, 7, 191-202.	0.5	8
1592	Changes in chest X-ray findings in 1- and 2-month group after treatment initiation for suspected pulmonary tuberculosis. Korean Journal of Internal Medicine, 2020, 35, 1145-1153.	0.7	6
1593	Insights into Bovine Tuberculosis (bTB), Various Approaches for its Diagnosis, Control and its Public Health Concerns: An Update. Asian Journal of Animal and Veterinary Advances, 2014, 9, 323-344.	0.3	9
1594	Rolling out Xpert MTB/RIF® for tuberculosis detection in HIV-positive populations: An opportunity for systems strengthening. African Journal of Laboratory Medicine, 2017, 6, .	0.2	8

#	Article	IF	Citations
1595	Drug resistant tuberculosis. Journal of Postgraduate Medicine, 2013, 59, 196-202.	0.2	6
1596	Combating tuberculosis infection: A forbidding challenge. Indian Journal of Pharmaceutical Sciences, 2016, 78, 8.	1.0	18
1597	Rifampicin resistant mycobacterium tuberculosis in Nasarawa State, Nigeria. Nigerian Journal of Basic and Clinical Sciences, 2017, 14, 21.	0.1	6
1598	Diagnosis & Diagno	0.4	106
1599	Diagnostic accuracy of xpert test in tuberculosis detection: A systematic review and meta-analysis. Journal of Global Infectious Diseases, 2016, 8, 32.	0.2	34
1600	Utility of GeneXpert in the Diagnosis, Reliance on Urine Microscopy and Clinical Characteristics of Genitourinary Tuberculosis at a Tertiary Care Hospital. Indian Journal of Medical Microbiology, 2018, 36, 93-96.	0.3	4
1601	Efficacy and role of Xpert (sup) \hat{A}^{\otimes} (sup) Mycobacterium tuberculosis/rifampicin assay in urinary tuberculosis. Indian Journal of Urology, 2018, 34, 268.	0.2	10
1602	Evaluation of Xpert® Mycobacterium tuberculosis/rifampin in sputum-smear negative and sputum-scarce patients with pulmonary tuberculosis using bronchoalveolar lavage fluid. Lung India, 2018, 35, 295.	0.3	23
1603	Assessment of GeneXpert MTB/RIF performance by type and level of health-care facilities in Nigeria. Nigerian Medical Journal, 2019, 60, 33.	0.6	7
1604	Drug Sensitivity and Molecular Diversity of M. tuberculosis in Cameroon: A Meta-analysis. Journal of Vascular Medicine & Surgery, 2016, 04, .	0.1	1
1605	Rifampicin Resistant Tuberculosis in a Secondary Health Institution in Nigeria, West Africa. Journal of Infectious Disease and Therapy, 2014, 02, .	0.1	4
1606	Results of Single-Staged Posterior Decompression and Circumferential Fusion Using a Transpedicular Approach to Correct a Kyphotic Deformity due to Thoracolumbar Spinal Tuberculosis. Asian Spine Journal, 2016, 10, 1106.	0.8	4
1607	Isoniazid and Rifampicin as Therapeutic Regimen in the Current Era: A Review. Journal of Tuberculosis Research, 2014, 02, 40-51.	0.1	11
1608	Oxidative Stress and Reduced Vitamins C and E Levels Are Associated with Multi-Drug Resistant Tuberculosis. Journal of Tuberculosis Research, 2014, 02, 52-58.	0.1	12
1609	Diagnostic Accuracy of IS6110 Insertion Gene, <i>Hsp65</i> , and Xpert MTB/RIF for Rapid Diagnosis of Pulmonary Tuberculosis. Journal of Tuberculosis Research, 2017, 05, 1-12.	0.1	2
1610	Effectiveness of GeneXpert Technology in the Diagnosis of Smear-Negative Pulmonary <i>Mycobacterium tuberculosis</i> in HIV Positive Patients in Namibia. Open Journal of Medical Microbiology, 2016, 06, 133-141.	0.1	4
1611	Reducing Uncertainty for Acute Febrile Illness in Resource-Limited Settings: The Current Diagnostic Landscape. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1285-1295.	0.6	13
1612	Diagnostic Usefulness of Cytokine and Chemokine Levels in the Cerebrospinal Fluid of Patients with Suspected Tuberculous Meningitis. American Journal of Tropical Medicine and Hygiene, 2019, 101, 343-349.	0.6	14

#	Article	IF	CITATIONS
1613	Genetic Diversity and Molecular Epidemiology of Mycobacterium tuberculosis in Roraima State, Brazil. American Journal of Tropical Medicine and Hygiene, 2019, 101, 774-779.	0.6	3
1614	Recent Advances in the Diagnosis of Tuberculosis. Journal of Postgraduate Medicine Education and Research, 2013, 47, 181-187.	0.1	1
1615	Tuberculosis of Central Nervous System. Journal of Postgraduate Medicine Education and Research, 2013, 47, 202-213.	0.1	6
1616	Smear-Negative Pulmonary Tuberculosis. Eurasian Journal of Pulmonology, 2015, 17, 75-79.	0.2	3
1617	Laboratory Diagnosis of Tuberculosis - Latest Diagnostic Tools. , 0, , .		2
1618	Surveillance of Vancomycin-resistant Enterococci colonization with GeneXpert vanA/vanB test and culture method. Journal of Microbiology and Infectious Diseases, 2014, 4, 97-101.	0.1	1
1619	A user-friendly, open-source tool to project impact and cost of diagnostic tests for tuberculosis. ELife, 2014, 3, .	2.8	12
1620	Diagnosis of Multi-drug Resistant Tuberculosis Mutations Using Hain Line Probe Assay and GeneXpert: A Study Done in Zimbabwe. British Journal of Medicine and Medical Research, 2015, 5, 1044-1052.	0.2	6
1621	Drug Resistant Mycobacterium tuberculosis in Benue, Nigeria. British Microbiology Research Journal, 2014, 4, 988-995.	0.2	10
1622	ROLE OF GENE XPERT AND LIQUID CULTURE IN DIAGNOSIS OF EXTRA PULMONAR TUBERCULOSIS. , 2021, , 34-36.		0
1623	Recent Advances in Drug Susceptible Pulmonary Tuberculosis Diagnosis and Treatment. Korean Journal of Medicine, 2021, 96, 390-399.	0.1	0
1624	Achilles' heel of antibiotic resistance. Nature Microbiology, 2021, 6, 1339-1340.	5.9	5
1626	Two target genes based multiple cross displacement amplification combined with a lateral flow biosensor for the detection of Mycobacterium tuberculosis complex. BMC Microbiology, 2021, 21, 267.	1.3	9
1627	Superfast TB test slashes waiting time. Nature, 0, , .	13.7	0
1628	Malaria Diagnostics: Lighting the Path. , 2011, , 293-307.		0
1629	The Latest Achievements in Study of Tuberculosis. Tuberculosis and Respiratory Diseases, 2011, 71, 395.	0.7	0
1631	Imported extensively drug-resistant Mycobacterium tuberculosis Beijing genotype, Marseilles, France, 2011. Eurosurveillance, 2011, 16, .	3.9	7
1632	Global Threats and the Control of Multidrug-Resistant Tuberculosis. Journal of Disaster Research, 2011, 6, 443-450.	0.4	1

#	Article	IF	CITATIONS
1635	Mycobacterium Species Non-tuberculosis. , 2012, , 786-792.e6.		8
1636	Late post transplant HIV infection with BK viremia and allograft tuberculosis in a renal transplant recipient with Kaposi sarcoma. Indian Journal of Nephrology, 2012, 22, 388.	0.2	O
1637	New Diagnostic Methods for Tuberculosis. Korean Journal of Medicine, 2012, 82, 263.	0.1	4
1638	Klinische Anwendungen von mikrobiologischen Schnelltests. , 2012, , 279-298.		0
1639	Rifampin-resistant Relapsed Tuberculosis Confirmed by Molecular Technique. Infection and Chemotherapy, 2012, 44, 485.	1.0	0
1641	Rapid diagnosis of drug resistant tuberculosis: current perspectives and challenges. Indian Journal of Medical Specialities, 2012, 3, .	0.1	1
1644	Benchmarking to Assess Potential Under-Diagnosis of Smear-Negative and Extrapulmonary Tuberculosis. A Case Study from Mozambique. The Open Infectious Diseases Journal, 2013, 7, 1-5.	0.6	1
1645	Tuberculosis control in India: the critical need for reducing diagnostic and treatment delays. The Journal of Clinical and Scientific Research, 2013, , 123-125.	0.1	0
1646	The Race to Eliminate Tuberculosis. North Carolina Medical Journal, 2013, 74, 415-419.	0.1	1
1647	Tuberculosis resistente y extrapulmonar: dos retos para el médico de hoy. Revista Colombiana De NeumologÃa, 2016, 25, .	0.1	0
1649	Renal Imaging: Infection., 2014,, 251-276.		1
1650	Validitas Metode Polymerase Chain Reaction GeneXpert MTB/RIF pada Bahan Pemeriksaan Sputum untuk Mendiagnosis Multidrug Resistant Tuberculosis. Majalah Kedokteran Bandung, 2013, 45, 234-239.	0.2	1
1651	Rapid detection of Mycobacterium tuberculosis and Rifampicin Resistance in extra pulmonary samples using Gene Xpert MTB/RIF assay. IOSR Journal of Dental and Medical Sciences, 2014, 13, 50-53.	0.0	2
1653	Tropical diseases. , 2014, , 743-751.e2.		0
1654	Propuesta de esquemas de tratamiento antituberculosis basados en la susceptibilidad a isoniacida y rifampicina. Revista Peruana De Medicina De Experimental Y Salud Publica, 2014, 30, .	0.1	5
1655	Think global, act local: chronic dysuria and sterile pyuria in an Eritrean-American woman. BMJ Case Reports, 2014, 2014, bcr2013201546-bcr2013201546.	0.2	0
1656	Multidrug-resistant tuberculosis. , 2014, , 313-324.		0
1657	Evaluation of Human Serological Response to Recombinant TB10.4 Antigen of Mycobacterium tuberculosis. Vaccine Research, 2014, 1, 38-41.	0.3	0

#	Article	IF	CITATIONS
1658	Knowledge, Attitude and Practice of Laboratory Staff on Computer: Role in Scaling up Xpert MTB/RIF in Nigeria. Science Journal of Public Health, 2015, 3, 40.	0.1	0
1659	Mycobacterium tuberculosis complex: Detection and patterns of resistance to the first line anti-TB drugs at the King Abdulaziz University Hospital, Saudi Arabia. The International Arabic Journal of Antimicrobial Agents, 0, , .	0.3	0
1660	Diagnosis of Pulmonary Tuberculosis Using Genotype MTBDRplus Assay in Three Local Government Primary Health Centres of Osun State, Nigeria- a Pilot Study. , 0, s3, .		0
1661	Computational Systems Biology Perspective on Tuberculosis in Big Data Era. Advances in Bioinformatics and Biomedical Engineering Book Series, 2015, , 240-264.	0.2	1
1663	Management of Opportunistic Infections Associated with Human Immunodeficiency Virus Infection., 2015, , 1642-1665.e5.		0
1664	Cardiac tamponade caused by tuberculous pericarditis: A case report. International Research Journal of Medicine and Medical Sciences, 2015, 06, .	0.0	0
1665	Role of Molecular Tests for Diagnosis of Tuberculosis in Children. Pediatric Oncall, 2015, 12, .	0.0	1
1666	Diagnostic Testing: General Principles. , 2016, , 59-78.		0
1667	Nucleic Acid Amplification Procedures for Identification from Specimen., 0, , 7.6.1.1-7.6.2.7.		0
1669	Comparison of GeneXpert MTB/RIF Assay in Broncho Alveolar Lavage and Gastric Lavage Samples. Advances in Infectious Diseases, 2016, 06, 107-112.	0.0	0
1670	₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽₽	⁴ĐižĐ" Đž ()@•D•D"•D~Đš
1671	Flash Diagnostic Tool for MDR TB in HIV Era. Scholars Journal of Applied Medical Sciences, 2016, 4, 2252-2255.	0.0	0
1672	Use of High-Resolution Computed Tomography (HRCT) in Diagnosis of Sputum Negative Pulmonary Tuberculosis. Turk Toraks Dergisi, 2016, 17, 59-64.	0.2	3
1673	Evaluation of Sensitivity of Molecular Methods for Detection of Rifampin-Resistant Strains Amongst Drug-resistant Mycobacterium tuberculosis Isolates. Archives of Pediatric Infectious Diseases, 2016, inpress, .	0.1	0
1674	Management of Multidrug-Resistant Tuberculosis Involving the Nervous System., 2017,, 511-524.		0
1676	Drug Resistance Assays for Mycobacterium tuberculosis. , 2017, , 1359-1365.		0
1677	Xpert MTB/RIF® como herramienta diagnóstica en una cohorte de niños menores de 15 años con sospecha clÃnica de tuberculosis pulmonar en un hospital de alta complejidad de MedellÃn. Infectio, 2017, 21, .	0.4	0
1678	OBSOLETE: Tuberculosis, Public Health Aspects. , 2017, , .		O

#	Article	IF	CITATIONS
1679	Diagnosis of Tuberculosis: Current Pipeline, Unmet Needs, and New Developments., 2017, , 77-98.		0
1680	Methods of Microbiological Confirmation in Tuberculous Meningitis. , 2017, , 375-388.		0
1681	POCT in der Entwicklungszusammenarbeit. , 2017, , 337-342.		0
1682	Performance of Xpert® MTB/RIF among tuberculosis outpatients in Lilongwe, Malawi. African Journal of Laboratory Medicine, 2017, 6, 464.	0.2	8
1683	To study the incidence of Pulmonary Tuberculosis in newly diagnosed HIV patients. Asian Pacific Journal of Health Sciences, 2017, 4, 137-139.	0.0	0
1684	Role of Gene Xpert in Early Diagnosis and Treatment of Tuberculosis. , 2018, , 623-627.		0
1685	Estrategias alternativas para el diagnolstico de tuberculosis: una opcioln para los pacientes paucibacilares. Medicina Y Laboratorio, 2017, 23, 513-550.	0.0	0
1686	POCT in international development cooperation. , 2018, , 337-342.		0
1687	Recent Development in the Molecular Diagnosis of Tuberculosis. Bengal Physician Journal, 2018, 5, 10-15.	0.1	0
1688	Evidence-based comparison of molecular-genexpert and microscopic method in the diagnosis ofÂmycobacteriumtuberculosisamong subjects in the limited resource setting of Niger delta. Journal of Microbiology & Experimentation, 2018, 6, .	0.1	0
1689	THE DIFFERENCE OF MAP1LC3 LEVEL AS MACROPHAGE AUTOPHAGY MARKER BETWEEN RESISTANT AND SENSITIVE TUBERCULOSIS PATIENTS ON RIFAMPICIN. Indonesian Journal of Tropical and Infectious Disease, 2018, 7, 6.	0.1	0
1690	Review on advanced diagnostic techniques for Mycobacterium species and its significance to control Tuberculosis. Journal of Bacteriology & Mycology Open Access, 2018, 6, .	0.2	1
1692	Prevalence of Nontuberculous Mycobacteria: A Single Center Study in Tehran, Iran. Archives of Clinical Infectious Diseases, 2018, 13, .	0.1	1
1694	DETECTION OF TUBERCULOSIS IN PLWHA- A STUDY OF YIELD BY MICROSCOPY AND CBNAAT WITH CD4 CORRELATION. Journal of Evolution of Medical and Dental Sciences, 2018, 7, 4182-4187.	0.1	0
1695	Pulmonary tuberculosis (PTB) among suspected cases in delta state, South-Southern Nigeria. Journal of Lung, Pulmonary & Respiratory Research, 2018, 5, 145-149.	0.3	0
1696	Drug-Resistant Tuberculosis and HIV. , 2019, , 203-237.		0
1697	Overview of the HIV-Associated Tuberculosis Epidemic. , 2019, , 1-7.		0
1698	Computational Systems Biology Perspective on Tuberculosis in Big Data Era. , 2019, , 2230-2254.		0

#	Article	IF	CITATIONS
1699	The Right Frame. Journal of Hospital Medicine, 2019, 14, 246.	0.7	0
1700	Tuberculosis series 2019. Jornal Brasileiro De Pneumologia, 2019, 45, e20190064.	0.4	3
1701	Multidrug-Resistant Tuberculosis Disease in North-Kivu Province, Democratic Republic of Congo. Journal of Tuberculosis Research, 2019, 07, 56-64.	0.1	0
1702	A Retrospective Review of Rifampicin-Resistant Mycobacterium tuberculosis between 2015 and 2017 in Port Harcourt, Nigeria. International Journal of Tropical Disease & Health, 0, , 1-6.	0.1	О
1703	Valuing the use of GeneXpert test as an unconventional approach to diagnose pulmonary tuberculosis. Egyptian Journal of Bronchology, 2019, 13, 403-407.	0.3	2
1704	Diagnostic Accuracy of Xpert MTB/RIF in Sputum Smear-Negative Pulmonary Tuberculosis. Cureus, 2019, 11, e5391.	0.2	12
1705	EVALUATION OF DIAGNOSTIC PERFORMANCE OF GENEXPERT MTB IN CEREBROSPINAL FLUID FOR EARLY DIAGNOSIS OF TUBERCULOUS MENINGITIS. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 2253-2256.	0.0	0
1707	THE LONG-TERM IMPACT OF WASTEWATER IRRIGATION IN THE ERA OF GLOBAL CONCERN OF ANTIBIOTIC RESISTANCE: A PERSPECTIVE FROM A DEVELOPING COUNTRY. Journal of Experimental Biology and Agricultural Sciences, 2019, 7, 481-488.	0.1	2
1708	Isolated ano-perianal tuberculosis: challenging diagnosis. Gastroenterology & Hepatology (Bartlesville, Okla), 2019, 10, 254-256.	0.0	0
1709	Combination of Xpert MTB/RIF and MTBDRplus for Diagnosing Tuberculosis in a Chinese District. Medical Science Monitor, 2020, 26, e923508.	0.5	1
1710	Utility of smear microscopy and GeneXpert for the detection of Mycobacterium tuberculosis in clinical samples. Germs, 2020, 10, 81-87.	0.5	12
1713	Getting to the point in point-of-care diagnostics for tuberculosis. Journal of Clinical Investigation, 2020, 130, 5671-5673.	3.9	5
1714	Host and Bacterial Iron Homeostasis, an Underexplored Area in Tuberculosis Biomarker Research. Frontiers in Immunology, 2021, 12, 742059.	2.2	8
1715	A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Frontiers in Cellular and Infection Microbiology, 2021, 11, 707244.	1.8	14
1716	Applications of Antibodies in Therapy, Diagnosis, and Science. Learning Materials in Biosciences, 2021, , 129-159.	0.2	O
1717	Diagnostic accuracy of TB-LAMP assay in patients with pulmonary tuberculosisa case-control study in northern India. Pulmonology, 2022, 28, 449-453.	1.0	9
1719	Multicentric validation of indigenous molecular test Truenatâ,, MTB for detection of Mycobacterium tuberculosis in sputum samples from presumptive pulmonary tuberculosis patients in comparison with reference standards. Indian Journal of Medical Research, 2020, 152, 378.	0.4	10
1720	ASSESSMENT OF THE MICROSCOPIC– OBSERVATION- DRUG - SUSCEPTIBLITY ASSAY (MODS) AND GENEXPERT ASSAY FOR DIAGNOSIS OF PULMONARY TUBERCULOSIS. Al Azhar Medical Journal = Majallat Al-Tibb Al-Azhar, 2020, 49, 91-102.	0.0	1

#	Article	IF	CITATIONS
1721	Rifampicin-resistant tuberculosis in a toddler: A report of a rare paediatric case in obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria. Nigerian Medical Journal, 2020, 61, 281.	0.6	0
1722	Validation of an indigenous assay for rapid molecular detection of rifampicin resistance in presumptive multidrug-resistant pulmonary tuberculosis patients. Indian Journal of Medical Research, 2020, 152, 482.	0.4	3
1723	Evaluation of rapid diagnostic tests and assessment of risk factors in drug-resistant pulmonary tuberculosis. Journal of Family Medicine and Primary Care, 2020, 9, 1028.	0.3	1
1725	Role of Gene Xpert in the Detection of Genital Tuberculosis in Endometrial Tissue among Women with Infertility. Journal of Human Reproductive Sciences, 2020, 13, 285.	0.4	6
1726	Mycobacteria and immunosuppression. Handbook of Systemic Autoimmune Diseases, 2020, 16, 83-107.	0.1	2
1727	Diagnostics: The Role of the Laboratory. , 2020, , 37-68.		0
1728	Molecular diagnosis of tuberculosis with emphasis on Xpert Mycobacterium tuberculosis assay – Clinical review. Journal of Clinical Sciences, 2020, 17, 93.	0.0	2
1729	Comparative Evaluation of GeneXpert MTB/RIF Assay and Microscopy for Rapid Diagnosis of Tuberculous Meningitis in Children. International Journal of Current Microbiology and Applied Sciences, 2020, 9, 25-31.	0.0	0
1730	Use of nucleic acid amplification testing for rapid detection of <i>Mycobacterium tuberculosis</i> complex among U.S. tuberculosis patients from 2011â€'2017. Open Forum Infectious Diseases, 2021, 8, ofab528.	0.4	0
1731	Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 25, 100286.	0.6	0
1732	Head-to-head comparison of Xpert MTB/RIF with real-time polymerase chain reaction assay in bronchial washing specimens. Tuberculosis and Respiratory Diseases, 2021, , .	0.7	3
1733	Long-Term GeneXpert Positivity after Treatment for Pulmonary Tuberculosis. European Journal of Case Reports in Internal Medicine, 2019, 7, 001737.	0.2	6
1734	Monitoring during and after tuberculosis treatment. , 0, , 308-325.		1
1735	COMPARATIVE ANALYSIS OF CYTOMORPHOLOGY PATTERNS AND AFB POSITIVITY OF LYMPH NODE ASPIRATE VS CBNAAT FOR DETECTION OF TUBERCULAR LYMPHADENOPATHY― , 2020, , 1-3.		0
1736	Evaluation of the Xpert MTB/RIF test accuracy for diagnosis of tuberculosis in areas with a moderate tuberculosis burden. Apmis, 2021, 129, 9-13.	0.9	2
1737	Management and control of tuberculosis control in socially complex groups: a research programme including three RCTs. Programme Grants for Applied Research, 2020, 8, 1-76.	0.4	3
1738	An electrochemical biosensor for the detection of Mycobacterium tuberculosis DNA from sputum and urine samples. PLoS ONE, 2020, 15, e0241067.	1.1	8
1739	Detection of tuberculous meningitis by various microbiological modalities at a tertiary care hospital in north India. Indian Journal of Microbiology Research, 2020, 7, 273-280.	0.0	1

#	Article	IF	CITATIONS
1742	Time to develop capacity to diagnose drug resistant tuberculosis. Ghana Medical Journal, 2010, 44, 41.	0.1	0
1743	Need to confirm isoniazid susceptibility in Xpert MTB/RIF rifampin susceptible cases. Indian Journal of Medical Research, 2012, 135, 560-1.	0.4	6
1744	Why India should become a global leader in high-quality, affordable TB diagnostics. Indian Journal of Medical Research, 2012, 135, 685-9.	0.4	5
1745	Serological tests for the diagnosis of active tuberculosis: relevance for India. Indian Journal of Medical Research, 2012, 135, 695-702.	0.4	16
1746	Challenges in the diagnosis & treatment of miliary tuberculosis. Indian Journal of Medical Research, 2012, 135, 703-30.	0.4	39
1747	Current tuberculosis diagnostic tools & role of urease breath test. Indian Journal of Medical Research, 2012, 135, 731-6.	0.4	6
1748	The potential impact of new diagnostic tests on tuberculosis epidemics. Indian Journal of Medical Research, 2012, 135, 737-44.	0.4	14
1750	Tuberculosis drug resistance and outcomes among tuberculosis inpatients in Lilongwe, Malawi. Malawi Medical Journal, 2012, 24, 21-4.	0.2	7
1751	Has the answer to diagnosing TB in resource-limited settings been found?. Medical Laboratory Observer, 2011, 43, 25.	0.1	1
1753	Rapid diagnosis of pleural tuberculosis by Xpert MTB/RIF assay using pleural biopsy and pleural fluid specimens. Journal of Research in Medical Sciences, 2015, 20, 26-31.	0.4	32
1754	Evaluation of FLASH - PCR forrapid detection of Mycobacterium tuberculosis from clinical specimens. Iranian Journal of Microbiology, 2013, 5, 383-90.	0.8	1
1755	Tuberculosis in a South African prison - a transmission modelling analysis. South African Medical Journal, 2011, 101, 809-13.	0.2	39
1757	Smear grading and the Mantoux skin test can be used to predict sputum smear conversion in patients suffering from tuberculosis. GMS Hygiene and Infection Control, 2017, 12, Doc12.	0.2	2
1758	Impact of Laboratory Practice Changes on the Diagnosis of Tuberculosis with the Introduction of Xpert MTB/RIF in Kiribati. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2018, 77, 30-34.	0.4	4
1760	Rapid detection of multidrug resistant tuberculosis in respiratory specimens at a tertiary care centre in south coastal Karnataka using Genotype MTBDR assay. Iranian Journal of Microbiology, 2018, 10, 275-280.	0.8	2
1761	Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery. Microorganisms, 2021, 9, 2330.	1.6	8
1763	La tuberculose auriculaire au VietnamÂ: aspects cliniques et difficultés diagnostiques. Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale, 2021, 138, 469-471.	0.0	0
1764	Clinical Validation of the Xpert MTB/RIF Test for Identification of the Mycobacterium tuberculosis Complex in Acid-Fast Bacillus Smear-Positive MGIT Broth Cultures. Journal of Clinical Microbiology, 2022, 60, JCM0216421.	1.8	1

#	Article	IF	CITATIONS
1765	$ \begin{array}{l} + \frac{1}{2} + \frac{1}{2$	Ð °ÑÐ 1∕4Ð,	Đ2Ñ€ĐµÑ†Đ
1766	Lab-on-a-chip analytical devices. , 2022, , 355-374.		0
1767	Precision Medicine in Low- and Middle-Income Countries. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 387-402.	9.6	11
1768	The Structural Basis of Mycobacterium tuberculosis RpoB Drug-Resistant Clinical Mutations on Rifampicin Drug Binding. Molecules, 2022, 27, 885.	1.7	4
1769	Color and distance two-dimensional visual and homogeneous dual fluorescence analysis of pathogenic bacteria in clinical samples. Sensors and Actuators B: Chemical, 2022, 357, 131422.	4.0	15
1770	Status of drug resistant tuberculosis among patients attending a tuberculosis unit of West Bengal: A record based cross-sectional study. Journal of Family Medicine and Primary Care, 2022, 11, 84.	0.3	4
1771	Performance of WHO-Endorsed Rapid Tests for Detection of Susceptibility to First-Line Drugs in Patients with Pulmonary Tuberculosis in Bangladesh. Diagnostics, 2022, 12, 410.	1.3	5
1772	Assessing the diagnostic accuracy of the Xpert MTB/RIF assay in detecting epididymal tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 615-620.	1.3	2
1774	Drug-resistant tuberculosis: advances in diagnosis and management. Current Opinion in Pulmonary Medicine, 2022, 28, 211-217.	1.2	10
1775	GeneXpert: A Rapid and Supplementary Diagnostic Tool for Tuberculous Meningitis, Experience from Tertiary Neurocenter. Journal of Neurosciences in Rural Practice, 0, 13, 204-210.	0.3	3
1777	Development and validation of a multiplex real-time qPCR assay using GMP-grade reagents for leprosy diagnosis. PLoS Neglected Tropical Diseases, 2022, 16, e0009850.	1.3	8
1778	DETECTION OF PULMONARY AND EXTRA-PULMONARY TUBERCULOSIS FROM CLINICAL SAMPLES WITH RIFAMPICIN (RIF) RESISTANCE BY GENE-XPERT MTB/RIF ASSAY AT A TERTIARY CARE TEACHING HOSPITAL, UDAIPUR, RAJASTHAN., 2022,, 38-40.		0
1779	Culture-Free Enumeration of Mycobacterium tuberculosis in Mouse Tissues Using the Molecular Bacterial Load Assay for Preclinical Drug Development. Microorganisms, 2022, 10, 460.	1.6	3
1780	Establishment and evaluation of an overlap extension polymerase chain reaction technique for rapid and efficient detection of drug-resistance in Mycobacterium tuberculosis. Infectious Diseases of Poverty, 2022, 11, 31.	1.5	1
1781	Determination of the predictive factors for diagnostic positivity of nucleic acid amplification tests for diagnosing pulmonary tuberculosis., 2022, 1, 17-22.		2
1782	Diagnostic Advances in Childhood Tuberculosis—Improving Specimen Collection and Yield of Microbiological Diagnosis for Intrathoracic Tuberculosis. Pathogens, 2022, 11, 389.	1.2	14
1783	Effectivity of in-house developed sandwich ELISA for antigen detection in resource constraint settings. International Journal of Health Sciences, 0, , 897-906.	0.0	0
1784	The scientific response to TB $\hat{a}\in$ " the other deadly global health emergency. International Journal of Tuberculosis and Lung Disease, 2022, 26, 186-189.	0.6	8

#	Article	IF	CITATIONS
1786	Efetividade do GeneXpert $\hat{A}^{@}$ no diagn \tilde{A}^{3} stico da tuberculose em pessoas que vivem com HIV/aids. Revista De Saude Publica, 2021, 55, 89.	0.7	5
1787	Tendência temporal da incidência de tuberculose e sua distribuição espacial em Macapá-AP. Revista De Saude Publica, 2021, 55, 96.	0.7	6
1788	Triage of Persons With Tuberculosis Symptoms Using Artificial Intelligence–Based Chest Radiograph Interpretation: A Cost-Effectiveness Analysis. Open Forum Infectious Diseases, 2021, 8, ofab567.	0.4	6
1789	Multiple Cross Displacement Amplification Combined With Real-Time Polymerase Chain Reaction Platform: A Rapid, Sensitive Method to Detect Mycobacterium tuberculosis. Frontiers in Microbiology, 2021, 12, 812690.	1.5	4
1790	Epidemiological profile of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis among Congolese patients. Annals of Clinical Microbiology and Antimicrobials, 2021, 20, 84.	1.7	4
1791	Clinical Features, Histopathology and Differential Diagnosis of Sarcoidosis. Cells, 2022, 11, 59.	1.8	28
1792	Diagnostic accuracy of Truenat Tuberculosis and Rifampicin-Resistance assays in Addis Ababa, Ethiopia. PLoS ONE, 2021, 16, e0261084.	1.1	9
1793	Predicting the risk of active pulmonary tuberculosis in people living with HIV: development and validation of a nomogram. BMC Infectious Diseases, 2022, 22, 388.	1.3	4
1806	Comparison of Two Molecular Assays For Detecting Smear Negative Pulmonary Tuberculosis. Biomedical and Environmental Sciences, 2016, 29, 248-53.	0.2	9
1807	Rapid Molecular Diagnosis of Extra-Pulmonary Tuberculosis by Xpert/RIF Ultra. Frontiers in Microbiology, 2022, 13, .	1.5	6
1808	Diagnosis of Mycobacterium tuberculosis using GeneXpert MTB / RIF and TB-LAMP techniques from pulmonary and extra-pulmonary TB patients in Iraq. Revista Bionatura, 2022, 7, 1-8.	0.1	2
1809	Gene-Based Diagnosis of Tuberculosis from Oral Swabs with a New Generation Pathogen Enrichment Technique. Microbiology Spectrum, 2022, 10, e0020722.	1.2	6
1810	Analysis of the Application Value of Molecular Diagnostic Technology of Mycobacterium Tuberculosis. SSRN Electronic Journal, 0, , .	0.4	0
1811	Rapid Detection of MCR-Mediated Colistin Resistance in Escherichia coli. Microbiology Spectrum, 2022, 10, .	1.2	4
1812	Application of core needle biopsy in the diagnosis of epididymal tuberculosis: a retrospective analysis of 41 cases. International Journal of Infectious Diseases, 2022, 122, 33-37.	1.5	2
1813	Pus cell as an indicator for Mycobacterium tuberculosis diagnostic yield by GeneXpert MTB/RIF in South-South Nigeria: A prospective study. Journal of Clinical Sciences, 2022, 19, 62.	0.0	1
1814	Exploring the role of Microbiome in Susceptibility, Treatment Response and Outcome among Tuberculosis Patients from Pakistan: study protocol for a prospective cohort study (Micro-STOP). BMJ Open, 2022, 12, e058463.	0.8	0
1815	Nucleic Acids Detection for Mycobacterium tuberculosis Based on Gold Nanoparticles Counting and Rolling-Circle Amplification. Biosensors, 2022, 12, 448.	2.3	4

#	Article	IF	CITATIONS
1816	Accuracy of Tongue Swab Testing Using Xpert MTB-RIF Ultra for Tuberculosis Diagnosis. Journal of Clinical Microbiology, 2022, 60, .	1.8	18
1817	Nucleic acid amplification tests reduce delayed diagnosis and misdiagnosis of pulmonary tuberculosis. Scientific Reports, 2022, 12, .	1.6	2
1818	Tuberculosis diagnostics to reduce HIV-associated mortality. Clinical Infection in Practice, 2022, , 100152.	0.2	0
1819	The Use of Selected Commercial Molecular Assays for the Microbiological Diagnosis of Tuberculosis. Pneumonologia I Alergologia Polska, 2012, 80, 6-12.	0.6	5
1820	Stabilization of Tuberculosis Reporter Enzyme Fluorescence (REFtb) Diagnostic Reagents for Use at the Point of Care. Diagnostics, 2022, 12, 1745.	1.3	0
1821	Health Maintenance., 2021,, 88-94.		0
1822	Prevalence of rifampicin resistant tuberculosis among pulmonary tuberculosis patients In Enugu, Nigeria. African Health Sciences, 2022, 22, 156-161.	0.3	5
1823	A Global Bibliometric Analysis on Antibiotic-Resistant Active Pulmonary Tuberculosis over the Last 25 Years (1996–2020). Antibiotics, 2022, 11, 1012.	1.5	8
1824	Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB). Open Forum Infectious Diseases, 2022, 9, .	0.4	2
1825	Combining metabolome and clinical indicators with machine learning provides some promising diagnostic markers to precisely detect smear-positive/negative pulmonary tuberculosis. BMC Infectious Diseases, 2022, 22, .	1.3	9
1826	Genome-wide association studies of global Mycobacterium tuberculosis resistance to 13 antimicrobials in 10,228 genomes identify new resistance mechanisms. PLoS Biology, 2022, 20, e3001755.	2.6	27
1827	Predicting antibiotic resistance in complex protein targets using alchemical free energy methods. Journal of Computational Chemistry, 0, , .	1.5	2
1828	Cost-effectiveness of GeneXpert Omni compared with GeneXpert MTB/Rif for point-of-care diagnosis of tuberculosis in a low-resource, high-burden setting in Eastern Uganda: a cost-effectiveness analysis based on decision analytical modelling. BMJ Open, 2022, 12, e059823.	0.8	3
1829	A Peptidomic Approach to Identify Novel Antigen Biomarkers for the Diagnosis of Tuberculosis. Infection and Drug Resistance, 0, Volume 15, 4617-4626.	1.1	4
1830	Evaluation of the role of HRCT chest in the differentiation of pattern of spectrum in lung diseases. International Journal of Health Sciences, 0, , 7591-7603.	0.0	0
1831	A university-clustered tuberculosis outbreak during the COVID-19 pandemic in eastern China. Frontiers in Public Health, 0, 10 , .	1.3	0
1833	Evaluation of GeneXpert and liquid culture for detection of Mycobacterium tuberculosis in pediatric patients. Indian Journal of Medical Microbiology, 2022, 40, 547-551.	0.3	1
1834	Contributions of GeneXpert (sup) \hat{A}^{\otimes} (sup) to TB diagnosis in Myanmar. International Journal of Tuberculosis and Lung Disease, 2022, 26, 875-879.	0.6	0

#	Article	IF	CITATIONS
1835	Detection of Mycobacterium tuberculosis and rifampicin resistance by Xpert® MTB/RIF assay among presumptive tuberculosis patients in Addis Ababa, Ethiopia from 2014 to 2021. IJID Regions, 2022, 5, 97-103.	0.5	2
1836	Excess tuberculosis cases and deaths following an economic recession in Brazil: an analysis of nationally representative disease registry data. The Lancet Global Health, 2022, 10, e1463-e1472.	2.9	4
1837	Accuracy of GenoQuick MTB test in detection of <i>Mycobacterium tuberculosis</i> in sputum from TB presumptive patients in Uganda. SAGE Open Medicine, 2022, 10, 205031212211168.	0.7	0
1838	Role of GeneXpert MTB/RIF assay for the diagnosis of cervical lymph node tuberculosis and rifampicin resistance. Tzu Chi Medical Journal, 2022, 34, 418.	0.4	4
1839	A rare case of multidrug-resistant lupus vulgaris with a mixed pattern of resistance – A long journey to diagnosis and treatment. Indian Dermatology Online Journal, 2022, 13, 633.	0.2	0
1840	Tuberculosis-loop-mediated isothermal amplification implementation in Cameroon: Challenges, lessons learned and recommendations. African Journal of Laboratory Medicine, 2022, 11, .	0.2	1
1841	GeneXpert rollout in three high-burden tuberculosis countries in Africa: A review of pulmonary tuberculosis diagnosis and outcomes from 2001 to 2019. African Journal of Laboratory Medicine, 2022, 11, .	0.2	6
1842	Tuberculosis Detection from Chest Radiographs: Stop Training Radiologists Now. Radiology, 2023, 306, 138-139.	3.6	1
1843	Raman spectroscopy and machine learning-based optical probe for tuberculosis diagnosis via sputum. Tuberculosis, 2022, 136, 102251.	0.8	5
1844	Frequency of rifampicin-resistant mycobacterium tuberculosis by GeneXpert MTB/RIF assay and its correlates among 2605 probable tuberculosis patients in upper Egypt. Indian Journal of Tuberculosis, 2022, , .	0.3	0
1845	Bronchial washing using a thin versus a thick bronchoscope to diagnose pulmonary tuberculosis: A randomized trial. Clinical Infectious Diseases, 0, , .	2.9	1
1846	Detection of differentially culturable tubercle bacteria in sputum from drug-resistant tuberculosis patients. Frontiers in Cellular and Infection Microbiology, $0,12,.$	1.8	2
1847	Mycobacterium tuberculosis functional genetic diversity, altered drug sensitivity, and precision medicine. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3
1848	Multi pathogenic microorganisms determination using DNA composites-encapsulated DNA silver nanocluster/graphene oxide-based system through rolling cycle amplification. Mikrochimica Acta, 2022, 189, .	2.5	7
1849	Evaluation of Gene-Xpert in paediatric tuberculous meningitis cases: A hospital-based study. Advances in Human Biology, 2022, .	0.1	0
1850	Review and Updates on the Diagnosis of Tuberculosis. Journal of Clinical Medicine, 2022, 11, 5826.	1.0	13
1853	THE DIAGNOSTIC UTILITY OF FNA CYTOLOGY FOR TB, FNAC FOR CBNAAT, IN PATIENTS WITH TUBERCULOUS LYMPHADENOPATHY. , 2022, , 28-30.		0
1854	The Value of GeneXpert MTB/RIF for Detection in Tuberculosis: A Bibliometrics-Based Analysis and Review. Journal of Analytical Methods in Chemistry, 2022, 2022, 1-11.	0.7	3

#	Article	IF	CITATIONS
1855	Molecular diagnosis of bovine tuberculosis on postmortem carcasses during routine meat inspection in Benin: GeneXpert® testing to improve diagnostic scheme. Veterinary World, 0, , 2506-2510.	0.7	1
1856	Progression of LAMP as a Result of the COVID-19 Pandemic: Is PCR Finally Rivaled?. Biosensors, 2022, 12, 492.	2.3	6
1857	Use of Whole-Genome Sequencing for Detection of Antimicrobial Resistance: <i>Mycobacterium tuberculosis</i> , a Model Organism. Clinical Laboratory Science: Journal of the American Society for Medical Technology, 2019, 32, ascls.2019001784.	0.1	О
1859	Mycobacterium Nontuberculosis Species. , 2023, , 823-830.e7.		1
1860	Mechanisms and Detection of Antimicrobial Resistance. , 2023, , 1506-1516.e4.		1
1861	Epidemiology and control strategies for tuberculosis in countries with the largest prison populations. Revista Da Sociedade Brasileira De Medicina Tropical, 0, 55, .	0.4	4
1862	A clinicopathological profile and role of newer methods in diagnosis of paediatric tubercular lymphadenopathy. International Clinical Pathology Journal, 2022, 9, 9-13.	0.1	0
1863	Evaluation Study of xMAP TIER Assay on a Microsphere-Based Platform for Detecting First-Line Anti-Tuberculosis Drug Resistance. International Journal of Environmental Research and Public Health, 2022, 19, 17068.	1.2	1
1864	The value of Xpert MTB/RIF assay of urine samples in the early diagnosis of smear-negative urinary tuberculosis. European Journal of Medical Research, 2022, 27, .	0.9	0
1865	Diagnostic accuracy of loop-mediated isothermal amplification for pulmonary tuberculosis in China. Frontiers in Tropical Diseases, 0, 3, .	0.5	0
1866	Epidemiology of tuberculosis and susceptibility to antituberculosis drugs in Reunion Island. BMC Infectious Diseases, 2023, 23, .	1.3	2
1867	The PE-PPE Family of Mycobacterium tuberculosis: Proteins in Disguise. Immunobiology, 2023, 228, 152321.	0.8	7
1868	The Role of Post-Bronchoscopy Sputum Examination in Screening for Active Tuberculosis. Tropical Medicine and Infectious Disease, 2023, 8, 13.	0.9	3
1870	Khảo sát ban Äʻầu năng lá»±c và má»™t sá»ʻ khó khăn trong chẩn Äʻoán, Äʻiá»u trị bệnh HIV tiáº, vị Äʻiá»u trị tại Việt Nam. Tap Chi Nghien Cuu Y Hoc, 2023, 160, 136-147.	in triển 0.0	vễ nhiá»
1872	Comparison of Gastric lavage/ Sputum and Stool specimens in the diagnosis of Pediatric Pulmonary Tuberculosis- A pilot study― Indian Journal of Tuberculosis, 2023, , .	0.3	0
1873	An analytic feasibility study of the BD MAXâ,, MDR-TB assay for testing of non-sputum specimens for detection of the Mycobacterium tuberculosis complex (MTBC) and isoniazid (INH) and rifampin (RIF) resistance. Diagnostic Microbiology and Infectious Disease, 2023, 106, 115925.	0.8	O
1874	Analysis of Xpert MTB/RIF results in retested patients with very low initial bacterial loads: A retrospective study in China. Journal of Infection and Public Health, 2023, 16, 911-916.	1.9	0
1875	The development and establishment of a heat inactivated preparation of Mycobacterium tuberculosis (H37Rv) as the first international standard for nucleic acid amplification techniques. Biologicals, 2023, 82, 101667.	0.5	0

#	Article	IF	CITATIONS
1876	Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort. Journal of Clinical Microbiology, 2023, 61, .	1.8	2
1877	Biomarker discovery for tuberculosis using metabolomics. Frontiers in Molecular Biosciences, 0, 10, .	1.6	7
1878	The diagnostic performance of endobronchial ultrasound with Xpert MTB/RIF Ultra in smear-negative pulmonary tuberculosis. BMC Infectious Diseases, 2023, 23, .	1.3	1
1879	Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infectious Diseases, The, 2023, 23, e122-e137.	4.6	14
1880	Performance of microbiological tests for tuberculosis diagnostic according to the type of respiratory specimen: A 10-year retrospective study. Frontiers in Cellular and Infection Microbiology, 0, 13, .	1.8	4
1881	Analytical evaluation of Mycobacterium tuberculosis detection in a local comprehensive tuberculosis center following the introduction of genexpert: A cartridge-based nucleic acid amplification test. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria. 2022. 31. 686.	0.0	0
1882	Advances in the Diagnosis of HIV-Associated Tuberculosis. European Medical Journal Respiratory, 0, , 60-70.	1.0	0
1883	Laboratory Diagnosis of Tuberculosis. Integrated Science, 2023, , 89-115.	0.1	0
1884	Diagnostic Performance of Different Laboratory Methods for the Detection of Extrapulmonary Tuberculosis. Microorganisms, 2023, 11, 1066.	1.6	4
1901	Clinical Features and Management of HIV/AIDS in Adults. , 2024, , 110-133.		0
1904	International efforts to reverse and end the tuberculosis pandemic: past, present and future global strategies., 2023,, 1-17.		0
1918	Molecular testing for diseases associated with bacterial infections. , 2024, , 133-145.		0
1919	WHO Goals and Beyond: Managing HIV/TB Co-infection in South Africa. SN Comprehensive Clinical Medicine, 2023, 5, .	0.3	1
1929	Laboratory Examination for Drug-Resistant Tubercle Bacillus. , 2023, , 19-27.		O